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Abstract 
During normal cell development, many genes are activated and repressed, usually 
through epigenetic mechanisms. These are modifications of the DNA and protein 
within the nucleus that result in changes in gene expression without alteration in DNA 
sequence.  Key proteins for epigenetic modifications are the histone proteins bound to 
DNA in the nucleus. The best-characterised epigenetic complexes that modify histone 
proteins are the polycomb group proteins (PcG), comprising polycomb repressive 
complexes 1 (PRC1) and 2 (PRC2). The repressive modifications generated by these 
complexes can be removed, and the blocked genes reactivated, by enzymes that are 
the subject of this project. PRC1 repressive marks are removed by deubiquitinases 
USP12, USP16 and BAP1, whereas PRC2 marks are removed by demethylases 
KDM6A, KDM6B and potentially UTY. During the development of cancer, the 
regulation of many genes becomes abnormal, allowing the cells to escape normal 
growth restrictions. In this thesis, the expression of this set of chromatin-modifying 
enzymes in a leukaemia cell line was investigated. The FANTOM consortium has been 
helping to understand patterns of gene expression for over 10 years. The FANTOM4 
dataset described changes in gene expression and promoter usage during 
differentiation of the THP-1 acute monocytic leukaemia cell line, using CAGE (Cap 
Analysis of Gene Expression) technology. This human monocyte-like cancer cell line 
can be stimulated with phorbol esters to halt proliferation and differentiate into 
macrophages. However, the FANTOM4 time course did not capture detailed 
mechanisms of regulatory factors in macrophage differentiation due to sparse time 
points and low read coverage. 
 
The main aim of this project was therefore to repeat the time course with tighter time 
points and deeper sequencing of the transcriptome to develop a very precise picture of 
sequential activation of gene expression, transcription start site (TSS) usage and the 
activity of enhancers during the transition from proliferating monocytes to 
differentiated macrophage phenotype of the THP-1 leukaemia cell line, using CAGE. 
The focus of this research was on the chromatin-modifying enzymes, but other key 
cell cycle and macrophage genes have also been examined. The differentiation time 
course was repeated in triplicate. RNA was extracted and CAGE libraries generated 
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for 18 time points, including the 6 originally studied in FANTOM4. Sequencing results 
were analysed and normalised using bioinformatics tools. It was shown that analysing 
8 samples on one Illumina HiSeq 2500 lane yielded enough read coverage to detect 
activity from even low expression TSSs, such as those associated with enhancer 
activity. Clusters of genes which were up- and downregulated at different time points 
during the differentiation process were identified and characterised. CAGE results for 
key genes encoding chromatin modifying enzymes and macrophage markers were 
validated by qRT-PCR. There was a rapid increase of histone demethylase KDM6B 
mRNA once differentiation was initiated. Histone deubiquitinase USP12 mRNA was 
also upregulated early in the process. Histone deubiquitinase BAP1 mRNA shows an 
interesting cyclic regulation pattern which was not seen in the more limited samples 
of FANTOM4. 
 
These interesting chromatin-modifying enzymes and their close paralogues 
(deubiquitinases USP12, USP16 and BAP1, together with demethylases KDM6A, 
KDM6B and UTY) were investigated by bioinformatics and genetic tools. USP16 
knockout THP-1 cell line was successfully created using CRISPR-Cas9 and its ability 
to differentiate into macrophages was examined using cell cycle analysis and CAGE 
sequencing. The USP16 knockout cell line, along with siRNA knock downs of USP12, 
USP16 and BAP1, was also compared to wildtype THP-1 differentiation using CAGE. 
Unfortunately, creating other mutant THP-1 cell lines was unsuccessful due to low 
THP-1 viability after single cell sorting. Investigating KDM6A, KDM6B and UTY 
using bioinformatics showed that UTY and KDM6A gene expression is positively 
correlated and this is disrupted in cancer samples. Gene expression and sequence 
comparison suggested that KDM6A and UTY are coregulated and may act in a similar 
way in histone demethylation. 
 
In summary, the results in this thesis show the transcriptomic changes as the leukaemia 
cell line ceases proliferation and commences differentiation. Detailed examination 
suggests that histone modifications are important in the transition between 
proliferation and differentiation and provide better understanding of regulatory factors 
in macrophage differentiation and leukaemia. 
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Lay summary 
All the cells which make up our body contain the same genetic material (DNA), but 
perform different functions. For example, muscle cells are specialised to contract and 
expand, whereas white blood cells need to fight against pathogens. They are able to do 
different things from the same DNA by expressing different genes to make different 
proteins for their specialised functions.  
 
These changes in gene expression are controlled by various mechanisms, one of which 
is by altering the histone proteins that bind to DNA, forming chromatin. The presence 
of chemical modifications of the histones tells the cell to either start or stop expressing 
the gene. In this thesis, the enzymes responsible for removing some of these 
modifications are investigated.  
 
The removal of these chromatin marks is especially important in the process of cell 
differentiation, in which cells are transformed from general precursors into specialised 
cells. Monocytes are precursor cells found in the blood which can stop multiplying and 
differentiate into macrophages. These specialised macrophages are able to recognise 
and dispose of any dangerous pathogens or cancer cells by a process called 
phagocytosis. Studying macrophages is important for understanding how the body can 
fight against bacteria, viruses and abnormal cancer cells.  
 
For this study, a human leukaemia cell line was used as it is very similar to monocytes 
and can be induced to differentiate from monocyte to macrophage. Changes in gene 
expression across the entire DNA were looked at hour by hour in this experiment. By 
examining the activity of the DNA (gene expression) at close time points, it was 
possible to understand what was happening in the cell in great detail as differentiation 
progressed. In particular, the study looked at how chromatin modifying enzymes 
affected differentiation.  
 
This study also looked at what happened to cancer cells when the chromatin-modifying 
enzymes were inactivated and how this affected differentiation into macrophages. This 
research helps in the understanding how cancer progresses and how we can prevent it. 
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Chapter 1: Introduction 
 
All organisms store information about how to build their cells in deoxyribonucleic acid 
(DNA). This molecule contains data encrypted in a four-letter code using adenine (A), 
thymine (T), guanine (G) and cytosine (C). Although elements of this code have been 
known for decades, all the ways in which the genetic material is implemented are still 
not fully understood. Almost every cell in the body of a multicellular organism 
contains the same genetic (DNA) material, but each cell only transcribes a part of this 
DNA into ribonucleic acid (RNA) that has specific functions, including translation 
into proteins which are essential for most tasks carried out by a cell. The overall aim 
of this thesis is to expand knowledge on the differential expression of RNA in different 
types of cells and cellular states. 
  
1.1 Transcriptional control of gene expression 
The term gene has been defined as a genomic sequence encoding a functional product, 
be it protein or non-translated RNA (Gerstein et al., 2007). Gene expression (the 
conversion of this information into a form that can be interpreted by the cell) is an 
extremely complex and dynamic process. It is highly specific to the cell and situation, 
and thus is influenced by many different factors.  
 
1.1.1 Gene promoters 
Protein-coding genes and some types of non-coding RNA genes are transcribed into 
mRNA by RNA polymerase II, an enzyme which initiates transcription at the 
beginning of the gene, called the transcription start site (TSS) (as reviewed by Jonkers 
and Lis (2015)). The region around the TSS is defined as the promoter, which is the 
site at which the transcriptional machinery is assembled, bringing together the RNA 
polymerase with the associated regulatory and processing molecules (Jonkers and Lis, 
2015). Promoter structures can be identified as narrow (sharp) or broad, each 
associated with different characteristics, such as promoter architecture (Carninci et al., 
2006). Textbooks usually describe an AT rich sequence (the TATA box) as a key 
component of eukaryotic promoters with transcript initiation beginning a precise 
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distance upstream, typically 25 nucleotides (Alberts et al., 2013). This type of TATA 
box promoter is associated with a sharp promoter structure and tends to show tissue 
specific gene expression (Carninci et al., 2006). In contrast, recent studies have shown 
that the majority of promoters in vertebrates lack the TATA box and are found in 
regions of the genome called CpG islands (Carninci et al., 2006, Forrest et al., 2014). 
These regions contain many doublets of cytosine followed by guanine (CpG) and 
higher average GC content compared to frequencies in the genome overall (Saxonov 
et al., 2006). Around 70% of human promoters overlap with CpG islands, and these 
allow transcription to initiate from many different nucleotides within a broad region 
(Carninci et al., 2006, Forrest et al., 2014). These broad promoters tend to be 
associated with genes that are widely expressed in multiple tissues, such as 
housekeeping genes (Saxonov et al., 2006, Deaton and Bird, 2011, Carninci et al., 
2006, Forrest et al., 2014).  
 
In addition to transcript initiation occurring at diverse points within a promoter region, 
many genes can have alternative promoters which express different transcripts from 
various TSS, depending on the context (Ayoubi and Van De Ven, 1996, Davuluri et 
al., 2008). This can result in transcripts with alternative 5’ regions which may be 
subject to different post-transcription regulation, and sometimes omit protein-coding 
exons thereby potentially changing the function of the resulting protein (Forrest et al., 
2014). Moreover, 10% of human promoters are bidirectional (Trinklein et al., 2004), 
so they are transcribed from both DNA strands - this is discussed further in section 
1.1.2. 
 
A cell must respond immediately to environmental cues, so the activation and 
inactivation of genes and the choice of promoter must be rapid and flexible. For 
example, when treated with lipopolysaccharide (LPS), macrophages produce an early 
response of rapid changes in gene expression (Baillie et al., 2017). This is achieved by 
multiple regulatory elements, which either enhance or repress transcription from 
specific genes. The main regulatory elements are transcription factors (TFs), which 
recognise and bind to 6-12 bp DNA sequences within the promoter region (called 
motifs), These TFs work with other elements to recruit the RNA polymerase and allow 
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transcription to start (Spitz and Furlong, 2012). The processes that facilitate the 
binding of transcription factors are discussed in more detail below. 
1.1.2 Enhancers 
As well as the proximal regulatory elements, such as transcription factor binding 
motifs within promoter sequences, gene expression is influenced by more distal DNA 
sequences – enhancers (Fukaya et al., 2016). Enhancers play a crucial role in driving 
specific gene expression by delivering the transcriptional machinery to the promoters 
(Calo and Wysocka, 2013). Studies using different methodologies and criteria have 
identified between 40,000 and 400,000 enhancers in the human genome, as many as 
20 enhancers per gene (ENCODE, 2012, Andersson et al., 2014). 
 
Not all enhancers are considered equal in strength and importance. “Super-enhancers” 
are large clusters of enhancers within up to 50 kb of DNA that drive expression of 
those genes that define the identity of the cell (Hnisz et al., 2013). Enhancers act 
through binding both master transcription factors and mediator coactivators.  For 
example, super-enhancers in embryonic stem cells (ESCs) are occupied by well-
known stem cell transcription factors such as OCT4 (also known as POU5F1), SOX2 
or NANOG (Whyte et al., 2013). Differences between normal enhancers and super-
enhancers include size, transcription factor density, activation of transcription and 
sensitivity to perturbation (Whyte et al., 2013).  
 
Another category of enhancers is the latent enhancers, which are found in 
differentiated cells. Latent enhancers are defined as regions of the genome which do 
not have any transcription factors bound to them, nor do they normally have enhancer 
activity but they can acquire it in response to stimuli (Ostuni et al., 2013).  Once 
activated, these enhancers do not go back to their inactive state even after the removal 
of the stimulus. This could allow this type of enhancer to provide a memory of the 
environment. These latent enhancers illustrate the dynamism and versatility of 
enhancer elements in regulating gene expression.  
 
Discovering new enhancers is difficult as no consensus sequence exists and their 
distance from their target gene is highly variable (Pennacchio et al., 2013). They can 
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be found upstream or downstream of the gene, in close proximity or many kilobases 
away. One way to characterise new enhancers is to look for specific histone 
modifications known to be associated with enhancers (Pennacchio et al., 2013).  This 
was the approach used by ENCODE to identify putative enhancers (ENCODE, 2012). 
In addition, a number of reports have recently shown that enhancers are characterised 
by bidirectional transcription which can be used to identify candidate enhancers 
(Andersson et al., 2014, Kaikkonen et al., 2013, Li et al., 2013b, Kim et al., 2010, Hah 
et al., 2015). This method, notably used by the FANTOM5 consortium (discussed in 
section 1.4.1), detected far fewer enhancers than the ENCODE project.  
 
1.1.3 Epigenetic control of gene expression 
In a broad sense, epigenetic modifications are stable heritable alterations of the DNA 
and proteins within the nucleus that result in changes in gene expression without 
alteration in DNA sequence (Berger et al., 2009). Genetic information is efficiently 
stored by packing the DNA around proteins into a structure called chromatin. The 
basic unit of chromatin is the nucleosome, which is comprised of 2 copies of each of 
the core histones, H2A, H2B, H3 and H4. Wrapped around this histone octamer is a 
147 bp long stretch of DNA (Richmond and Davey, 2003, Struhl and Segal, 2013). 
Gene expression requires enzymes such as RNA polymerase II to access the DNA, so 
packaging into nucleosomes could potentially obstruct cellular processes. Therefore, 
epigenetic modifications are used to disrupt nucleosomes and open the chromatin in 
the region of a gene that needs to be expressed. These modifications mark the 
functional elements of DNA to guide enzymes and other proteins that regulate gene 
expression, allowing activation or repression of gene expression depending on the 
requirements, state of differentiation and environmental stimuli to the cell. 
 
The importance of these chromatin modifications is highlighted by studies which 
indicate that the epigenetic state of enhancers dictates the regulation of gene 
expression (as reviewed in Ong and Corces (2011)). This epigenetic patterning occurs 
before cell differentiation, suggesting that the information needed to determine the fate 
of the cell is located on the enhancers themselves (Ong and Corces, 2011). This 
information is dynamic and may differ from one enhancer to another. Further research 
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could help us to determine how various developmental pathways are regulated and 
several key epigenetic marks are discussed in the next section.  
 
1.2 Epigenetic marks  
Epigenetic marks can be found on both the DNA and proteins of chromatin. The DNA 
can be modified, usually by methylation of cytosine residues, which usually results in 
repression of activity when found in a promoter region (Long et al., 2016, Deaton and 
Bird, 2011). Methylation of cytosine is essential for proper development, as it is 
involved in many cellular processes including genomic imprinting, which leads to 
differently expressed alleles from mother and father, and X-inactivation, which 
ensures that only one copy of X chromosome is expressed in mammalian females 
(Sharp et al., 2011, Elhamamsy, 2017). Although the human genome is widely 
methylated, one functional feature usually contains long stretches of unmethylated 
cytosines – the CpG islands (Deaton and Bird, 2011) characteristic of broad promoters 
(section 1.1.1). It is likely that the low level of methylation in these elements is 
necessary to ensure that the promoter is accessible to RNA polymerase, representing 
one form of epigenetic regulation of gene expression. 
 
A major epigenetic target, and the focus of the present study, are histone proteins. 
Unlike epigenetic modifications of DNA, there are hundreds of potential modifications 
for histones including methylation, ubiquitination, acetylation and others (Gates et al., 
2017). Ubiquitination involves attaching the highly-conserved 76 amino acid protein, 
ubiquitin, which is an important regulator in various cell processes, such as the protein 
degradation and the cell cycle (Hard et al., 2010). Epigenetic marks are primarily 
found on the N-terminal ends of the histone molecules and each has different meaning 
for the cell, for example, histone acetylation almost always means gene activation 
(Bannister and Kouzarides, 2011). The focus of this thesis is on chromatin modifying 
enzymes which remove repressive histone marks to pave the way to gene activation. 
 
1.2.1 Polycomb group proteins 
The best-characterised epigenetic complexes that modify histone proteins are the 
polycomb group proteins, comprising polycomb repressive complexes 1 (PRC1) and 
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2 (PRC2) (Lanzuolo and Orlando, 2012). The repressive modifications generated by 
these complexes can be removed by chromatin modifying enzymes, deubiquitinases 
and demethylases, allowing the blocked genes to be reactivated (Figure 1-1). 
 
PRC1 is composed of many proteins in mammals, most importantly RING1A and 
RING1B ubiquitin ligases (Lanzuolo and Orlando, 2012). PRC1 ubiquitinates the 
lysine at position 119 of histone 2A (H2AK119) most usually via RING1B, creating a 
repressed state of chromatin (Lanzuolo and Orlando, 2012) (Figure 1-1). H2A 
ubiquitination (H2Aub) blocks transcription through preventing RNA polymerase II 
from progressing along the DNA, for example at the promoters of developmental 
genes needed for differentiation in ESCs (Embryonic stem cells) (Stock et al., 2007). 
Recent studies showed that H2Aub also marks bivalent genes (genes containing both 
repressive and active histone marks) and regulates their expression in ESCs (Yang et 
al., 2014, Stock et al., 2007, Ku et al., 2008). Depletion of RING1A and RING1B 
causes the loss of ESC identity (Stock et al., 2007). PRC1 may also contribute to gene 
repression by directly compacting chromatin, blocking remodelling and inhibiting 
transcription initiation (Yang et al., 2014).  
 
The best-known repressive epigenetic mark is trimethylation of histone 3 at lysine 27 
(H3K27me3), which is generated and maintained by PRC2 (Lanzuolo and Orlando, 
2012) (Figure 1-1). Mammalian PRC2 is composed of EED, EZH1/2, SUZ12 and 
RbAp46/48 proteins (Lanzuolo and Orlando, 2012) and H3K27 trimethylation is 
produced by the EZH1 or EZH2 methyltransferases (Yoshimi and Kurokawa, 2011). 
H3K27me3 is responsible for gene silencing and is implicated in bivalent gene 
domains in ESCs (Ku et al., 2008). The activating epigenetic mark, H3K4me3, is 




Figure 1-1 PRC1 and PRC2 create a repressive state through methylation and ubiquitination of histones. 
USP12/USP16/BAP1 erasers remove repressive mark H2AK119Ub and RNF20/40 writers create an 
active H2BK123ub. KDM6A and KDM6B (possibly also UTY) erasers remove repressive mark 
H3K27me3 and MLL1 writer creates an active H3K4me3 mark. 
 
1.2.2 Removal of PRC1 associated marks 
As mentioned above, during transcriptional activation, H2A deubiquitinases remove 
ubiquitin from H2AK119, and H2B histone is ubiquitinated on K123 (Abdel-Wahab 
and Dey, 2013). This ubiquitination switch is very important for the balance between 
repression and activation of gene expression. A small number of H2AK119 
deubiquitinases have been identified, among as many as 100 deubiquitinases encoded 
in the human genome (Belle and Nijnik, 2014, Komander et al., 2009). These are the 
six ubiquitin specific proteases (USPs; USP3, USP12, USP16, USP21, USP22, 
USP44), one ubiquitin C-terminal hydrolase (BAP1) and one Zn2+ metalloprotease 
(MYSM1).  
 
Three of these enzymes were selected for detailed examination in this study – BAP1, 
USP12 and USP16, which were found to control Hox gene expression during 
embryonic development in the mouse. USP12 and USP16 are less well-known in the 
scientific literature than BAP1, but all three have been implicated as possible tumour 
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suppressor genes. Another deubiquitinase, MYSM1, was found to be a regulator of B 
cell development and defects in Mysm1 expression were detrimental to proper 
differentiation of other hematopoietic cells in the mouse (Jiang et al., 2011, Forster et 
al., 2015). USP21 has a possible role in T cell development and the cell cycle (Li et 
al., 2016, Urbe et al., 2012). The roles of USP3, USP22 and USP44 were mostly in 
DNA damage repair, with USP22 also implicated in carcinogenesis (Sharma et al., 
2014, Ramachandran et al., 2016, Schrecengost et al., 2014, Mosbech et al., 2013). 
 
1.2.2.1 BAP1 (BRCA1-associated protein 1) 
BAP1 was first identified as a ubiquitin carboxy-terminal hydrolase, which binds to 
Breast/Ovarian Cancer Susceptibility Gene product (BRCA1) (Jensen et al., 1998). 
BAP1 deubiquitinase activity (against H2A though not H2B) was discovered much 
later, when BAP1 was identified as a human homologue of Drosophila calypso 
(Scheuermann et al., 2010). BAP1 may also take part in many cellular pathways and 
processes, such as cell cycle progression, promoting cell proliferation and repair of 
DNA double strand breaks (Yu et al., 2014). 
 
BAP1 is a component of Polycomb Repressive Deubiquitinase (PR-DUB) complexes, 
which have an important role in changes of gene expression. FOXK2, a forkhead 
transcription factor, was shown to recruit PR-DUB complexes (and thus BAP1) to 
chromatin, where BAP1 can promote local histone deubiquitination and causes 
changes in gene expression (Ji et al., 2014). This shows how BAP1 could be recruited 
to the regulatory regions of the genome. 
 
In humans, heterozygous mutation of the BAP1 gene is associated with tumour 
predisposition syndrome (OMIM 614327) (Abdel-Rahman et al., 2011, Rai et al., 
2016). The BAP1 gene is commonly deleted or mutated in multiple cancers, such as 
renal cell carcinoma, hepatic cancer and others (Battaglia, 2014, Popova et al., 2013, 
Testa et al., 2011, Wiesner et al., 2011). The loss of BAP1 function is usually 
considered a mark of poor prognosis in cancer patients (Joseph et al., 2014). 
Downregulation of BAP1 was also found in chronic myeloid leukaemia patients with 
Philadelphia chromosome, which contains oncogenic BCR-ABL1 fusion (Dkhissi et 
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al., 2015). This downregulation of BAP1, a direct effect of BCR-ABL, further 
upregulates ubiquitination of BRCA1, which is then targeted for degradation. Biallelic 
BAP1 expression loss has also been associated with metastasis formation in uveal 
melanoma (Gezgin et al., 2017), where lack of BAP1 drives T cell influx and thus adds 
to the development of an inflammatory environment. Bap1-/- (knockout; KO) mice are 
embryonically lethal, where the embryos are reabsorbed by E9.5 (Dey et al., 2012). 
Conditional knockout in haematopoietic lineages in mice resulted in human 
myelodysplastic syndrome-like phenotype, emphasising the role of BAP1 as a tumour 
suppressor (Dey et al., 2012). These mice developed various haematological disorders, 
such as splenomegaly, monocytosis and neutrophilia.   
 
Myelodysplastic syndrome and acute myeloid leukaemia patients have increased 
incidence of mutations of ASXL1 (Abdel-Wahab et al., 2012), which directly 
associates with BAP1 (Scheuermann et al., 2010). BAP1 (Calypso)-ASXL1 complex 
was found on the HOX genes, where it deubiquitinated H2A (Scheuermann et al., 
2010). Interestingly, Abdel-Wahab et al. (2012) showed that ASXL1 promotes 
myeloid transformation through H3K27me3 loss, independently of BAP1. However, 
Bap1 loss drives an increase in H3K27me3 levels due to elevated Ezh2 in 
mesothelioma in mice (LaFave et al., 2015). Inhibitor against EZH2 was successful in 
treating mesothelioma cells, but caution must be taken to extend these results to other 
cancers such as uveal melanoma, where BAP1 loss did not increase EZH2 
(Schoumacher et al., 2016).  
 
In summary, there is substantial evidence that BAP1 acts as a tumour suppressor, both 
in experimental models (Bap1 knockout mice) and cancer patients. However, the 
mechanism by which BAP1 represses cancer is still unknown, as is the question of 
whether it is linked to H2A deubiquitinase activity. Conflicting reports about the effect 




1.2.2.2 USP12 (Ubiquitin-specific peptidase 12) 
USP12 H2A deubiquitinase activity was first identified by Joo et al. (2011), together 
with that of USP46, which shares over 88% amino acid homology. H2A ubiquitin is 
removed by a complex between USP12 and the nucleosomal substrate, WDR48 (Joo 
et al., 2011). USP12 was found to deubiquitinate H2A and H2B with the same 
efficiency in vitro and in vivo (Joo et al., 2011). The expression of USP12 and USP46 
was found to be coordinated, so that when USP12 expression was knocked down, 
USP46 gene expression increased, suggesting that they may have similar functions. 
Long term knock down of usp12 (over 4 days) severely affected the development of 
Xenopus laevis, which suggests that USP12 is required for proper development (Joo 
et al., 2011). 
 
USP12 has not been well-studied, but it has been found to serve multiple functions in 
the cell aside from the H2A deubiquitinase activity. For example, USP12 is a negative 
regulator of NOTCH signalling (Moretti et al., 2012) and together with WDR48 it 
negatively regulates AKT activation and promotes cellular apoptosis (Gangula and 
Maddika, 2013). Knock down of USP12 was shown to increase proliferation of tumour 
cells and thus USP12 was a potential tumour suppressor gene (Gangula and Maddika, 
2013). USP12, together with WDR20 and UAF1, was found to be a co-activator of the 
androgen receptor, which is a transcription factor commonly altered in prostate cancer 
(Burska et al., 2013). These proteins and their mRNAs were found to be upregulated 
in prostate cancer (McClurg et al., 2015), with higher levels of USP12 when the other 
two were also present, suggesting a positive feedback loop. In contrast with findings 
of Gangula and Maddika (2013), knock down of USP12 in prostate cancer cells 
reduced cancer proliferation (McClurg et al., 2015). USP12 also regulated cross talk 
between androgen receptor and AKT pathways in prostate cancer (McClurg et al., 
2014). A super-enhancer (section 1.1.2) close to USP12, was found in colorectal 
carcinoma, which increased the expression of USP12 (Zhang et al., 2016). USP12 is 
also involved in regulating cell cycle progression by involving cMyc, cyclin D2 and 
BMI1 (Tang et al., 2016), and its knock down induced a cell cycle arrest in HeLa cells. 
USP12 also acts as a crucial component of the T-cell receptor, and the Jurkat cell line 
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without USP12 expression is defective in important cell signalling such as through 
NFκB, NFAT and MAPK (Jahan et al., 2016). 
 
1.2.2.3 USP16 (Ubiquitin-specific peptidase 16) 
USP16 was first mentioned by Cai et al. (1999) as UBP-M, and this 823 amino acid 
protein was localised to cytoplasm. Further research revealed that USP16 forms a 
tetramer, which is actively exported from the nucleus during interphase (Xu et al., 
2013). However, at the onset of mitosis USP16 is phosphorylated at Serine 552, by 
CDK1 (Xu et al., 2013) and localises to nucleus, where it is required for G2/M 
progression. In mitosis, USP16 deubiquitinates PLK1, which is needed for proper 
chromosome alignment and without which cell cycle progression is stopped (Joo et 
al., 2007). 
 
USP16 can also act as a negative regulator of the process of DNA damage repair. A 
DNA double strand break induces H2A ubiquitination at the site, and once the break 
is repaired the ubiquitin is removed by USP16 and HERC2 (Zhang et al., 2014). Levels 
of USP16 mRNA are upregulated directly after DNA damage, and both 
downregulation and overexpression of USP16 leads to reduced response to DNA 
damage (Zhang et al., 2014). Disruption of USP16 expression may contribute to the 
inability of cancer cells to resolve the DNA repair process, and has been found 
downregulated or mutated in several human cancers, such as leukaemia, lung 
adenocarcinoma and hepatocellular carcinoma (Fernandez et al., 2004, Qian et al., 
2016, Gelsi-Boyer et al., 2008). 
 
The function of USP16 which is most important for this project is gene activation. 
USP16 binds to promoter regions in various genes on all chromosomes of ESCs, and 
this was correlated with low H2A ubiquitination levels but high gene expression (Yang 
et al., 2014). USP16 was also shown to bind to active genes and promoters, taking on 
a role in shifting mouse B-cells from a quiescent to an active state (Frangini et al., 
2013).  In addition, USP16 was shown to regulate developmental hox genes in Xenopus 
laevis (Joo et al., 2007). All three of these functions may contribute to the embryonic 
lethality of Usp16 -/- mice, where defects in the development were found as early as 
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E7.5 stage embryos after implantation (Yang et al., 2014). USP16 catalytic function 
was shown to be required for ESC differentiation, but not ESC viability (Yang et al., 
2014). In addition, knock down of USP16 in HeLa cells caused growth rates to slow, 
as there was a sharp decrease in G2/M cells and HOX gene expression. (Joo et al., 
2007).  
 
USP16 is located on human chromosome 21. Trisomy of this chromosome results in 
Down syndrome (Adorno et al., 2013). A study by Adorno et al. (2013) in mice 
showed that USP16 is the main candidate in causing accelerated senescence and aging-
related phenomena in Down syndrome patients. Consequences of overexpression of 
Usp16 in mice include reduction of hematopoietic stem cells and their self-renewal 
ability, cellular defects owing to increased removal of H2A ubiquitins and decreased 
proliferation (Adorno et al., 2013). Down syndrome patients also have increased 
incidence of leukaemia and decreased rate of solid tumours (Mateos et al., 2015). 
USP16 overexpression was also shown to cause reduced DNA damage response in 
human Down syndrome cell lines (Zhang et al., 2014).  
 
Taken together, these reports suggest that cells are sensitive to any changes in USP16 
dosage, as either increase (Down syndrome) or decrease (mutations in cancers) causes 
decreased DNA damage response and higher incidence of some cancers. 
 
1.2.3 Removal of PRC2 associated marks  
Trimethylation of lysine 27 of histone 3 (H3K27me3) is catalysed by PRC2 and is 
associated with gene repression. Histone demethylases, which remove di- and 
trimethyl groups on H3K27, are responsible for radical alteration of epigenetic states 
to create new cell-specific gene expression profiles (Miller et al., 2010). Two 
demethylases that contain a Jumonji C (JmjC) catalytic domain are responsible for 




1.2.3.1 KDM6A (UTX) and UTY 
Like the deubiquitinating chromatin modifying enzymes discussed in the previous 
section, the demethylase KDM6A has also been identified as a tumour suppressor 
protein, which was deleted in several human tumours, including multiple myeloma, 
oesophageal, pancreatic and renal cancer (Van der Meulen et al., 2014, van Haaften et 
al., 2009, Waddell et al., 2015, Ler et al., 2017). Using an inhibitor against EZH2 
seemed to antagonise the carcinogenesis caused by loss of KDM6A in bladder cancer, 
which shows a potential new therapeutic target for treating this type of cancer (Ler et 
al., 2017).  
 
The KDM6A gene is located on the X chromosome in mammals, and it has a 
homologue on the Y chromosome called UTY, which shows similar patterns of 
expression to KDM6A (Xu et al., 2008). UTY shares 84% sequence homology to 
KDM6A, but the protein was thought to be enzymatically inactive. However, a recent 
report suggests that UTY might also have a demethylase activity (Walport et al., 
2014). All Kdm6a-/- females but only some Kdm6a- males (which carry Uty on the Y 
chromosome) die in utero. Uty KO mice are viable, but Kdm6a/Uty double KO mice 
are embryonically lethal (Shpargel et al., 2012). Most likely UTY can compensate to 
some extent for loss of KDM6A in adults and partially during development. UTY has 
not been widely recognised as sharing full redundancy with KDM6A; these 
observations suggested that further analysis of the similarities between KDM6A and 
UTY was necessary, which is presented in Chapter 5 of this thesis.   
 
Although KDM6A seems to have no role in ESC renewal, it is needed for bivalency 
resolution and activation of retinoic acid inducible genes during differentiation of 
mouse ESCs (Dhar et al., 2016). Furthermore, Morales Torres et al. (2013) discovered 
that KDM6A is required for proper differentiation of ectoderm and mesoderm in 
mouse ESC, but not their proliferation. Remarkably, ectoderm and mesoderm are 
established in the absence of the demethylase activity of KDM6A (Morales Torres et 
al., 2013). UTY and KDM6B have been shown to partially compensate for  KDM6A 
loss in male ESCs. During their knock down using RNAi, there was a significant but 
small downregulation of genes needed for ectoderm and mesoderm differentiation 
(Morales Torres et al., 2013). 
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In humans, expression levels of the KDM6A gene are the highest in haematopoietic 
stem and progenitor cells than decline during haematopoietic differentiation (Van der 
Meulen et al., 2014). KDM6A has been identified as a novel regulator for 
haematopoietic cell migration using conditional Kdm6a KO mice (Thieme et al., 
2013). KDM6A was also found to epigenetically activate expression of cytokines IL-
6 and IFN-β in primary macrophages by removing H3K27me3 from their promoters 
(Li et al., 2017).  
 
1.2.3.2 KDM6B (JMJD3) 
The related histone demethylase KDM6B lacks the tetratricopeptide repeats (TPRs) 
that are present at N-terminal regions of the KDM6A and UTY proteins (see section 
5.1). These TPRs are important for protein-protein interactions (van den Meulen et al., 
2014), which might suggest a lack of redundant functions between KDM6A and 
KDM6B. 
 
No correlation between KDM6B recruitment and changes in H3K27me3 levels has 
been observed (De Santa et al., 2009, De Santa et al., 2007). KDM6B interacts with 
the p53 tumour suppressor and is transcriptionally upregulated following DNA 
damage (Williams et al., 2014). The authors speculated that KDM6B could act as a 
fail-safe mechanism to maintain low levels of H3K27me3, so the chromatin stays 
permissive for activation by H3K27 acetylation at p53 response elements, instead of 
directly activating target genes. Recently, KDM6B was found to downregulate OCT4 
expression at both mRNA and protein level without its demethylase activity (Xun et 
al., 2017). Therefore, this data further supports the theory that both KDM6A and 
KDM6B and possibly UTY have a secondary function independent of their 
demethylase activity.  
 
Both KDM6A and KDM6B were found to catalyse the removal of the repressive 
histone mark at genes important for T cell differentiation (Manna et al., 2015). 
Interestingly, a recent study identified KDM6B as an oncogene and KDM6A as a 
tumour suppressor gene in T-cell acute lymphoblastic leukaemia, but did not 
completely address the role of UTY (Ntziachristos et al., 2014). KDM6B is also 
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upregulated in macrophages, where it is important for the activation of inflammatory 
cytokine genes such as IL23A (also known as IL-23p19), CSF3 (GCSF) and TREM1 
(Yan et al., 2014). 
 
Deletion of Kdm6b results in perinatal lethality at E18.5 of mouse development, where 
KDM6B has been shown to have a role in the maintenance of the embryonic 
respiratory neuronal network, breathing and survival (Burgold et al., 2012).  
 
1.2.3.3 Link between PRC1 and PRC2  
Bivalent domains in mouse ESCs containing both PRC1 and PRC2 modifications 
appear to retain H3K27me3 more efficiently upon differentiation, show high 
evolutionary conservation and associate with a large number of gene promoters 
controlling development (Ku et al., 2008). According to the study by Ku et al. (2008), 
both sets of PRCs are required for proper gene silencing and for differentiation. It is 
not yet known how ubiquitously expressed chromatin-modifying enzymes are capable 
of establishing and maintaining specific patterns of gene expression for differentiating 
cells. Most probably, cell-type specific gene expression patterns require distinct 
combinations of chromatin regulators at different times, with PRC1 and PRC2 
working together (DeVilbiss et al., 2013).  
 
There are several instances of this happening. Blackledge et al. (2014) discovered that 
H2Aub deposited by PRC1 leads to recruitment of PRC2 and trimethylation of H3K27 
to establish a repressive state of chromatin. BAP1 interacts with ASLX1, as discussed 
above (section 1.2.2.1), and expression of ASXL1 was associated with abundance of 
the H3K27me3 repressive PRC2 mark, suggesting that ASXL1 could be responsible 
for recruitment and stabilisation of PRC2 complex (Abdel-Wahab et al., 2012). Both 
BAP1 and ASLX1 are probably involved in a large number of interactions, but these 
observations show that they could form a link between PRC1 and PRC2 gene 
silencing, even if they do not occur together. These results present a mechanism by 
which PRC1 and PRC2 might interact to regulate chromatin state. 
 
 16 
1.3 Cellular differentiation 
The change from totipotent single celled zygote to a multicellular adult organism with 
hundreds of different cell types involves a series of developmental and differential 
processes. Studying cell differentiation is useful for determining the cause of 
developmental anomalies of the organism and for understanding disease processes, 
particularly those caused by inappropriate expression or repression of genes, such as 
cancer. Chromatin plasticity is tested to an extreme degree during differentiation, as 
various genes need to be blocked and others turned on in quick succession. It is to be 
expected that chromatin modifying enzymes will have an important role in influencing 
these transitions in gene expression during differentiation.  
 
The aim of this thesis is to explore the transcriptomic changes involving chromatin-
modifying enzymes in relation to cell differentiation. All of these genes are implicated 
as having an effect in cancers, with most of them confirmed or suspected as tumour 
suppressor genes.  The system chosen for transcriptomic analysis was monocyte to 
macrophage differentiation, as haematopoiesis involves rapidly dividing and 
proliferating cells which undergo transitions in cell state as the final mature phenotype 
is developed (Gordon and Taylor, 2005). 
 
1.3.1 Monocyte-macrophage differentiation 
Monocytes originate from a common myeloid progenitor in bone marrow, where they 
are released into peripheral blood (Gordon and Taylor, 2005). They circulate for 
several days, before differentiating into macrophages, characterised by growing in 
size, increasing the number of lysosomes and becoming adherent (Figure 1-2). This 
differentiation is dependent on stimulation by macrophage colony stimulating factor 
(CSF1), which binds to the extracellular domain of the CSF1 receptor (CSF1R) 
(Wallner et al., 2016). Further changes are orchestrated by a cascade of different 
transcriptomic modifications enabled by upregulation or downregulation by various 
transcription factors, such as PU.1 (also known as SPI1) or FOXP1 (Shi et al., 2008, 
Zhang et al., 1994, Hume and Freeman, 2014). Monocytes undergo maturation in the 
circulation to generate subsets of cells that differ in expression of marker genes 
including CD14 and CD16 (Schmidl et al., 2014).  Further monocyte differentiation 
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in response to CSF1 produces major changes in the transcriptome, analysed using 
CAGE (see section 1.4.1), including down-regulation of pattern recognition receptors 
and proinflammatory mediators (Baillie et al., 2017, Hume et al., 2016).  
 
 
Figure 1-2 A) Human primary peripheral blood monocytes harvested from a female donor. B) The same 
cells differentiated into macrophages after 5 days in culture with CSF1. Scale bar = 50 µm. Images 
provided by Dr Tim Regan, The Roslin Institute, UK. 
 
Monocytes and macrophages differ immensely in their epigenetic signatures (Wallner 
et al., 2016, Hoeksema and de Winther, 2016). Even the chromatin landscapes of 
macrophages in different tissues vary, based on their microenvironment (Lavin et al., 
2014). This data suggests that the role of chromatin modifying enzymes must be 
critical in their dynamic transcriptomic change in differentiation of monocytes into 
macrophages. Thus, monocyte to macrophage differentiation was chosen as a model 
for studying these changes. 
 
1.3.2 Leukaemia cell lines as an experimental model 
Most experiments using genome-wide approaches to study gene expression require a 
large number of cells to be processed and analysed, which is difficult to achieve with 
primary cells from a single donor. There are many cell lines which were established 
from human cancer patients to provide a good source of monocyte or macrophage-like 
cells for researchers. Some of these are outlined below. 
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U-937 is an acute myeloid leukaemia cell line, established from a 37-year male patient 
(Sundstrom and Nilsson, 1976). At establishment, U-937 grew as a single-cell 
suspension with identical morphology to the tumour cells it was established from. Its 
karyotype years later was found to be quite variable with ~56-60 chromosomes, two 
X chromosomes and no Y chromosome (Lee et al., 2002). Even though this cell line 
was established from lymphoma, it expressed myelocytic markers, and can be 
stimulated to express monocyte-like phenotype in response to stimuli such as 
interferon γ or retinoic acid (Tanaka et al., 1995, Harris et al., 1985).  U-937 cells can 
also be differentiated into macrophages by the protein kinase C agonist phorbol 12-
myristate 13-acetate  (PMA) (Yang et al., 2017), Another cell line is HL-60, which 
was established from an acute promyelocytic leukaemia. The morphology of HL-60 
cells is predominantly that of the neutrophilic promyelocyte, but they appear to be able 
to phagocytose (Gallagher et al., 1979). Their karyotype is close to the human diploid 
complement of 46 chromosomes, with few chromosomal deletions (Gallagher et al., 
1979). The Mono Mac 6 cell line was also derived from patient with monoblastic 
leukaemia (Ziegler-Heitbrock et al., 1988). This cell line exhibits characteristics of 
more mature monocytes, and can also be stimulated to acquire macrophage-like 
function by addition of PMA (Ziegler-Heitbrock et al., 1994). 
 
The human cell line most widely used as a model to study macrophage differentiation 
and function is THP-1, which currently boasts 9083 papers indexed by PubMed 
(accessed November 2017). The THP-1 cell line was originally established from a 1-
year-old male patient with acute monocytic leukaemia (Tsuchiya et al., 1980). This 
cell line differentiates into a macrophage-like phenotype in response to treatment with 
PMA, which initially inhibits cell growth prior to differentiation by upregulation of 
the cyclin-dependent kinase inhibitor CDKN1A (also known as p21WAF1/CIP1); this, in 
turn inhibits the activating phosphorylation of CDK2. The increase of CDKN1A was 
mediated by an increase in binding of the transcription factor SP1 to the promoter and 
accompanied by an immediate increase in reactive oxygen species (ROS) generation. 
PKC signalling was essential for this response (Traore et al., 2005). Another chemical 
widely used to induce THP-1 differentiation is vitamin D (1,25 dihydroxyvitamin D3). 
However, this results in a less differentiated phenotype based on phagocytosis, loss of 
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proliferation and downregulation of CD11B and CD14, as vitamin D and PMA 
stimulate different cellular pathways in THP-1 cells (Schwende et al., 1996). Thus, 
PMA stimulation is usually used to study macrophage function (Qin, 2012). THP-1 
cells are considered to have a more mature monocytic phenotype than U937 (Altieri 
and Edgington, 1988), but less than Mono Mac 6 cell line (Ziegler-Heitbrock et al., 
1988).  
 
In the parent THP-1 cell line available from the American Type Culture Collection 
(ATCC® TIB-202™), around 50% of cells become adherent in response to PMA 
(Traore et al., 2005). To enable a detailed study of the transcriptomic response to 
PMA, the FANTOM consortium isolated a clonal line that was highly responsive to 
PMA and uniformly differentiated into macrophage-like state (Suzuki et al., 2009). 
The clonal line’s genome has not been sequenced, but its karyotype was established 
by microarray based comparative genomic hybridisation (Adati et al., 2009). This 
method concluded that the karyotype of the THP-1 cell line was 46XY, with minimal 
chromosome aberrations, which are deletions at 6p, 12p, 17p and a deletion on the X-
chromosome, which coincidentally deleted the first few exons of KDM6A (Adati et 
al., 2009). 
 
THP-1 cells are also very useful for the study of leukaemia. Their origin from an acute 
monocytic leukaemia predisposes them to certain genetic changes naturally occurring 
in cancer, such as mutations in multiple tumour suppressor genes (for example TP53 
and PTEN), and MLL fusions (Adati et al., 2009). Information on gene expression 
changes during differentiation could be used to discover drug targets and understand 
more of the biology of this form of cancer. 
 
The THP-1 cell line was selected to use as an experimental system for this project due 
to its high responsiveness to PMA stimulation, homogeneity in genetic background in 
comparison with primary cells from donors, documented successful transfection with 
small interfering RNA (siRNA) (Suzuki et al., 2009, Maess et al., 2011), published 
previous transcriptomic data (Suzuki et al., 2009), and a wide ranging scientific 
audience potentially interested in detailed characterisation of this differentiation 
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process, from those using THP-1 cells as models for macrophages to those interested 
in the biology and treatment of haematopoietic cell cancers. 
 
1.4 Transcriptomic analysis of monocytes and macrophages 
Many genome-wide methods of analysis of gene expression have been implemented 
in study of monocytes and macrophages. Such studies are usually part of large datasets 
studying various primary cells, for example HaemAtlas examining microarray 
expression data in blood cells (Watkins et al., 2009). Both the epigenome and the 
transcriptome of primary monocytes compared with primary macrophages has been 
analysed extensively (Wallner et al., 2016, Saeed et al., 2014, Martens and 
Stunnenberg, 2013, ENCODE, 2012). The THP-1 transcriptome was also previously 
studied, for example recently after vitamin D3 stimulation by RNA sequencing 
(RNAseq) (Neme et al., 2016).  
 
However, previous studies did not address the dynamic process of change in gene 
expression during monocyte to macrophage differentiation, as in general only the 
difference between these two types of cells and no intermediate states were 
investigated. 
 
1.4.1 FANTOM (Functional annotation of mammalian genome) 
One study which looked at the progression of changes in gene expression during THP-
1 differentiation time course in response to PMA was that of the FANTOM4 
consortium. This uncovered the transcriptional network using genome scale 5’ RACE 
(rapid amplification of cDNA ends) (Suzuki et al., 2009). They termed this method 
cap analysis of gene expression (CAGE). CAGE is a high-throughput method for 
transcriptome analysis utilising a cap-trapping technique, in which short tags (27 nt 
long) at the 5’ end of RNA transcript are sequenced (Takahashi et al., 2012). This 
technique relies on biotinylation of the methylguanosine cap, which is characteristic 
for RNA polymerase II transcripts (Carninci et al., 1996). By isolating RNA 
containing the 5’ cap, the TSS of individual transcripts can be precisely tracked (see 
Figure 2-1; further details of the CAGE methodology are given in section 2.2.6). The 
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analysis of CAGE data provides information not only on the base-pair resolution of 
TSS across the genome but also on the number of individual transcripts at TSSs, 
(Forrest et al., 2014). Thus, CAGE data can be used to characterise various functional 
elements, such as promoters (Forrest et al., 2014), and enhancers (Andersson et al., 
2014, Arner et al., 2015), as well as quantifying expression from specific promoters to 
develop a transcriptomic atlas of gene expression across cell types or states. 
 
In an initial analysis, the FANTOM4 dataset of THP-1 differentiation in response to 
PMA (Suzuki et al., 2009) was used to investigate the expression pattern of the 
chromatin modifying enzyme genes. The datasets are available at 
http://fantom.gsc.riken.jp/zenbu/. The time course examined samples taken at 0, 1, 4, 
12, 24 and 96 hours after stimulation with PMA. These results showed a peak in the 
mRNA levels for KDM6B and USP12 around four hours after initiation of 
differentiation, with almost no change in levels of expression for BAP1, USP16 or 
UTY (Figure 1-3, Figure 1-4). However, the FANTOM4 time course lacked time points 
at critical stages in the differentiation, between one and four hours (when both KDM6B 
and USP12 were upregulated), between four and 12 hours (when KDM6B was 
downregulated) and between 12 and 24 hours (when USP12 was downregulated).  
 
The most recent phase of the FANTOM collaboration released a set of promoter and 
enhancer expression patterns for single time point static samples for nearly 1,000 
human samples as well as time courses of cellular state changes in various systems 
(Forrest et al., 2014, Arner et al., 2015). In this data, USP12 and KDM6B mRNA levels 
also increased drastically in a time course of human primary macrophages (derived 
from peripheral blood monocytes) stimulated by lipopolysaccharide (LPS) (Baillie et 
al., 2017) (Figure 1-5). These results support the results of an earlier study, where 
THP-1 derived macrophages stimulated by LPS also showed more than 2-fold increase 
in USP12 (Iglesias et al., 2012). The FANTOM5 data was also explored in relation to 
epigenetic regulators in haematopoiesis (Prasad et al., 2014). 
 
These results from the two FANTOM studies indicate that at least some of the 
chromatin modifying enzymes are regulated in monocytes undergoing differentiation 
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and macrophages responding to LPS. However, the depth of study for the THP-1 time 
course was hampered by the lack of key time points and the relatively low depth of 
sequencing available at that time. Therefore, further detailed study of the THP-1 gene 
expression in differentiation and the effect of chromatin modifying enzymes is likely 
to reveal additional information about key processes relating to cessation of 
proliferation and maturation into macrophages. 
 
The main hypothesis of this project is that the activity and certain level of various 
chromatin modifying enzymes is crucial for monocyte to macrophage differentiation. 
Due to the fact that the gene expression of these enzymes seems to be tightly regulated 
in the THP-1 differentiation, inhibition of their activity or regulation of their level of 
expression should prevent the repressive epigenetic marks to be removed efficiently, 




Figure 1-3 FANTOM4 time course of PMA-induced THP-1 differentiation for deubiquitinases analysed in 
this study. X axis shows the time points. Y axis shows normalised expression levels, in Tags per million. 
Three replicates are shown. mRNA levels increase for USP12 at around 4 hours after initiation of 
differentiation, whereas the levels for BAP1 and USP16 do not appear to change significantly. 
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Figure 1-4 FANTOM4 time course of PMA-induced differentiation of THP-1 for demethylases analysed 
in this study. X axis shows the time points. Y axis shows normalised expression levels, in Tags per 
million. Three replicates are shown. mRNA levels increase for KDM6B but not for UTY. KDM6A is not 
expressed in THP-1 cells due to a deletion of first few exons. 
 
Figure 1-5 LPS treatment of monocyte-derived macrophages. X axis shows the time points. Y axis shows 
normalised expression levels, in Tags per million. Results for three different human donors are shown. 
mRNA levels for USP12 peak at around 3 hours after LPS treatment, whereas KDM6B mRNA levels are 
highest slightly earlier for donor 2 and similar to USP12 for the other donors. On the right, various 
unstimulated monocyte controls from FANTOM5 are shown at the same scale as the time course, with 
KDM6B having variable levels for various monocyte samples, while USP12 levels are less than 20% of 
the peak level in activated monocytes. 
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1.5 Aims and objectives of this thesis 
A primary objective of this thesis was to obtain detailed knowledge of the 
transcriptomic changes involved differentiation of the cells. This study used THP-1 
monocyte to macrophage differentiation as an experimental model, with data primarily 
generated by the CAGE technique, with the emphasis on the different chromatin 
modifying enzymes (Chapter 3). Addition of multiple time points not covered in the 
FANTOM4 study, especially in the 24 hours of the time course, and the greater depth 
of sequencing possible following technical advances in next generation sequencing, 
bring more resolution into the whole picture of the interplay between repression and 
activation of genes in differentiating cells.  
 
The second part of the study (Chapters 4, 5 and 6) details the bioinformatics analyses 
of publicly available database data for H2Aub deubiquitinases (Chapter 4) and 
H3K27me3 demethylases (Chapter 5). This knowledge is used to assess the impact on 
the monocyte to macrophage differentiation when the level of activity of these 
chromatin modifying enzymes is affected either by RNA interference or enzyme-
specific inhibitors (Chapters 4 and 5). In addition, the relationship between UTY and 
KDM6A is explored in Chapter 5 using various bioinformatic methods. Due to the fact 
that using RNA interference to knock down gene expression produced variable results 
(Chapters 4 and 5), the last experimental chapter asks the question whether knocking 
out these genes using the CRISPR-Cas9 genome editing system affects the THP-1 
differentiation and if it is suitable to use in this type of cell line. 
 
The impact of this study is to characterise the monocyte to macrophage transition in 
this model system in depth and highlight the potential roles of chromatin modifying 
deubiquitinases and demethylases, which may lead to therapeutic targets as well as 
greater understanding of the transcriptomic changes in the innate immune system. 
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Chapter 2: General Materials and Methods 
 
This chapter presents the materials and methods that were used throughout the 
experiments presented in this thesis. More detailed and experiment-specific materials 
and methods are provided in the relevant chapters. All water used, if not mentioned 
otherwise, was Ultra Pure™ DNase/RNase free distilled water by Gibco (now Thermo 
Fischer Scientific/Invitrogen, Paisley, UK). 
 
2.1 Cell line and THP-1 differentiation assay 
THP-1 cells (clone 5, from FANTOM4 consortium, passage number 8, provided by 
Dr Mark Barnett, The Roslin Institute, UK) were cultured in sterile-filtered (0.2 µm) 
RPMI 1680 medium with HEPES modification (25 mM HEPES + NaHCO3) (R5886 
Sigma-Aldrich, Gillingham, UK), 10% heat inactivated foetal bovine serum (FBS, GE 
Healthcare, PAA laboratories, Pasching, Austria), 1x Glutamax (35050-038, Gibco), 
1 mM sodium pyruvate (11360-039, Gibco), 1x MEM non-essential amino acids 
solution (11140-035, Gibco), 50 µM 2-mercaptoethanol (31350-038, Gibco) and 
penicillin-streptomycin (16 U/ml and 16 µg/ml, Gibco) (later referred to as THP-1 
medium). Cells were incubated at 37°C, 5% CO2 and their concentration was 
maintained between 2x105 – 8x105 cells per ml by splitting in half three times a week.  
 
For THP-1 differentiation assays, THP-1 cells were grown up at a low passage number 
(typically p10-13). The day before the start of the differentiation, cells were counted 
by haemocytometer and for each time point between 3x106 and 5x106 cells were 
pelleted and resuspended in 10 ml fresh medium. THP-1 cells were then differentiated 
by adding 30 ng/ml (48.6 nM) phorbol 12-myristate 13-acetate (PMA; P1585, Sigma-
Aldrich) in DMSO. The cells were plated on a Sterilin plate (without tissue culture 
treatment of the plastic), and after 4-6 hours of differentiation, the cells were lifted off 
by flushing with a blunt-end needle syringe. 
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2.2 Gene expression analysis 
2.2.1 RNA extraction and DNase I treatment 
RNA was extracted from pelleted cells using RNABee (AMS Biosciences, 
Frienswood, TX, USA) or TRIzol (ThermoFischer Scientific) according to the 
manufacturers’ instructions. Cells were pelleted and resuspended in 1 ml RNABee or 
TRIzol, then frozen down to -80°C. The protocol was resumed later at a suitable time. 
The cells in RNABee or TRIzol were defrosted on ice, 0.2 ml pure chloroform was 
added and the tube was vortexed for 30 seconds. The samples were stored on ice for 5 
minutes and centrifuged at 12,000 x g for 15 minutes at 4°C. The top aqueous phase 
was transferred to a clean tube, 0.5 ml isopropanol was added and the sample was 
incubated for 10 minutes at room temperature. Samples were again centrifuged at 
12,000 x g for 15 minutes at 4°C. The pellet was washed twice with 1 ml 75% ethanol 
and centrifuged again for 5 minutes at 4°C. The pellet was air-dried and resuspended 
in 50 µl water. 
 
The RNA samples were then treated with DNase I according to manufacturer’s 
instructions (Ambion DNase kit AM1906, Thermo Fischer Scientific) by adding 5 µl 
10x DNase I buffer and 1 µl rDNase I to the RNA. Samples were incubated at 37°C 
for 20 minutes, and then mixed with 5 µl DNase inactivation reagent to stop the 
reaction. RNA was incubated for 2 minutes at room temperature and centrifuged at 
10,000 x g for 1.5 minutes at 4°C. The supernatant containing the RNA was moved to 
a fresh tube.  
 
The RNA was precipitated with 5 µl (0.1 of the volume) 3 M sodium acetate and 100 
µl (2 volumes) 100% ethanol and frozen at -20°C (short term, usually overnight)  or 
-80°C (long term, more than one day). Finally, the sample was centrifuged to pellet 
the RNA which was then washed with 75% ethanol. The pellet was air-dried and again 
resuspended in 50 µl water. 
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2.2.2 RNA concentration and quality check 
The concentration of RNA was measured using a NanoDrop spectrophotometer ND-
1000 (Nanodrop technologies, Wilmington, DE, USA) and quality was assessed using 
the Agilent RNA ScreenTape System (Agilent Technologies, Santa Clara, CA, USA) 
according to the manufacturer’s instructions. The reagents were allowed to warm to 
room temperature 30 minutes before usage. 1 µl RNA was mixed with 5 µl sample 
buffer by vortex at 2000 rpm for 1 minute at room temperature. Afterwards, the 
samples were centrifuged and incubated at 72°C for 3 minutes and at 4°C for 2 
minutes. The samples were then run on the TapeStation 2200 apparatus. The RINe 
value (RNA compactness value) measured the integrity of the RNA by comparing the 
ratio of 18S and 28S rRNA (Schroeder et al., 2006). Only RNA samples with values 
around or above 8 (out of 10) were used for CAGE sequencing.  
 
2.2.3 cDNA synthesis 
The Superscript III Reverse Transcriptase protocol was adapted from manufacturer’s 
instructions as follows: 500 ng DNase I treated RNA was used, together with 2 µl 
random primers (50 ng/µl, Invitrogen, Paisley, UK) and 1 µl dNTPs (10 mM, 
Invitrogen), with water to top up the reaction to 13 µl. The RNA with random primers 
was denatured at 65°C for 5 minutes and then cooled at 4°C for at least 1 minute. 
Afterwards, 4 µl 5x first strand buffer (Invitrogen), 1 µl 0.1 M DTT (Invitrogen, 
Canada), 1 µl RNAsin Plus (Promega, Madison, WI, USA) and 1 µl Superscript III 
Reverse Transcriptase (RT; Invitrogen) were added to the mixture. RT negative 
control was prepared using RNAse-free water instead of RT. The cDNA synthesis 
reaction was incubated at 25°C for 5 minutes, 50°C for 60 minutes, and finally 70°C 
for 15 minutes to stop the reaction. 
 
2.2.4 qRT-PCR 
Before Quantitative Polymerase Chain Reaction (qPCR), the cDNA was diluted 1:1 
with 20 µl water. The concentration of cDNA, if starting from 500 ng RNA, was 
estimated to be 12.5 ng/µl. 
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To establish standard curves for different primers, cDNA from THP-1 RNA was 
diluted three times. The first point of the standard curve was undiluted cDNA 
(estimated 12.5 ng/µl), then 1:1 (estimated 6.25 ng/µl), then 1:4 (estimated 3.125 
ng/µl) and 1:8 (estimated 1.5625 ng/µl). 
 
qPCR was used to assess the levels of gene expression and validate the results from 
CAGE. qPCR was carried out using standard Roche protocols for SYBR Green 1 
Master Mix with Light Cycler 480 96-well white plates (Roche, Mannheim, 
Germany). For 20 µl reaction, 10 µl SYBR Green 2x (Roche) was mixed with 7 µl 
PCR-grade H2O (Roche) and 1 µl forward and reverse primers (10mM each, see Table 
2-1). 2 µl cDNA was then added to the well (25 ng cDNA in total). RT negative and 
no cDNA (just H2O) controls were used with every run for every primer set master 
mix.  
 
The settings for all qPCR analyses (both quantification and melting curves for primers) 
were as follows: pre-incubation was carried out at 95°C for 5 minutes (ramp rate 
4.40°C/second), then amplification steps were repeated for 45 cycles. Amplification 
steps were as follows: 95°C for 10 seconds (ramp rate 4.40°C/second), 60°C for 15 
seconds (ramp rate 2.20°C/second) and 70°C for 30 seconds (ramp rate 
4.40°C/second). Afterwards, the melting curve for primers was measured by 
incubating at 95°C for 5 seconds (ramp rate 4.40°C/second), 65°C for 1 minute (ramp 
rate 2.20°C/second) and then the temperature was increased to 97°C by 0.11C°/second. 
At the end, the plate was cooled for 30 seconds at 40°C.  
 
All qRT-PCR analysis was carried out using the Advanced Quantification setting of 
the Light Cycler 480 Roche software. ∆Ct was calculated with previously established 
values of primer efficiencies from standard curves (calculated using the same software, 
by using Abs Quant/2nd Derivative Max setting). 
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Gene Target Sequence 5' - 3' Slope value 
ACTB_F ATTGCCGACAGGATGCAGAA -3.398 
ACTB_R GCTGATCCACATCTGCTGGAA   
GAPDH  Qiagen -3.498 
MYB_ex5-6_F ACAGATGGGCAGAAATCGCA -3.483 
MYB_ex5-6_R GCAGGGAGTTGAGCTGTAGG   
CD14_ex2-3_F TAAACTGTCAGAGGCAGCCG -3.345 
CD14_ex2-3_R TCGTCCAGCTCACAAGGTTC   
BAP1_ex3-4_F GGGTGCAAGTGGAGGAGATC -3.316 
BAP1_ex3-4_R TAGAGACCTTTCGCCGGGA   
KDM6B_ex3-4_F GGAGGCCACACGCTGCTAC -3.442 
KDM6B_ex3-4_R GCCAGTATGAAAGTTCCAGAGCTG   
USP12_ex6-7_F GCAGCAAACAGGAAGCACAC -3.366 
USP12_ex6-7_R AGGTCGTACATTCTGTCTGGA   
USP16_ex4-5_F TGCCAAGACTGTAAGACTGACA -3.543 
USP16_ex4-5_R TGGCGTCAGATAGTGCTTCA   
USP16_ex15-16_F AGTATGCACACGGAGACAGT -3.528 
USP16_ex15-16_R AGAGTAAGAACAGGAGGAGCA   
USP16_ex17-18_F CCTACGCAAAGTTAACAAACACA -3.014 
USP16_ex17-18_R GTGTAATGCCCCGACCTCAT   
UTY_F GGAACAACTGCGAGCAAATAG -3.270 
UTY_R TGCTGCATTAAGACAAACTGACT   
Table 2-1  qPCR primers and efficiencies. The slope value for each primer set was calculated from 
standard curves using LightCycler 480 Roche software 
2.2.5 Primer validation and optimisation 
Two sets of primers for two different housekeeping genes were used in this study. The 
first one was designed for the human beta actin gene (ACTN) by Maess et al. (2010); 
the second for GAPDH was purchased from Qiagen (QuantiTect Primer Assay, 
QT0112646, Hilden, Germany). The rest of the primers were designed to span an 
intron, to have melting temperature (Tm) of 60°C and to generate a cDNA product of 
approximately 200bp using Primer3 programme (http://primer3.ut.ee/). The ideal 
slope value from standard curves is around -3.345 when the primer efficiency is 2, but 
values from -3.0 to -3.5 were considered acceptable (Table 2-1).  
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2.2.6 CAGE (Cap Analysis of Gene Expression) 
Each CAGE library was made from 7 or 8 samples of 5 µg RNA each, following a 
protocol adapted from Takahashi et al. (2012). All the primer sequences were taken 
from Takahashi et al. (2012). A list of oligonucleotide sequences is located in 
Appendix 8.1 and they were all synthesized by IDT (Coralville, IA, USA). They were 
prepared with help of Lucas Lefèvre (The Roslin Institute) according to the Takahashi 
et al (2012) protocol. 
 
For each sample, 5 µg RNA was concentrated to 5.3 µl using a vacuum concentrator 
(Speed Vac, RC 10.22, Jouan SA, Saint-Herblain, France). This was mixed with 2.2 
µl 210 µM (2 µg/µl) RT-N15-EcoP primer (7.5 µl total) and incubated at 65°C for 5 
minutes then cooled on ice immediately. This RNA-primer mix was reverse 
transcribed to produce a cDNA/RNA duplex by adding the components detailed in 
Table 2-2 and incubating at 25°C for 30 seconds, 42°C for 30 minutes, 50°C for 10 
minutes, 56°C for 10 minutes, and 60°C for 10 minutes.  
 
Component Volume (µl) Final concentration 
PrimeScript buffer (TAKARA 
Clontech, Otsu, Japan) 
7.5 1x 
dNTPs (10 mM each, Invitrogen) 1.87 0.5 mM each 
Sorbitol (3.3 M)/(0.66 M) trehalose 
mix solution (kindly provided by 
Lucas Lefèvre) 
7.5 0.66 M/0.132 M 
PrimeScriptTM reverse transcriptase 
(200 U/µl; TAKARA Clontech) 
3.75 750 U 
Water 9.38 - 
Total Volume 30 - 
Table 2-2 CAGE: Reverse transcription of RNA 
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Figure 2-1 CAGE library preparation. Total RNA from cells is reverse transcribed with random primers 
with an EcoPI site (1). Next, NaIO4 oxidises diol groups (2) to open them so the biotin can attach to the 
cap (3). The ssRNA on the ends is digested and the biotin-labelled cap with cDNA/RNA hybrid is captured 
by streptavidin beads (4). The cap is deattached, the RNA is digested, and 5’ linker with a barcode and 
EcoP15I site is attached (5). Second strand of cDNA synthesized and prior to endonuclease digestion, 
phosphates are removed by Antarctic phosphatase to prevent nonspecific binding of 3’linker in the further 
step (6). EcoP15I cleaves 27 nt downstream, leaving only 5’linker with 27 nt of cDNA, to which 3’ end 
another linker is attached. Excess linkers need to be removed by vigorous washing steps (7), otherwise 
PCR amplification picks up high levels or linker DNA (8). Lowest possible number of PCR cycles is 
chosen (from 9 to 11, usually 10) to reduce PCR bias (8).   
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To purify these cDNA/RNA hybrids, Agencourt RNAClean XP beads (ratio 1.8 
to sample; Beckman Coulter, Indianapolis, IN, USA) were used according to 
manufacturer’s instructions. The mix of beads and samples were incubated at room 
temperature for 30 minutes, mixing 10 times every 10 minutes. A 96-well magnetic 
stand (DynaMag 96-slide, Life Technologies, USA) was used to separate the beads 
from the supernatant and to perform two washes with 150 µl 70% ethanol. To elute, 
40 µl water was heated to 37°C and mixed thoroughly with the beads. This mix was 
incubated at 37°C for a minimum of 5 minutes. The magnetic stand was used to 
separate the beads from the eluate containing the cDNA/RNA hybrids, which were 
transferred to a new tube.   
 
The 3’ end of the RNA and the 7-methylguanylate cap on the 5’ end were diol oxidated 
using 250 mM NaIO4 (0.053 g NaIO4 in 1 ml water; Sigma-Aldrich) according to 
Table 2-3. The reagents were mixed and incubated on ice for 45 minutes in darkness. 
 
Component Volume (µl) Final concentration 
RNA-cDNA hybrid 40 - 
Sodium acetate (1 M, pH 4.5, sterile-
filtered) 
2 45.7 mM 
NaIO4 (250 mM) 2 11 mM 
Total volume 44 - 
Table 2-3 CAGE: Diol oxidation 
Following incubation, 2 µl 40% (wt/vol) glycerol (Fischer Scientific, Waltham, MA, 
USA) was added to stop the oxidation reaction. 14 µl 1 M Tris-HCl (pH 8.5, sterile-
filtered) was then added to bring the pH above 5.6 (total volume 60 µl). The 
cDNA/RNA hybrids were purified again with Agencourt RNAClean XP beads as 
above.  
 
Biotin was added to the RNA diols using 15mM biotin hydrazide (long arm; 0.0038g 
in 675µl water; Vector Laboratories, Burlingame, CA, USA) by mixing the reagents 
in Table 2-4 and incubating at 23°C overnight. 
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Component Volume (µl) Final concentration 
Purified oxidated cDNA/RNA 
hybrids 
40 - 
Sodium citrate (1M, pH 6.0, 
sterile-filtered) 
4 70mM 
Biotin hydrazide (long arm, 
15mM) 
13.5 3.5mM 
Total volume 57.5 - 
Table 2-4 CAGE: Biotinylation reaction 
 
The next day, all single stranded RNA was degraded by RNase ONE ribonuclease 
(Promega), mixing the reagents in Table 2-5 and incubating at 37°C for 30 minutes 
followed by 65°C for 5 minutes. This process left only cDNA/RNA hybrids containing 
a biotinylated 5’ cap which were purified with Agencourt RNAClean XP beads as 
above. 
 
Component Volume (µl) Final concentration 
Biotinylation reaction 57.5 - 
Tris-HCl (1 M, pH 8.5, sterile-filtered) 6 86 mM 
EDTA (0.5 M, pH 8.0, Ambion) 1 7.2 mM 
RNase ONE ribonuclease (10 U/µl, 
Promega) 
5 50 U 
Total volume 69.5 - 
Table 2-5 CAGE: RNase digestion 
MPG Streptavidin beads (Takara Clontech) were prepared by mixing 100 µl beads 
and 1.5 µl tRNA (20 µg/µl; prepared by Lucas Lefèvre; transfer ribonucleic acid from 
Escherichia coli, Sigma-Aldrich) per sample, incubating at 4°C for at least an hour 
by continuous mixing. Beads were then separated from the supernatant by magnetic 
stand (SureBeads BioRad, USA) and washed twice with 50 µl per sample wash 
buffer 1 (45 ml 5 M NaCl and 5 ml 0.5 M EDTA pH 8; all wash buffers were prepared 




The tRNA-coated streptavidin beads were used to trap the biotinylated RNA/cDNA 
hybrids. Each purified sample was mixed with 80 µl prepared beads and incubated at 
room temperature for 30 minutes, mixing 10 times every 5 minutes. The beads were 
separated from the supernatant using 96-well magnetic stand and washed 6 times total 
with various buffers: once with 150 µl wash buffer 1, once with 150 µl wash buffer 2 
(3 ml 5 M NaCl, 100 µl 0.5 M EDTA pH 8, 46.9 ml water), twice with 150 µl wash 
buffer 3 (1 ml 1M Tris-HCl pH 8.5, 100 µl 0.5M EDTA pH 8, 25 ml 1 M sodium 
acetate pH 6.1, 2 ml 10% (w/v) SDS, 21.9 ml water), and twice again with 150 µl wash 
buffer 4 (500 µl 1 M Tris-HCl pH 8.5, 100 µl 0.5 M EDTA pH 8, 25 ml 1 M sodium 
acetate pH 6.1, 24.4 ml water). 
 
RNA was degraded and the cDNA released from the beads by the addition of 60 µl 50 
mM NaOH solution and incubation at room temperature for 10 minutes, pipetting 
every 2-3 minutes. The solution was then buffered to a lower pH by adding 12 µl ice 
cold 1 M Tris-HCl pH 7.0 (Trizma hydrochloride, Sigma-Aldrich). 
 
The single stranded cDNA was purified with Agencourt AMPure XP beads (1.8x to 
sample ratio; Beckman Coulter) according to manufacturer’s instructions. The beads 
with the samples were incubated at room temperature for 30 minutes, mixing 10 times 
every 10 minutes. The 96-well magnetic stand was used to separate the beads from the 
supernatant and to wash twice with 150 µl 70% ethanol. To elute, 40 µl of preheated 
37°C water was mixed with the beads thoroughly and incubated at 37°C for a 
minimum of 5 minutes. The magnetic stand was then used to separate the beads from 
the eluent containing the cDNA which was transferred to a new tube. 
 
The cDNA was concentrated to 4 µl at room temperature using a centrifugal vacuum 
concentrator as described previously. The cDNA was incubated at 65°C for 5 minutes 
and cooled on ice for 2 minutes. For each sample, 1.5 µl 5’ linker was added to a 
separate tube and incubated at 37°C for 5 minutes then cooled on ice for a minimum 
of 2 minutes. 1 µl of the linker and mixed with 10 µl of DNA Ligation Kit Mighty Mix 
(Takara Clontech) was added to each cDNA sample for incubation at 16°C overnight. 
 
 35 
The next day, the samples were purified twice using Agencourt AMPure XP beads 
as above. In the first purification step, up to 4 samples could be pooled in 1 tube (60 
µl) and 10 µl of water was added. In the second purification step, up to 8 samples total 
could be pooled. Two tubes (4 samples each) were incubated with beads, but at the 
first wash step, 150 µl 70% ethanol was used to wash both wells and the contents were 
mixed. The samples were eluted in 30.5 µl preheated 37°C water. 
 
The second stand was synthesized using La Taq Polymerase, by adding the reagents 
listed in Table 2-6 (including a biotinylated primer) and incubating at 94°C for 3 
minutes, 42°C for 5 minutes, 68°C for 20 minutes and 62°C for 2 minutes. 
 
Component Volume (µl) Final concentration 
10x La Taq buffer (TAKARA 
Clontech) 
5 1x 
MgCl2 (25 mM, TAKARA 
Clontech) 
5 2.5 mM 
dNTPs (2.5 mM, TAKARA 
Clontech) 
8 0.4 mM each 
2nd SOL primer (200 ng/µl) 1 2.4 µM 
La Taq Polymerase (5 U/µl, 
TAKARA Clontech) 
0.5 2.5 U 
Total volume 19.5  
Table 2-6 CAGE: Second strand synthesis 
 
A phosphate group was removed from the 5’ lower linker of the cDNA by adding 6 µl 
10x Antarctic Phosphatase Reaction Buffer and 4 µl Antarctic Phosphatase (5 U/µl). 
The mixture was then incubated at 37°C for 60 minutes followed by 65°C for 5 
minutes. The cDNA was then purified with Agencourt AMPure XP beads as above. 
 
The cDNA was digested by EcoP15I restriction endonuclease which binds to a 
recognition site in the second strand primer and cuts 27 nucleotides into the cDNA. 
The reagents in Table 2-7 were combined, 10 µl master mix was added to 30 µl sample. 
This mix was incubated for 3 hours at 37°C and then put on ice for at least 2 minutes.  
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Component Master Mix (enough for 10 
tubes, µl) 
Final concentration for 1 
sample 
Water  11  
10x NEB buffer 3.1 
(NEB, Hitchin, UK) 
40 1x 
100x BSA (NEB) 4 10x 
10x ATP (10 mM, 
NEB) 
40 1 mM 
Sinefungin (10 mM, 
kindly provided by 
Lucas Lefèvre) 
4 0.1 mM 
EcoP15I (10 U/µl, 
NEB) 
1 1 U 
Table 2-7 CAGE: EcoP15I restriction digest  
After 3 hours, 1 µl MgCl2 0.4 M was added and the mix incubated at 65°C for 20 
minutes then 4°C for 2 minutes. The 3’ linker was ligated to the cDNA by mixing 39 
µl of the mix listed in Table 2-8 and incubating at 16°C overnight (14-16 hours).  
 
Component Volume (µl) Final amount 
5x 3’linker ligation buffer (see 
Table 2-9)  
16  
3’ linker (100 ng/µl) 1 100 ng 
T4 DNA ligase (400 U/µl, NEB) 3 1200 U 
Water 19  
Total volume 39  
Table 2-8 CAGE: 3' linker ligation 
Component Volume (µl) 
Tris-HCl (1 M, pH 7.0, Trizma hydrochloride, 
Sigma-Aldrich) 
50 
ATP (10 mM, NEB) 100 
BSA (10 mg/ml, NEB) 0.5 
Water  49.5 
Table 2-9 CAGE: 5x 3' ligation buffer 
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The next day, 15 µl MPG Streptavidin beads (Takara Clontech) were incubated on 
ice with 1.5 µl tRNA (20 µg/µl) for 30 minutes, mixing them every 5 minutes. The 
supernatant was separated from the beads using magnetic stand, and the beads were 
washed twice with 75 µl of the wash buffer 1. The beads were then suspended in 37.5 
µl wash buffer 1. 
 
The samples were further purified from the 3’ linker using the biotin from the second 
strand primer. 25 µl prepared MPG beads with tRNA were added to 80 µl sample from 
the previous day and incubated at room temperature for 30 minutes, mixing every 5 
minutes. The beads were separated from the supernatant using 96-well magnetic stand 
and washed 7 times total with various buffers: once with 150 µl Wash buffer 1, once 
with 150 µl Wash buffer 2, twice with 150 µl Wash buffer 3, twice again with 150 µl 
Wash buffer 4, and once with 50 µl water. The beads were then suspended in 20 µl 
water and used as the PCR template below. 
 
A PCR reaction was carried out to find out how many cycles were needed to maximise 
the 96 bp product and minimise the amount of linkers (around 70 bp length). One 
reaction mix was prepared as in Table 2-10, and 2 µl of the beads were added to the 
mix.  
 
Component Volume (µl) Final 
concentration 
Water 32.5  
5xHF buffer (Thermo Scientific) 10 1x 
dNTPs (2.5 mM, Invitrogen) 4  0.2 mM 
Forward primer (100 µM) 0.5 1 µM 
Reverse primer (100 µM) 0.5 1 µM 
Phusion Polymerase (2 U/µl, Thermo 
Scientific or NEB) 
0.5 1 U 
Total  48 µl  
Table 2-10 CAGE: final PCR reaction 
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The reaction was incubated in the PCR machine at 98°C for 30 seconds, then 20 cycles 
of 98°C for 10 seconds and 60°C for 10 seconds. The machine was paused after 8, 10, 
12, 14 and 16 cycles to take 4 µl out of the tube quickly. 
 
The optimum PCR cycle number was determined by D1000 ScreenTape (Agilent 
Technologies). The ladder was prepared mixing 3 µl D1000 Sample Buffer with 1 µl 
D1000 ladder, and the samples were prepared by mixing 3 µl D1000 sample buffer 
with 1 µl of the cDNA sample that had been removed at different cycle numbers. The 
samples were vortexed at 2000 rpm for 1 minute, centrifuged, and then analysed on 
the Agilent 2200 TapeStation system. The number of cycles chosen was from 9 to 11, 
usually 10. 
 
Afterwards, the PCR with the optimal number of cycles was repeated in 6 replicates 
as shown in Table 2-10 to generate more product. Three reactions were pooled (150 
µl in total) and 1 µl Exonuclease I (20 U/µl, NEB) was added to each of the 150 µl 
PCR solutions. These two samples were incubated at 37°C for 30 minutes, then the 
Exonuclease I- treated CAGE tags were purified using Minelute PCR purification kit 
(Qiagen), following the manufacturer’s instructions. CAGE tags were then eluted in 
12 µl EB buffer each and the two samples pooled (final volume 24 µl). Quantity and 
quality of the tags was measured using D1000 ScreenTape as described previously. 
 
The libraries were sent to Edinburgh Genomics (Edinburgh, UK) for sequencing on an 
Illumina HiSeq 2500 machine (Illumina) in high throughput mode. One library made 
out of 7 or 8 pooled samples was sequenced on 1 lane, with custom sequencing primer 
and inline barcodes. 
 
2.3 Perturbing gene expression using siRNA  
ON-TARGETplus SMARTpool siRNAs and ON-TARGETplus Control non-
targetting pool (D-001810-10-05) (GE Healthcare Dharmacon, Lafayette, CO, USA) 
were used. Each is a pool of 4 different siRNAs targeting the same gene (Table 2-11) 
to ensure maximal silencing. Non-targeting control (NT) from the same manufacturer 
was also used. 5 nmol were diluted in 250 µl RNase-free water (stock concentration 
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20 µM). Final concentration of siRNA when added to cells was 50 nM (6.25 µl 20 µM 
siRNA for a 6 well plate with 2.5 ml total volume).  
 
A 6-well plate was seeded with 5x105 THP-1 cells per well in 2 ml of THP-1 medium. 
6.25 µl 20 µM siRNA was diluted in 250 µl OPTI-MEM I reduced serum medium 
(Gibco, UK), mixed gently and incubated at room temperature for 5 minutes. 
Meanwhile, 5 µl Lipofectamine 2000 (Invitrogen, USA) was diluted in 250 µl OPTI-
MEM I reduced serum medium, mixed gently and incubated at room temperature for 
5 minutes. The diluted siRNA and diluted Lipofectamine 2000 were combined (final 
volume 500 µl), mixed gently and incubated at room temperature for 20 minutes. The 
mixture was then added to 2 ml of cells before being replaced after 4-6 hours. 
 
The efficiency of the siRNA pools was tested by a preliminary experiment, in which 
the siRNA pool was added at day -1, the differentiating agent (PMA) was added to 
final concentration of 30 ng/ml at day 0, and samples were collected at day 1, 2, 3 and 
7 to examine the level of the target mRNA. 
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Target gene Target sequences Location of target 
sequence 
BAP1 GAUGAUACGUCCGUGAUUG Exon 4 
 CAACCGUGCUGUCCGUGAU Exon 13 
 CCAUCAACGUCUUGGCUGA Exon 13 
 GAGCAAAGGAUAUGCGAUU Exons 5+6 
KDM6B CUGUACAGACCCUCGAAAU Exon 13 
 CAACCGUGCUGUCCGUGAU Exon 14 
 AAAGGGAAGUUUCGAGAGU Exon 12 
 UGGGAGACCAUCAGCGCUU Exon 18 
USP12 UGGAUCAACUUCAUCGAUA Exon 7 
 UAGCAGAUCUCUUCCAUAG Exon 3 
 AGAAGUUCAUCACAAGAUU Exon 3 fw 
 GAAGCACACAAACGGAUGA Exon 6+7 
USP16 CGAAUAAACUGCUUUGUGA Exon 15 
 GUAAGAAUGUUGCAGAAGA Exon 17 
 GGACCAAAGGCAAAUAUAA Exon 15 
 GGCAUUAACAGAACCAUUA Exon 8+9 
UTY GUAUUAAGAAGGCGAAUG Exon 18 
 GCUAGAAGCAAACGUUGUA Exon 12 
 CCAUGGAGAUUCACCAAAU Exon 18 
 GCUAGGCAGUAAUUGUAUA Exon 17 
Table 2-11 siRNA pools used in this study 
 
Following the preliminary siRNA experiments, a larger experiment was set up to 
harvest RNA for CAGE. Each sample was collected by pooling the RNA from 3 wells 
of a 6-well. The siRNA was administered on day -1, PMA (30 ng/ml) was added on 
day 0 and samples were harvested at day 0 (24 hours after siRNA treatment, 
immediately prior to PMA treatment) and day 1 (48 hours after siRNA treatment, 24 
hours after PMA treatment).  
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2.4 Cell culture techniques 
2.4.1 MTT assay 
A 96-well plate was seeded with 2x104 THP-1 cells in 100 µl of media per well. 10 µl 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 5 mg/ml, Sigma 
Aldrich) was added to each well and incubated for 3 hours at 37°C in 5% CO2. Then 
100 µl solubilisation solution (89% (v/v) Isopropanol, 10% (v/v) Triton 100x, 1% (v/v) 
HCl) was added and left at 37°C 5% CO2 overnight. The following day, substrate 
conversion was determined via the optical densities which were measured using a plate 
reader at 570nm. 
 
2.4.2 Propidium iodide staining during the cell cycle 
A pellet of 1x106 THP-1 cells was produced by centrifugation at 400 x g for 5 minutes, 
this was resuspended in 1 ml ice-cold 70% ethanol and left at 4°C for at least 24 hours 
(up to 2 months). On the day of flow cytometry, the cells were centrifuged at 16,000 
x g for 5 minutes, washed twice with PBS (provided by the Roslin Institue core 
services), and 300 µl Cell Cycle Staining Solution was added to the pellet (See Table 
2-12). Samples were incubated in the dark for 1-2 hours and then 300 µl of PBS was 
added prior to flow cytometry. Samples were analysed on a Fortessa cytometer (BD 
Biosciences, Franklin Lakes, NJ, USA) using a 610nm laser. Results were analysed 
using FlowJo software version 10.0.8r1 (Flow Jo LLC, Ashland, OR, USA) by gating 
single viable cells by excluding doublets. Final window showed the histogram of the 
area of Propidium iodide channel, which was examined using the Cell cycle option of 










 Final concentration Volume for 1ml total 
Sodium citrate (0.1 M, kindly 
provided by Dr Mark Barnett, 
The Roslin Institute) 
38 mM 380 µl  
RNase A from Pancreas (1 
mg/ml, Sigma-Aldrich) 
10 µg/ml 10 µl  
Propidium iodide (1 mg/ml, 
Sigma-Aldrich) 
68 µM 45 µl 
Water   565 µl 
Table 2-12 Cell Cycle Staining Solution for propidium iodide staining 
 
2.5 Bioinformatic analysis 
2.5.1 CAGE data quality check, trimming and genome mapping 
The reads were at first split according to their barcodes using perl script split_library.pl 
(Appendix 8.2) which was kindly provided by Dr Lel Eory (The Roslin Institute). The 
quality and length of the reads was assessed using FastQC programme (Andrews, 
2010) and summarized using MultiQC programme (Ewels et al., 2016). The reads 
were then trimmed from nested 5’ and non-nested 3’ adapters using Cutadapt (Martin, 
2011). Single end reads were then aligned to hg38 (downloaded in September 2016 
from UCSC: http://hgdownload.cse.ucsc.edu/goldenPath/hg38/bigZips/, release Dec 
2013) with Burrows Wheeler Alignment (BWA) (Li and Durbin, 2009) using 
commands aln and samse. The files were then converted to bam file using Samtools 
(Li et al., 2009). 
 
2.5.2 Normalisation of CAGE data 
The expression levels (number of reads) were normalised using CAGEr package 
(Haberle et al., 2015) using getCTSS and normalizeTagCount commands with options 
“powerLaw” and a specific alpha value per million tags, which is provided in each 
chapter. The final expression value for each CTSS (CAGE transcription start site) was 
therefore provided as TPM (Tags per million).  
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2.5.3 Visualisation of CAGE data 
The normalised data was then formatted into OSCtable (details found at https://zenbu-
wiki.gsc.riken.jp/zenbu/wiki/index.php/OSCtable), providing chromosome, end, start 
and strand coordinates. A header was included as specified in the Zenbu website (see 
above) and uploaded into Zenbu (found at http://fantom.gsc.riken.jp/zenbu/) (Severin 
et al., 2014). Instructions to access this data are in Appendix 8.10. Normalised 
promoter TPM values were taken from Zenbu browser by manually highlighting the 
promoter region and copy pasting the data into an Excel spreadsheet.  
 
2.5.4 Clustering CTSS  
CTSS were clustered in each sample based on their distance apart using distclu option 
in CAGEr package (Haberle et al., 2015). The settings were as follows, the minimum 
CTSS TPM value was 1, the distance between CTSS was maximum of 20 bp and 
singletons (single CTSS not neighbouring any other CTSS) were not removed. To be 
able to compare the clustered CTSS across different samples, the CTSS range values 
needed to be aggregated. In this step, only the CTSS clusters with expression in at least 
one sample of higher than 5 TPM were kept, the others were filtered. The maximum 
distance between CTSS was kept at 100 bp. These commands created a single matrix 
file with cluster coordinates (start, end, strand) and normalised TPM values for the 
aggregated clusters. 
 
2.5.5 Miru network analysis 
The normalised and aggregated clusters of CTSS were annotated for their gene names 
by Dr Stephen Bush (The Roslin Institute). The gene names together with expression 
values for each sample were uploaded into Miru software (Kajeka Limited, 
Midlothian, UK; https://kajeka.com/download-miru/). Sample to sample correlation 
was created by transposing the data in pre-processing. The correlation graph was 
created at correlation coefficients (R) > 0.75 (R values for each analysis are provided 
in individual chapters) using Fast Multiple Multilevel Method (FMMM) format. Gene 
network analysis created a graph by visualising each node as one aggregated cluster 
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of CTSS. The analysis was done by clustering using a Markov Cluster Algorithm 
(MCL) at inflation value of 2.0, which created clusters of correlated CTSS. 
 
2.5.6 DAVID GO analysis 
The cluster gene lists compiled by Miru were individually entered into the upload tool 
DAVID (Database for annotation, visualisation and integrated discovery), which was 
used to decipher the functional GO (gene ontology) annotation (Huang da et al., 2009). 
OFFICIAL_GENE_SYMBOL was chosen as an identifier for the gene list. The 
background was selected as Homo sapiens, other settings were left as default.  
 
2.5.7 EdgeR 
Differential expression between groups of genes was analysed using EdgeR package 
(Robinson et al., 2010, McCarthy et al., 2012). As EdgeR normalises the data, data 
from CAGEr were left raw (using NormalisedTagCount with option method = 
"none"). CTSS were clustered and aggregated the same way as in section 2.5.4, with 
raw data options. Aggregated clusters matrix was exported into an R object. The two 
time points compared were substracted from the object, and they were uploaded into 
EdgeR by DGEList command. Differential expression was calculated with subsequent 
commands calcNormFactors(), estimateCommonDisp(), estimateTagwiseDisp(), and 
exactTest(). The cut off p-value was 0.01 with command 
summary(decideTestsDGE()). The top hits were displayed with command topTags(). 
 
2.5.8 Shifting promoters  
The shifting promoters score was calculated by CAGEr package using scoreshift() 
command, between two groups of time points. The optional settings were to use 
testKS=TRUE for using Kolomogorov-Smirnov test to calculate the shift and 
useTpmKS=TRUE for using normalised values of the data. The data was subsequently 
filtered to only include promoters with score shift > 0.6 and false discovery rate (FDR) 
threshold lower than 0.01. 
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2.5.9 Statistical tests 
Statistical analyses were done using two sample T-test, for a difference between two 











Chapter 3: Characterising monocyte to macrophage 
differentiation in THP-1 cells 
 
3.1 Introduction 
As discussed in section 1.1.3, cells undergoing a state change have altered gene 
expression patterns, in part mediated by epigenetic changes including histone 
modifications that alter the chromatin state. In their extensive survey of cell state 
transition time courses, Arner et al. (2015) showed that alteration in enhancer 
expression precedes alterations in transcription factor expression which are then 
followed by altered expression of target genes. In particular, the time points considered 
included closely spaced samples in the early stages of the transition to detect changes 
in expression of immediate early genes. The original THP-1 time course paper (Suzuki 
et al., 2009) had a much coarser time course, and would have missed many changes 
that were transient, as well as potentially missing the peak of expression or repression 
of some genes. However, this earlier study did demonstrate differences in expression 
of several chromatin modifying enzymes (section 1.4.1). Therefore, more detailed 
exploration of the time course of THP-1 differentiation was warranted.  
 
The original THP-1 cell line is sensitive to PMA stimulation, but only a subset of the 
cells undergo differentiation in any one experiment. To increase the sensitivity of the 
study and ensure that the majority of the cells would undergo differentiation, the line 
was cloned by limiting dilution and clone 5 was selected for further study (Suzuki et 
al., 2009). This clone of the THP-1 line differentiates relatively homogeneously into 
adherent cells resembling macrophages, and was also used in the present study, to 
ensure comparability with the previous work and achieve a high level of 
differentiation.  
 
CAGE (cap analysis of gene expression) relies on high-throughput sequencing. This 
allowed a high depth of sequencing (called deepCAGE when applied to CAGE 
libraries) that can therefore reveal low level and rare transcripts. The FANTOM4 study 
used the 454 Life Sciences large-scale pyrosequencing approach (Suzuki et al., 2009). 
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Subsequently, for FANTOM5 (Forrest et al., 2014, Arner et al., 2015) the Helicos 
Genetic Analysis System for single molecule sequencing (Thompson and Steinmann, 
2010) of CAGE libraries (HeliScopeCAGE; (Kanamori-Katayama et al., 2011)) was 
used. These two sequencing methods have been superseded by the whole genome 
approach implemented by Illumina, which provides high depth of coverage at a 
relatively low price, and was the sequencing method implemented in the present study. 
 
As shown by the FANTOM5 study (Forrest et al., 2014, Andersson et al., 2014, Arner 
et al., 2015), deepCAGE can detect a range of changes in transcriptional activity, 
including enhancer activation or repression and changes in promoter usage, as well as 
changes in the overall level of expression of a gene. The depth of coverage in the 
earlier study (Suzuki et al., 2009) was not sufficient to identify subtle changes in 
promoter usage or low expression enhancer sequences. Since the THP-1 time course 
using the high differentiation rate clone 5 was not repeated for FANTOM5 (Arner et 
al., 2015). Repeating the study would provide valuable additional insight into this 
popular model of differentiation from monocyte to macrophage. 
 
3.1.1 Aim of this chapter 
The aim of this chapter was to characterise the transcriptional changes associated with 
the monocyte to macrophage differentiation process by stimulating the pro-monocytic 
THP-1 cells with phorbol ester. A focus was on chromatin modifying enzymes. 
Various methods were used to assess differentiation state, from morphology, and cell 
cycle to transcription start site usage and gene expression. A time course of THP-1 
stimulation with PMA was carried out, with 18 different time points subjected to 
CAGE, to show the genome-wide changes in transcription start site usage. This repeat 
of the FANTOM4 THP-1 time course with more time points showed a detailed map 
of hour-to-hour expression, with deeper sequencing technology unravelling new 
previously unknown features of monocyte to macrophage differentiation. 
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3.2 Materials and methods 
3.2.1 THP-1 differentiation assay 
THP-1 cells were grown up at a low passage number (passage number 10-13 of clone 
5, as mentioned in section 2.1). The day before the start of the differentiation (24 
hours), cells were counted by haemocytometer, and around 3-5 x106 cells were 
pelleted and resuspended in 10 ml of fresh medium per time point. All THP-1 cells 
were then differentiated simultaneously by adding 30 ng/ml (48.6 nM) of Phorbol 12-
myristate 13-acetate - PMA (P1585, Sigma-Aldrich) in DMSO. Medium was not 
changed during the experiment, to prevent a serum-specific response during the time 
course. The cells were plated on a 90mm Sterilin plate (without tissue culture treatment 
of the plastic), and the cells were scraped off by washing with a blunt-end needle 
syringe and resuspended in 1 ml of RNABee (AMS Biosciences).  
 
For each experiment, one culture was used to set up two batches of cells. The first 
batch (annotated with .1 in the results and shown in red in Figure 3-1) was treated with 
PMA on the morning of the first day. Time points between 0 and 12 hours were taken 
from this batch. The second batch from the same culture (annotated with .2 and shown 
in blue in Figure 1-1) was treated with PMA in the evening of the first day, which is 
the 0 hour time point from this batch was taken at the same time as the 12 hour time 
point of the first batch. All cells were then incubated overnight. On the morning of the 
second day, the 24 hour time point of the first batch and the 12 hour time point of the 
second batch were taken, followed by time points between 12 and 24 hours taken from 
the second batch. Batches had several overlapping time points (0 hour, 12 hours, 24 
hours and 36 hours) to ensure that cells were at similar state of differentiation. This 




Figure 3-1 Distribution of time points included in the THP-1 time course. The experiments were done in 
two batches. First batch is a circle; second batch is a diamond.  
 
3.2.2 Cell cycle and morphological analysis of the differentiation 
Cell cycle analysis by propidium iodide staining was done as described in section 2.4.2 
and cell morphology was analysed using a fluorescent microscope (Zeiss Vert.A.1, 
Carl Zeiss Limited, Cambridge, UK). 
 
3.2.3 RNA extraction, cDNA production and qRT-PCR 
RNA was extracted using the RNABee method as described in section 2.2.1. CAGE 
sequencing was verified by assessing gene expression levels of important 
differentiation markers using qRT-PCR as described in section 2.2.4. 
 
3.2.4 CAGE 
Samples for CAGE were chosen to have multiple replicates per time point, including 
the time points used in the FANTOM4 study (Suzuki et al., 2009) and covering the 
important time points for myeloid differentiation missed in that study. After taking 
into consideration RNA quality and quantity (Appendix 8.3), 18 time points with 




Figure 3-2 Time points chosen for CAGE. Numbers indicate hours. Underlined time points were also in 
the original FANTOM4 study. 
 
CAGE was performed as described in Chapter 2. Results for 66 samples were uploaded 
into the CAGEr programme (Haberle et al., 2015) (Appendix 8.3). All 66 samples 
were normalised together using CAGEr using the power law with an alpha of 1.17, 





3.3.1 Characterisation of the THP-1 differentiation time course  
The differentiation of THP-1 cells (section 3.2.1) was carried out 5 different times to 
harvest RNA for CAGE sequencing. To ensure that differentiation from monocyte to 
macrophage phenotype had occurred, changes in morphology and attachment to the 
culture vessel surface were examined for each time course. 
 
3.3.1.1 Morphological changes 
Undifferentiated THP-1 monocyte-like cells grew in suspension, with most cells not 
touching the bottom surface of the vessel (as seen in the first picture in Figure 3-3). 
Stimulation with 30 ng/ml of PMA induced the THP-1 cells to start to adhere around 
6 to 8 hours, with all cells definitely attached to the bottom of the vessel at 12 hours. 
After this, the cells started to change their morphology to more macrophage-like cells, 
with the most dramatic difference observed at 48 or 96 hours. Their shape changed 
from being round to more variable and the cytoplasm contained more phagocytic 
vacuoles. There were a few cells where the morphology indicated they were more 
mature macrophages than the majority at that time point (for example as shown by the 
white arrow in the 18 hour time point in Figure 3-3). More than 99% cells were 
adherent and had similar morphology by the end of the time course.  
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Figure 3-3 Differentiation of THP-1 Clone 5 cells over time after PMA stimulation. Scale bar is 200 µm. 
White arrow shows macrophage of more mature morphology than the others at the same time point. 
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3.3.1.2 Cell cycle analysis 
As described in Chapter 1, THP-1 cells should cease proliferation upon stimulation 
with PMA to differentiate into macrophages. To validate that this was the case in these 
experiments of THP-1 differentiation with PMA, the cell cycle of the THP-1 cells was 
analysed using propidium iodide staining. 
 
Firstly, the cell cycle of non-synchronised THP-1 monocytes was assessed (Figure 
3-4). THP-1 cells were found in all three stages of the cell cycle, with the majority of 
the cells in G1 (growth) phase, followed by DNA synthesis phase (S-phase) and fewest 
cells were found in G2 phase, preparing for mitosis.  
 
 
Figure 3-4 Cell cycle analysis of THP-1 cells without PMA stimulation. Highest number of cells were in 
G1 phase (purple), followed by S-phase (orange) and least amount of cells were in G2 phase (green). 
Data was analysed using FlowJo, Watson model (pragmatic) (section 2.4.2). Pie chart shows the 
proportion of cells in each phase. Histogram of number of cells in each phase is taken from FlowJo 
software, with X axis showing histogram parameter of propidium iodide fluorescence-A (Area), Y-axis 
shows cell count. 
 
The cell cycle profile of THP-1 cells drastically changed after PMA stimulation 
(Figure 3-5). After 10 hours, the cell count found in the beginning of S-phase started 
to diminish (red arrow), cells stopping their cell cycle at G1/S checkpoint. At 24 hours, 
there were almost no cells left in S-phase, with majority of cells in G1 phase. Cells did 
not enter the S-phase for the remainder of the experiment and their proportion stayed 
the same. As shown by the pie charts in Figure 3-5, the proportion of cells in G2 phase 
decreased from 24 hours to 48 hours, with an increasing proportion found in G1 phase. 
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Figure 3-5 Cell cycle analysis of THP-1 cells, 10, 24, 30 and 48 hours post stimulation with PMA. Data 
was analysed using FlowJo, Watson model (pragmatic). Pie chart shows the proportion of cells in each 
phase. Red arrow shows the G1/S stage where the population of cells diminished after 10 hours of PMA 
stimulation. Histogram of number of cells in each phase is taken from FlowJo software, with X axis 
showing histogram parameter of propidium iodide fluorescence-A (Area), Y-axis shows cell count. 
 
3.3.2 CAGE sequencing 
3.3.2.1 RNA extractions and choosing samples for CAGE 
RNA samples from the time courses were assessed for quality (RINe score) and 
quantity (concentration). Taking together all the information, 66 samples were selected 
for CAGE library preparation (highlighted green in Figure 3-6). Samples which are 
highlighted red did not have sufficient RNA quality or quantity. RINe scores of each 





Figure 3-6 CAGE data points together with RINe number and recognised reads in CAGEr. Red X data 
entries denote insufficient RNA quality or quantity. Samples in green cells were used for CAGE. Black 
cells indicate that there was no sample for that time point. 
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3.3.2.1 CAGE sequencing quality assessment 
RNA samples were successfully made into CAGE libraries. The CAGE product was 
amplified using PCR with the lowest number of cycles to give an adequate amount of 
product. The amount of final PCR product (at around 97 bp) was assessed using the 
Agilent TapeStation (section 3.2.4), as shown in a typical graph in Figure 3-7. All 




Figure 3-7 Tapestation results of fifth CAGE library after 10 PCR cycles. Lower and upper markers used 
by the system to estimate fragment lengths are shown. CAGE tags are the highest product peak, at 
around 97 bp long. Arrow points to the smaller peak at 75 bp. 
 
The resulting sequences were sorted according to their barcode for each library, and 
their 5’ and 3’ barcodes trimmed off bioinformatically. Unfortunately, one barcode 
(CTT) seemed to have a large amount of sequences that had to be discarded due to 
their short length (see Appendix 8.3). FastQC analysis revealed that samples with this 
barcode had a high number of overrepresented sequences (sequences which are found 
in high numbers, indicating potential library contamination), which mostly belonged 





Figure 3-8 Overrepresented sequences in 8 barcodes in CAGE library number 3. Image created with 
MultiQC using FastQC data. 
 
By the time this problem became apparent, 6 libraries had been sequenced or already 
prepared. The contamination was determined to be due to a faulty oligonucleotide 
containing CTT barcode (Dr Lel Eory, personal correspondence, 2017), and the CTT 
barcode oligonucleotide was remade for the last few libraries (ninth and tenth). This 
seemed to reduce the amount of overrepresented sequences (Figure 3-9). The CTT 




Figure 3-9 Percentage of overrepresented sequences in CTT barcoded samples in ten CAGE libraries. 
Image created with MultiQC using FastQC data. 
 
Trimmed sequences were mapped to the human genome version hg38 (Yates et al., 
2016). The number of mapped reads in 94 samples (from both Chapter 3 and Chapter 
6) was very variable. The number could be as high as 33 million reads, or as low as 
around 3 million (Figure 3-10). The median value was around 9 million mapped reads. 
 
 
Figure 3-10 Box plot of all mapped reads from CAGE analysis showing maximum, interquartile ranges, 















Box Plot of all mapped CAGE reads
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CAGE reads from the 66 samples analysed in this chapter were imported into the 
CAGEr programme and normalised against each other with the resulting value being 
in Tags per million (TPM), i.e. how many of the specific tags (reads) are found in one 
million reads. These CAGE tags indicated CAGE transcription start sites (CTSS) 
which were aggregated together according to their TPM values and distance between 
each other, into individual group clusters. These aggregated CTSS were annotated with 
the name of the gene closest to the middle of the CTSS.  
 
3.3.2.2 THP-1 differentiation markers and qPCR validation of key enzymes 
To ensure the differentiation of THP-1 cells from pro-monocytic to macrophage-like 
phenotype was confirmed also at the transcriptional level, CAGE sequencing data was 
checked for two relevant markers, MYB which encodes a transcription factor 
associated with proliferating haematopoietic cells (reviewed by Zhou and Ness (2011)) 
and monocyte differentiation antigen gene CD14 (Bazil et al., 1982, Wright et al., 
1990). CAGE results were also simultaneously validated by qRT-PCR of the same 
genes by testing the RNA the CAGE libraries were made from.  
 
MYB was downregulated during THP-1 differentiation in the earlier study (Suzuki et 
al., 2009). In the present study, MYB expression was found to decrease after PMA 
stimulation in all biological replicates, with the lowest point being at 3 hours (Figure 
3-11). qRT-PCR experiments showed a similar pattern, where MYB was also 
downregulated, with the lowest level at between 2:30 and 3 hours (Figure 3-12). Note 
that qRT-PCR was carried out on all samples taken from the THP-1 differentiation 
experiment, not just the 18 time points selected for CAGE sequencing.  
 
Expression of CD14, which was not expressed at all in undifferentiated THP-1 clone 
5 cells (Bosshart and Heinzelmann, 2016), was found to be very highly upregulated in 
the last few points of the time course (Figure 3-13) according to CAGE sequencing. 




Figure 3-11 MYB expression in THP-1 differentiation based on CAGE sequencing showing all biological 
replicates. Data is normalised to Tags per million (TPM).  
 
 
Figure 3-12 MYB expression in the whole THP-1 differentiation time course (all time points taken) based 
on qRT-PCR. Pictured here is the MYB expression normalised to ACTN expression and error bars 




Figure 3-13 CD14 expression in THP-1 differentiation based on CAGE sequencing showing all biological 
replicates. Data is normalised to Tags per million (TPM). Note that the Y axis is in logarithmic scale. 
 
Figure 3-14 CD14 expression in the whole THP-1 differentiation (all time points taken) based on qRT-
PCR. Note that the Y axis is in logarithmic scale. Pictured here is the CD14 expression normalised to 
ACTN expression and error bars showing standard error (based on two technical replicates and 
calculated by the by Roche LightCycler 480 software). 
CAGE sequencing data (validated by qRT-PCR) indicated that the THP-1 cells had 
differentiated, and the quality and quantity of reads were deemed satisfactory. Thus, 
the next few sections of this chapter deal with analysis of this data, using various 
bioinformatic tools, looking for waves of gene activation and repression across the 
large number of tight time points in the time course and any additional information 
that could be found due to deep sequencing of the samples. 
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3.3.3 Clusters of CTSS throughout differentiation  
CAGE sequencing data values were loaded into the network analysis tool Miru 
(section 2.5.5) to find patterns of gene activation and repression across the time course. 
Firstly, a sample-to-sample network of all 66 samples with 18 different time points 
was created using a correlation coefficient of 0.92 or higher. (Figure 3-15). The 
samples at the beginning of the differentiation (0 hours, deep purple) are at the other 
end of the network from the fully differentiated THP-1 cells at 96 hours (deep red). 
The graph shows that the samples followed the differentiation pattern by hour, as for 
example samples of 0 hour are mostly correlated to 1 hour sample and so on. There 
are few exceptions, most notably 2 points of 4 hours (blue) samples (Dif1_11 and 
Dif4_11) which are connected to 36 hours and 8 hours (red and green). Most biological 
repeats of each time point clustered together, which shows that they were highly 
correlated to each other. Again, there were exceptions, especially the two 4 hour 
samples. These samples were also the least correlated to any other samples, as they 
disappeared from the graph when the correlation coefficient was raised to 0.94.  Thus, 
it was decided to exclude these two samples from further analysis. One of the samples 
(Dif1_11) had the lowest number of mapped reads of all samples (2.7 million). The 
second sample (Dif4_11) had 6.2 million mapped reads, which was one of the lower 
numbers of reads. 
 
When these two samples were removed, and correlation coefficient was raised to 0.94, 
the sample-to-sample correlation graph shows the differentiation stages more clearly, 
with 0 hours the furthest away from 96 hours (Figure 3-16). 
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Figure 3-15 Sample-sample network at correlation coefficient of ≥ 0.92 derived from Miru programme (all 
66 samples). Samples are nodes and edges are connections between them with a correlation coefficient 
of 0.92 or greater, i.e. how closely correlated the expression patterns are to each other across all 
samples. Nodes which are close are highly correlated. Each time point is different colour, as pictured in 
the figure. 
 
Figure 3-16 Sample-sample network at correlation coefficient of ≥ 0.94 derived from Miru programme of 
64 samples, excluding two samples at 4 hours. Samples are nodes and edges are connections between 
them with a correlation coefficient of 0.94 or greater, i.e. how closely correlated the expression patterns 
are to each other across all samples. Nodes which are close are highly correlated. Each time point is 
different colour, as pictured in the figure. 
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Next, aggregated CTSSs were correlated with each other based on the expression from 
64 samples (to create a gene-to-gene network). The analysis was done with a 
correlation coefficient threshold of 0.75, which included 12,275 nodes out of 15,341 
possible aggregated CTSS (Figure 3-17). Expression patterns of excluded CTSSs were 
not correlated with any other CTSS at a correlation coefficient of 0.75. 
 
 
Figure 3-17 Network analysis of CTSS expression patterns. A. Image from Miru shows the network layout 
based on correlations between CTSSs (nodes = CTSS; edges = correlations of ≥ 0.75). 64 THP-1 
differentiation samples were analysed using a Pearson’s correlation coefficient ≥ 0.75. Location of 
important clusters is annotated on the main element of the network correlation. B. Image showing the 
eight clusters that demonstrate the transition in expression patterns. Edges have been removed for ease 
of visualisation. Orientation is the same as for A. 
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Eight of the interesting clusters were selected for detailed analysis and their gene lists 
were screened for GO term enrichment using DAVID programme. Expression profiles 
of genes in these clusters are shown in Figure 3-18, ordered by the time point with the 
highest expression, from most monocyte-like (Cluster 1) to most macrophage-like 
cells (Cluster 7). These profiles show that there were waves of gene expression as 
differentiation progressed, with the functions of the group of genes changing as the 
phenotype of the cells changed. A list of genes associated with CTSSs in each cluster 




Figure 3-18 Expression profiles of different clusters found with Miru programme at correlation coefficient 
≥ 0.75 during THP-1 differentiation. Average expression for all CTSS in the cluster is shown. Clusters 
are ordered based on the highest level of expression, from monocyte-like expression (Cluster 1) to most 
macrophage-like expression (Cluster 7) of the THP-1 differentiation. Y axis is in Tags per million (TPM), 
X axis shows the individual colour-coded time points, from 0 hours to 96 hours. Colours are the same as 
in Figure 3-16. 
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Cluster 1   GO terms Group score 
  Group 1 Cell cycle, cell division 37.68 
  Group 2 Nucleosome, histone core 25.09 
  Group 3 DNA damage, DNA repair  17.01 
  Group 4 Kinetochore, centromere 16.31 
  Group 5 Telomere, nucleosome core, epigenetic regulation 9.19 
  Group 6 Histone H2A 7.09 
  Group 7 Mitochondria 6.51 
  Group 8 Fanconi anemia pathway 5.8 
  Group 9 ATP binding 4.84 
  Group 10  Histone H2B 4.77 
Cluster 17   GO terms Group score 
  Group 1 Transcriptional regulation, DNA binding 2.35 
  Group 2 Zinc finger 2.1 
Cluster 6   GO terms Group score 
  Group 1 Nucleotide (ATP) binding, protein kinase 3.42 
  Group 2 Transcriptional regulation, DNA binding 2.06 
Cluster 20   GO terms Group score 
  Group 1 Cell-cell adhesion, cadherin binding 2.34 
  Group 2 Signal transducer activity 2.19 
  Group 3 Endosomal transport, autophagy 2.07 
Cluster 3   GO terms Group score 
  Group 1 Lysosome 4.59 
  Group 2 Endoplasmic reticulum 3.3 
  Group 3 Phosphotyrosine interaction domain 2.41 
Cluster 23   GO terms Group score 
  Group 1 Antiviral defence, innate immunity 8.81 
  Group 2 Double stranded RNA binding, 2'-5' oligoadenylate 
synthetase activity 
4.61 
  Group 3 TPR repeat 1.94 
Cluster 2   GO terms Group score 
  Group 1 Lysosome 11.55 
  Group 2 Pleckstrin homology-like 7.29 
  Group 3 Membrane, transmembrane 5.01 
  Group 4 Phosphatidylinositol binding 3.89 
  Group 5 Integrin complex 3.48 
  Group 6 WD repeat domain 3.22 
Cluster 7   GO terms Group score 
  Group 1 Lysosome, Glycoside hydrolase 2.11 
  Group 2 Lipoprotein metabolic process, phospholipid efflux, 
cholesterol 
2.04 
Table 3-1 DAVID GO term annotation for different clusters found at a correlation coefficient ≥ 0.75 using 
Miru programme.  
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GO term analysis for most monocyte-like Cluster 1 (including cell cycle genes such 
as histone-coding genes (e.g. HIST1H1B) and BUB1 and mitochondrial genes such as 
NDUFA5) includes high scores for cell cycle, mitochondria and DNA repair (Albig et 
al., 1997, Tang et al., 2004, Marui et al., 2011). These CTSS were associated with 
high expression in THP-1 cells at their undifferentiated state (Table 3-1). As  
differentiation progressed, early response genes with functions such as transcriptional 
activation (Clusters 17 and 6, including genes such as SP3 for Cluster 17 and GTF2I 
for Cluster 6) were turned on at around 2 and 4 hours respectively, with concurrent 
upregulation of genes, such as EFR3A and HRH1, which code for proteins involved in 
signal transduction and cell adhesion at 4 hours (Cluster 20) (Essafi-Benkhadir et al., 
2009, Roy et al., 1993, Bojjireddy et al., 2015, Ayuso et al., 2013). Expression of 
genes (e.g. CD63 and CD109) in Cluster 3 slowly increased from the 2 hour time point, 
peaking at 12 hours, and this cluster was enriched for GO terms such as innate 
immunity and antiviral defence (Anzai et al., 2002, Lin et al., 2002). The second 
largest cluster, Cluster 2, contained genes (like ATP6 family members, CD163, CSF1R 
and integrin family members such as ITGAM) which code for proteins associated with 
lysosome activity, transmembrane location and integrin complex (Rojo et al., 2017, 
Hume and Freeman, 2014, Hume et al., 2016). This cluster contained genes with 
expression that steadily increased throughout differentiation, peaking at the end of the 
time course. Cluster 7 contained genes (for example CD14 and DNASE2) which were 
upregulated only very late in the time course, at 48 hours and 96 hours (Wright et al., 
1990, Kawane et al., 2001). This cluster was enriched for GO terms such as lysosome 
and lipoprotein metabolic processes.  
 
3.3.4 Novel enhancers found in THP-1 differentiation assay 
One of the features of CAGE sequencing is that this technology is sensitive enough to 
discern RNA derived from enhancers, which are characterised by balanced 
bidirectional transcription (Andersson et al., 2014). Thanks to the deep sequencing of 
the CAGE samples and the many closely spaced time points, it was possible to identify 
enhancer activity in this dataset. 
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MYB gene expression, as mentioned in section 3.3.2.2, decreases during THP-1 
differentiation with PMA. FANTOM5 identified one MYB enhancer, close to its 
promoter (orange arrow in Figure 3-19). However, in the THP-1 differentiation data, 
there was also a strong bidirectional peak further from the promoter (blue arrow in 
Figure 3-19), for which expression also declined throughout the THP-1 differentiation 
(Figure 3-20 and Figure 3-21). This putative enhancer has a similar pattern of 
expression to the confirmed FANTOM5 enhancer. There are two annotated transcripts, 
one in each direction, for which the TSS is at the same position as the putative enhancer 
(ENST00000455534.1 and ENST00000534736.1). Similar to the THP-1 samples prior 
to PMA treatment, the negative strand was not widely expressed in any FANTOM5 




Figure 3-19 MYB gene structure and its TSS. Image taken from genome viewer Zenbu. Upper tracks 
show the position, extent of the locus as determined by Ensembl, gene models from Gencode data, and 
identified CpG islands from UCSC data. Lower tracks show the number of tags at the TSS detected in 
this study (all 66 samples) and TSS detected in the FANTOM5 study (Forrest et al., 2014) re-mapped to 
hg38. Green indicates transcription from the forward strand; purple indicates transcription from the 
reverse strand. Red box shows MYB promoter, orange arrow shows known MYB enhancer, blue arrow 
shows MYB bidirectional TSS (putative enhancer). 
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Figure 3-20 MYB putative enhancer negative strand expression during THP-1 differentiation based on 
CAGE sequencing data. Y axis shows normalised values in Tags per million (TPM); X axis shows time 
points after PMA treatment. 
 
 
Figure 3-21 MYB putative enhancer positive strand expression during THP-1 differentiation based on 
CAGE sequencing data. . Y axis shows normalised values in Tags per million (TPM); X axis shows time 
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biphenotypic B myelomonocytic leukemia cell line:MV-4-11 2.628 109.853 
acute myeloid leukemia (FAB M5) cell line:THP-1 
(cytoplasmic fraction) 
1.187 91.758 
acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh) 1.959 85.813 
acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed) 2.298 84.189 
acute myeloid leukemia (FAB M5) cell line:THP-1 (revived) 1.456 64.367 
acute myeloid leukemia (FAB M5) cell line:U-937 DE-4  3.296 31.64 
acute myeloid leukemia (FAB M1) cell line:HYT-1 0.823 29.233 
acute myeloid leukemia (FAB M4eo) cell line:EoL-3 2.808 27.276 
acute myeloid leukemia (FAB M5) cell line:P31/FUJ 1.312 27.223 
myelodysplastic syndrome cell line:SKM-1 1.502 24.275 
acute myeloid leukemia (FAB M3) cell line:HL60 1.186 22.202 
acute myeloid leukemia (FAB M2) cell line:Kasumi-1 0.662 20.514 
acute myeloid leukemia (FAB M4eo) cell line:EoL-1 1.949 20.017 
non T non B acute lymphoblastic leukemia (ALL) cell 
line:P30/OHK 
2.554 19.579 
chronic myelogenous leukemia (CML) cell line:MEG-A2 3.709 19.102 
Table 3-2 Expression of putative MYB enhancer in FANTOM5 samples mapped to hg38. The 15 samples 
with highest positive strand expression are shown. Values are in Tags per million (TPM). 
 
3.3.5 Promoter switching found during THP-1 differentiation 
One of the advantages of CAGE technology is that it is able to identify specific 
promoter usage and thus whether the use of different promoters shifts (called promoter 
switching (Forrest et al., 2014)) during a cell state transition such as the differentiation 
of THP-1 monocytic cells. The programme CAGEr was used to identify whether there 
was a shift between two different promoters in the same aggregated CTSS between 
two time points using the scoreShift command. 
 
Most of the shifting promoters identified were false positives. Most false positives had 
low overall TPM value or the distance between the TSS was too small to count as a 
different promoter start. Three different genes were identified initially to have a 
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Table 3-3 Promoter switching identified using CAGEr programme. The time points where differential 
promoter usage was detected are given above each part of the table. PLAGL1 was flagged in two 
searches, 0 vs 8 hours and 0 vs 10 hours. Each part of the table shows chromosome number (chr), start, 
end and strand orientation of the region. Shifting score, p-value and FDR were calculated by CAGEr. 
Shifting score is from –Infinity to 1, 1 being complete shift of expression. P-value and False Discovery 
Rate (FDR) were calculated using Kolmogorov-Smirnov (KS) test. 
 
One of the shifting promoters identified was associated with ARHGAP30. ARHGAP30 
has two main transcripts, one is longer (ENST00000368013 coding for 1101 amino 
acid long peptide) and the other is shorter (ENST00000368016 coding for 890 amino 
acids) (Figure 3-22). According to the Ensembl database, the only protein coding 
transcripts are these two and ENST00000368015 coding for 924 amino acids, for 
which the promoter is near the longer transcript (Figure 3-22).  
 
The area shown as P1 (Figure 3-22) had ubiquitous expression in THP-1 
differentiation, with little variation throughout (Figure 3-23). This promoter was 
associated with ENST00000368013 and ENST00000368015. On the other hand, the 
area shown as P2 had a drastic change in its expression (Figure 3-24), as it sharply 
increased from around 5 TPM at 0 hour to 120 TPM (similar levels as P1) at 96 hours 
of the time course (both graphs are at the same Y axis scale). This promoter was 




Figure 3-22 ARHGAP30 has two promoters P1 (in blue box) and P2 (in red box) with differential 
expression during THP-1 differentiation. This picture is taken from the Zenbu browser, with the data from 
this chapter (labelled Transcription Start Sites THP-1 differentiation) and FANTOM5 data remapped to 
hg38 (labelled Transcription Start Sites (FANTOM5)). Protein-coding transcripts associated with these 
promoters are highlighted in blue (P1) or red (P2) box in the Gene Models track. Transcription is from 
the reverse strand, from right to left of the image. 
 
 
Figure 3-23 Expression of ARHGAP30 in area P1 during THP-1 differentiation according to CAGE 
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Figure 3-24 Expression of ARHGAP30 in area P2 during THP-1 differentiation according to CAGE 
sequencing. Expression is shown as normalised Tags per million (TPM) value. 
 
Looking at samples from FANTOM5 with the highest TPM for the same P1 and P2 
areas, P1 was mostly expressed in primary hematopoietic cells, especially T cells 
(Table 3-4). P2 did not have high TPM values for these samples. However, when 
looking at samples with the highest P2 expression, they were also primarily 
hematopoietic samples, with most hits being in the time course of monocyte-derived 
macrophages treated with LPS (highlighted grey in Table 3-4). Samples which had 
high TPM for P2 also had similar TPM levels for P1. 
 
When the amino acid sequences of the two most important transcripts according to 
Ensembl database (ENST00000368013 and ENST00000368016) were compared to 
each other using MEG AlignPro with Clustal Omega, the main difference in these two 
peptides is that the shorter transcript is missing a glutamic acid rich stretch at the C-










































































































ARHGAP30 P2 during THP-1 differentiation
Dif 1 Batch 1
Dif 1 Batch 2
Dif 2 Batch 1
Dif 2 Batch 2
Dif 3 Batch 1




  RNA samples with highest expression of P1 ARHGAP30 P1 P2 
1 
CD4+CD25-CD45RA- memory conventional T cells expanded, 
donor3 149.733 1.156 
2 gamma delta positive T cells, donor1 142.28 1.426 
3 
CD4+CD25+CD45RA+ naive regulatory T cells expanded, 
donor3 142.19 1.063 
4 CD8+ T Cells (pluriselect), donor090309, donation1 134.62 1.022 
5 CD8+ T Cells (pluriselect), donor090325, donation1 132.98 5.91 
6 CD8+ T Cells (pluriselect), donor090612, donation1 132.344 2.877 
7 
CD4+CD25+CD45RA+ naive regulatory T cells expanded, 
donor2 130.724 0.945 
8 CD8+ T Cells (pluriselect), donor090612, donation2 124.836 6.323 
9 CD8+ T Cells (pluriselect), donor090325, donation2 123.533 3.148 
1
0 
CD4+CD25+CD45RA- memory regulatory T cells expanded, 
donor2 119.32 0.38 
    
  RNA samples with highest expression of P2 ARHGAP30 P1 P2 
1 
Monocyte-derived macrophages response to LPS, 01hr00min, 
donor1 14.968 67.357 
2 
Monocyte-derived macrophages response to LPS, 10hr, 
donor1 22.489 54.617 
3 
Monocyte-derived macrophages response to LPS, 36hr, 
donor1 32.783 50.267 
4 Eosinophils, donor2 : CNhs12548 ctss 61.493 45.249 
5 Neutrophils, donor1 : CNhs10862 ctss 49.175 40.069 
6 
Monocyte-derived macrophages response to LPS, 16hr, 
donor1 19.892 39.785 
7 Neutrophils, donor3 : CNhs11905 ctss 65.25 37.689 
8 CD14-CD16+ Monocytes, donor2 : CNhs13207 ctss 34.454 34.454 
9 CD14-CD16+ Monocytes, donor1 : CNhs13229 ctss 46.338 33.098 
1
0 
Monocyte-derived macrophages response to LPS, 24hr, 
donor1 29.129 32.928 
Table 3-4 Highest TPM values for P1 and P2 regions of ARHGAP30 taken from FANTOM5.  
 
 
Figure 3-25 Two most important ARHGAP30 transcripts coding for polypeptides. This image is taken 
from MEGAlignPro software, which aligned the two amino acid sequences using Clustal Omega. The 
light grey area in ENST00000368016 is missing compared to the longer transcript. 
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Figure 3-26 TMEM70 has two promoters P1 (in blue box) and P2 (in red box) with differential expression 
during THP-1 differentiation. This picture is taken from Zenbu browser, with the data from this chapter 
(labelled Transcription Start Sites THP-1 differentiation) and FANTOM5 data remapped to hg38 
(Transcription Start Sites (FANTOM5)). Transcription is from the forward strand, from left to right of the 
image. 
 
Another gene with two promoter regions with varying expression during THP-1 
differentiation was TMEM70 (Figure 3-26). P1was located at the beginning of multiple 
coding transcripts, whereas P2 was at the beginning of the translated region of this 
gene, where none of the known transcripts’ start sites were located. P1 expression did 
not change very much throughout the THP-1 differentiation (Figure 3-27), but P2 was 
associated with increase of expression after the start of PMA stimulation, with 
decrease at 14 and 16 hours, and additional decrease as the cells become macrophage-
like (48 and 96 hours) (Figure 3-28). The P1 region of TMEM70 was most highly 
expressed in tumours and cell lines among the FANTOM5 samples (with almost no 
expression of P2) (Table 3-5), whereas the P2 region’s top 10 samples were mostly 
primary cells such as artery, skeletal muscle and monocyte-derived macrophages 
during the response to influenza virus. Samples with high P2 expression also had a 




Figure 3-27 Expression of TMEM70 in area P1 in THP-1 differentiation according to CAGE sequencing. 
Expression is shown as normalised Tags per million (TPM) value. 
 
 
Figure 3-28 Expression of TMEM70 in area P2 in THP-1 differentiation according to CAGE sequencing. 
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TMEM70 P2 during THP-1 differentiation
Dif 1 Batch 1
Dif 1 Batch 2
Dif 2 Batch 1
Dif 2 Batch 2
Dif 3 Batch 1




  RNA samples with highest expression of P1 TMEM70 P1 P2 
1 neuroepithelioma cell line:SK-N-MC 507.374 13.73 
2 peripheral neuroectodermal tumor cell line:KU-SN 233.5 1.02 
3 carcinoid cell line:SK-PN-DW 164.388 4.443 
4 293SLAM rinderpest infection, 12hr, biol rep2 160.383 1.302 
5 acute myeloid leukemia (FAB M0) cell line:KG-1 157.732 0.655 
6 NK T cell leukemia cell line:KHYG-1 152.036 2.438 
7 293SLAM rinderpest infection, 12hr, biol rep3 150.495 2.595 
8 293SLAM rinderpest infection, 00hr, biol rep2 132.649 3.007 
9 293SLAM rinderpest infection, 00hr, biol rep1  131.225 3.196 
10 293SLAM rinderpest infection, 06hr, biol rep1 129.222 4.561 
    
  RNA samples with highest expression of P2 TMEM70 P1 P2 
1 artery, adult 103.031 212.053 
2 skeletal muscle, adult, pool1 99.905 152.516 
3 
Monocyte-derived macrophages response to mock influenza 
infection, 24hr00min, donor2 (150 120:MI 24h) 42.208 105.05 
4 
Monocyte-derived macrophages response to udorn influenza 
infection, 02hr00min, donor1 (868 121:Ud 2h) 57.986 99.813 
5 
Monocyte-derived macrophages response to mock influenza 
infection, 24hr00min, donor1 (868 121:MI 24h) 53.296 91.497 
6 
Monocyte-derived macrophages response to mock influenza 
infection, 24hr00min, donor4 (227 121:MI 24h) 43.665 88.246 
7 skeletal muscle - soleus muscle, donor1 37.249 87.377 
8 
Monocyte-derived macrophages response to mock influenza 
infection, 00hr00min, donor2 (150 120:MI 0h) 44.215 83.125 
9 
Monocyte-derived macrophages response to LPS, 
01hr00min, donor3 (t5 Subject3) 38.682 79.739 
10 
Monocyte-derived macrophages response to udorn influenza 
infection, 02hr00min, donor4 (227 121:Ud 2h) 30.891 78.551 
Table 3-5 Highest TPM values for P1 and P2 regions of TMEM70 taken from FANTOM5. 
 
PLAGL1 promoter was also flagged by the CAGEr programme to have a shift in 
promoter usage between 0 and 8 hours and also between 0 and 10 hours. Further 
analysis revealed that PLAGL1 has multiple transcription start sites with generally two 
different sized transcripts, but the one recognized by CAGEr was found at the 5’ end 
of the gene (and thus codes for the longer transcript). This promoter could be divided 
into two areas, P1 (which is the one mostly used in FANTOM5 samples) and P2 
(Figure 3-29). The P1 region was highly expressed in undifferentiated THP-1 samples, 
its activity declining as differentiation progressed (Figure 3-30). On the other hand, P2 
had very low expression at 0 hour of differentiation, with its expression peaking (and 
being higher than P1) around hours 6 or 7 (Figure 3-31). 
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Figure 3-29 PLAGL1 has two promoters P1 (in blue box) and P2 (in red box) with differential expression 
during THP-1 differentiation. This picture is taken from Zenbu browser, with the data from this chapter 
(labelled Transcription Start Sites THP-1 differentiation) and FANTOM5 data remapped to hg38 




Figure 3-30 Expression of PLAGL1 in area P1 in THP-1 differentiation according to CAGE sequencing. 
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Figure 3-31 Expression of PLAGL10 in area P2 in THP-1 differentiation according to CAGE 
sequencing. Expression is shown as normalised Tags per million (TPM) value. 
 
  RNA samples with highest expression of P1 PLAGL1 P1 P2 
1 Neutrophils, donor1 69.21 0.304 
2 common myeloid progenitor CMP, donor1 63.591 0 
3 promyelocytes/myelocytes PMC, donor1 63.187 0 
4 Neutrophils, donor3 56.617 0 
5 granulocyte macrophage progenitor, donor1 55.263 0 
6 Eosinophils, donor2 51.824 0 
7 Eosinophils, donor3 47.367 0 
8 b cell line:RPMI1788 41.132 2.13 
9 CD133+ stem cells - adult bone marrow derived, pool1 38.932 0 
10 CD14+CD16- Monocytes, donor3 37.981 0.136 
        
  RNA samples with highest expression of P2 PLAGL1 P1 P2 
1 
Monocyte-derived macrophages response to LPS, 16hr, 
donor1 (t20 Subject1) 9.946 9.946 
2 COBL-a rinderpest infection, 12hr, biol rep3 10.244 5.885 
3 COBL-a rinderpest(-C) infection, 12hr, biol rep1 12.688 5.767 
4 COBL-a rinderpest infection, 48hr, biol rep1 20.771 5.36 
5 COBL-a rinderpest(-C) infection, 06hr, biol rep1 9.355 5.346 
6 cord blood derived cell line:COBL-a untreated 17.753 5.222 
7 COBL-a rinderpest(-C) infection, 06hr, biol rep2 7.715 5.143 
8 COBL-a rinderpest infection, 06hr, biol rep3 10.991 5.088 
9 COBL-a rinderpest(-C) infection, 24hr, biol rep1 11.355 5.047 
10 COBL-a rinderpest(-C) infection, 24hr, biol rep2 10.336 5.011 
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The FANTOM5 samples with highest expression in P1 PLAGL1 area were mostly 
primary hematopoietic cells, which simultaneously had almost no P2 expression. On 
the other hand, P2 was not really expressed highly except for monocyte-derived 
macrophages treated with LPS and the COBL-a cell line, untreated and treated with 
viral infection. COBL-a cell line is a relatively new cell line, established from human 
umbilical cord blood specifically to study measles virus (Kobune et al., 2007). 
 
3.3.6 Chromatin modifying enzymes gene expression in THP-1 differentiation 
As stated in the introduction (section 1.2), chromatin modifying enzymes play a 
regulatory role in cell differentiation, allowing genes to be switched on and off by 
opening or closing chromatin. During the exploration of FANTOM4 time course data, 
two genes encoding chromatin modifying enzymes (KDM6B and USP12) were found 
to be upregulated during the THP-1 stimulation with PMA (section 1.4.1). In this new 
tighter time course, this was validated in multiple ways.  
 
The FANTOM4 data showed that deubiquitinases gene USP12 was upregulated 
around hour 4 of the THP-1 time course. The new data from the present study show 
that the highest level of expression was actually at around the 5th hour of the 
differentiation (Figure 3-32). This result was also validated by qRT-PCR (Figure 
3-33). There was considerable batch-to-batch variability, with Diff2 Batch 1 having 
an expression level less than half that of Diff3 Batch 1. However, by following each 
batch separately it can be seen that USP12 expression was elevated between 4 and 12 




Figure 3-32 Expression of USP12 in THP-1 differentiation according to CAGE sequencing. Expression 
is shown as normalised Tags per million (TPM) value. 
 
 
Figure 3-33 USP12 expression in the whole THP-1 differentiation (all time points taken) based on qRT-
PCR. Pictured here is the USP12 expression normalised to ACTN expression and error bars showing 
standard error (calculated by the by Roche LightCycler 480 software). 
 
CAGE sequencing results were also used to look at other H2A deubiquitinases, BAP1 
and USP16 and histone demethylases KDM6B and UTY. The detailed time course 
allowed detection of small fluctuations in gene expression, and thus it was discovered 
that BAP1 has a cyclic expression pattern, peaking three times in the first 12 hours of 
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Figure 3-34 Expression of BAP1 in THP-1 differentiation determined by CAGE sequencing. Expression 
is shown as normalised Tags per million (TPM) value. 
 
 
Figure 3-35 Expression of USP16 in THP-1 differentiation according to CAGE sequencing. Expression 
is shown as normalised Tags per million (TPM) value. 
The level of USP16 did not change much throughout the time course (Figure 3-35), 
but KDM6B was found to be upregulated, just as in FANTOM4, with a steep increase 
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during the first few hours (Figure 3-36). The KDM6B data was also supported by qRT-
PCR analysis (Figure 3-37). UTY expression was found to be upregulated during the 
time course, but only towards the end, as the cells were becoming more macrophage-
like (Figure 3-38).  
 
 
Figure 3-36 Expression of KDM6B in THP-1 differentiation according to CAGE sequencing. Expression 
is shown as normalised Tags per million (TPM) value. 
 
 
Figure 3-37 KDM6B expression in the whole THP-1 differentiation (all time points taken) based on qRT-
PCR. Pictured here is the KDM6B expression normalised to ACTN expression and error bars showing 
standard error (calculated by the by Roche LightCycler 480 software). 
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Figure 3-38 Expression of UTY in THP-1 differentiation according to CAGE sequencing. Expression is 
shown as normalised Tags per million (TPM) value. 
 
These five deubiquitinases and demethylases were analysed in the Miru network 
created in section 3.3.3 using a Pearson correlation coefficient threshold of 0.75, and 
four of them were found to be in different clusters. USP16 was not included in any 
cluster. BAP1 was found in Cluster 15 (100 nodes; Figure 3-39), with other genes 
coding for proteins with K homology domain, and other ubiquitin-associated protein 
genes (Table 3-7). Interestingly the averaged expression profile for this cluster (Figure 
3-39) also seems to oscillate in the same way as BAP1 (Figure 3-34) suggesting that 
this cluster contains genes with a cyclical regulation during differentiation. USP12 was 
found in Cluster 36 (42 nodes), which was also enriched for ubiquitin pathway proteins 
(Figure 3-39, Table 3-7). KDM6B was in the small Cluster 122 (11 nodes), which was 
only enriched in cell junction GO terms (Figure 3-39, Table 3-7). UTY was grouped 
into Cluster 2, as analysed in section 3.3.3 (Figure 3-39). 
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Figure 3-39 Averaged expression profiles of different clusters containing expression of chromatin 
modifying enzymes found with Miru programme at correlation coefficient ≥ 0.75. Y axis is in Tags per 
million (TPM), X axis shows the individual colour-coded sample types, from 0 hours to 96 hours. Colours 
are the same as in Figure 3-16. 
 
Cluster 15   GO terms Group score 
  Group 1 K Homology domain 1.81 
  Group 2 Ubl conjugation pathway 1.67 
  Group 3 Protein import into nucleus 1.58 
Cluster 36   GO terms Group score 
  Group 1 Ubiquitin-dependent protein catabolic process 1.74 
  Group 2 Ubiquitin protein ligase binding 1.62 
Cluster 122   GO terms Group score 
  Group 1 Cell junction 1.1 
Table 3-7 DAVID GO term annotation for clusters 15, 36 and 155 found at a correlation coefficient ≥ 0.75 




3.4.1 Chapter overview 
The main point this chapter demonstrates is the wide range of information that can be 
ascertained from a detailed CAGE time course study. This chapter includes data from 
a time course of THP-1 differentiation similar to the FANTOM4 study (Suzuki et al 
2009), but with an increased number of time points (18) especially at the early stages, 
as well as deeper sequencing of the samples. Firstly, THP-1 differentiating into 
macrophage-like cells were confirmed based on morphological changes, and the cells 
were found to become adherent around hour 8 to 10, developing a macrophage-like 
phenotype. Next, cell cycle analysis was performed, showing that the differentiating 
THP-1 cells arrest their cell cycle in G1/S phase at around 10 hours of the time course, 
consistent with the cessation of proliferation as differentiation proceeds. The 
transcriptomic analysis of this monocyte to macrophage differentiation time course 
was carried out with at least three biological replicates per time point, using CAGE 
technology. Eight samples were multiplexed on one lane of the flow cell used in the 
sequencing machine, which resulted in around 9 million mapped reads per sample. 
The CAGE results were subsequently used to confirm macrophage differentiation of 
the samples, which were also validated by qRT-PCR on the RNA used for CAGE 
library preparation. The difference between FANTOM4 (Suzuki et al 2009) and this 
study was mainly in the number of time points and depth of sequencing, which 
revealed the continuous waves of gene activation hour to hour post PMA stimulation. 
This was achieved using Miru programme by analysis of correlation between the 
samples and the CTSS. Further information could also be extracted looking at 
enhancer transcriptional activity and analysis of shifting promoters using CAGEr 
programme. This work also looked at gene expression changes of epigenetic modifiers 
in the THP-1 cells during differentiation. 
 
3.4.2 THP-1 cells as a model for monocyte to macrophage differentiation 
Since their isolation nearly 40 years ago, THP- 1 cells have been widely used as a 
model cell line for monocyte and macrophage cells (Tsuchiya et al., 1980). As 
 89 
mentioned in section 1.3.2, THP-1 cells can be stimulated with various compounds, 
with the phorbol ester phorbol-12-myristate-13-acetate (PMA) as the most potent one. 
An important question is whether THP-1 cells are a good model for studying 
monocytes and macrophages. Firstly, they are of pro-monocytic origin, so they are not 
considered to be mature monocytes (Bosshart and Heinzelmann, 2016). Differentiated 
THP-1 cells also did not show comparable macrophage differentiation to primary bone 
marrow derived macrophages (Daigneault et al., 2010). They were derived from a 
monocytic leukaemia and have therefore undergone changes associated with the 
escape from growth controls typical of cancer cells. However, they do have an almost 
normal human karyotype, with few deletions and one trisomy of chromosome 8 (Adati 
et al., 2009). The THP-1 cells used throughout this study were of clonal lineage, in 
which a clone (clone number 5) was chosen by FANTOM4 collaboration as the cells 
were most uniform in differentiating and becoming adherent (Suzuki et al., 2009). This 
is in contrast with cells originally isolated (and the ones available at ATCC; 
http://www.atcc.org, product ATCC TIB-202), which are heterogeneous in response 
to PMA (Suzuki et al 2009). However, even clone 5 THP-1 cells were found to have 
different cell morphology at certain time points (as seen in Figure 3-3). Since the 
majority of the cells (up to 98%) follow a similar pattern during differentiation, the 
gene expression results collected from the RNA of around 5 million cells per time 
point should not be adversely affected by 2% of more or less differentiated cells. 
Having an extensive set of time points during THP-1 differentiation, it is now possible 
to take FANTOM5 data from primary monocytes and primary macrophages, and 
determine which stage of THP-1 differentiation is the most transcriptionally similar to 
that of primary cells.  
 
3.4.3 Stimulation of THP-1 cells and their effect on cell cycle 
As mentioned in the Introduction section 1.3.2, THP-1 cells can be stimulated in 
multiple ways to induce differentiation. In this repeated study of FANTOM4, the same 
conditions were used to allow for comparison. PMA (a phorbol ester) was added to 
the cell medium at concentration of 30 ng/ml (48.6 nM). Other studies have used 
concentrations from 5 to 100 ng/ml (Park et al., 2007). PMA at high concentrations (> 
50 nM) had been shown to stimulate the THP-1 cells in a way similar to the response 
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of monocyte derived macrophages responding to lipopolysaccharide (LPS), and their 
subsequent response to LPS was stronger than in THP-1 cells stimulated with lower 
PMA concentrations (Lund et al., 2016). It is possible that the lower concentration of 
PMA used in the present study was suboptimal for the full development of the 
macrophage phenotype. However, analysis of MYB, which is associated with 
progenitor cells and declined during the time course, and CD14, a macrophage marker 
which increased during the time course, was consistent with the transition from 
monocyte to macrophage (see section 3.4.4). 
 
Based on the cell cycle data, stimulation with PMA of THP-1 causes the cells to stop 
proliferating, with cells arrested at the G1/S checkpoint at around 8-10 hours. Cells at 
later stages of the cycle completed mitosis (Figure 3-5). The proportion of G2 phase 
cells fell between 24 hours and 48 hours – presumably as cells moved from G2 back 
to G1 phase after cell division. Even after 48 hours of starting the THP-1 
differentiation, there was a proportion of cells in G2 phase. Given the fact that no cells 
stayed in S phase after 24 hours, it could mean that the cells stayed in G2 phase (taking 
them longer to exit than usual). It could also indicate the imprecision of the cell cycle 
analysis, as just divided macrophages might not have completely finished telophase 
and cytokinesis so that single cells would appear to have four copies of the genome. 
Every possible care was taken to eliminate doublet cells from flow cytometry analysis 
(as cells tend to stick together), but the small proportion of cells in G2 could simply 
show cells with two nuclei.  
 
The cell cycle arrest is also visible in data from section 3.3.3, where genes for histone 
proteins, DNA replication and mitochondria were found in Cluster 1, for which the 
overall profile expression is downregulated as the differentiation progresses.  
 
Detailed study of this PMA-associated cell cycle arrest in THP-1 cells could also 
determine novel targets for oncological drugs against proliferation in leukaemia. 
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3.4.4 Validation of progression of THP-1 differentiation  
The THP-1 differentiation time course for each biological replicate was confirmed 
initially by morphological changes in the cells (section 3.3.1.1), and then by testing 
the level of expression of relevant markers by CAGE sequencing and qRT-PCR.  
 
The two markers (MYB and CD14) were chosen to represent two different patterns of 
gene expression, as MYB levels are affected by PMA within first few hours (Suzuki et 
al., 2009) and CD14 levels rise only after few days’ of PMA stimulation as a marker 
of macrophages (Daigneault et al., 2010). MYB (found in Cluster 1 in section 3.3.3) 
was downregulated within the first hour of differentiation in all biological replicates. 
CD14 (found in Cluster 7 in section 3.3.3) was very highly upregulated in the last two 
time points according to CAGE sequencing in all replicates. The CAGE data was 
validated by qRT-PCR, which contained all the original time points (including time 
points every 15 minutes in the first hour) and provided higher resolution for gene 
expression in the first hours of the time course.  MYB expression in qRT-PCR was less 
uniform within biological replicates than in CAGE sequencing data, which could be 
due to technical errors. All qRT-PCR results also include samples which were 
excluded from CAGE study due to their low quality of RNA, which could affect the 
result.  
 
3.4.5 CAGE technology limitations 
Initially, three biological replicates of the time course had been planned for CAGE 
analysis. However, since some RNA samples exhibited bad quality (low RINe score) 
or quantity, two more replicate experiments were conducted. 12 CAGE libraries were 
successfully created, but some libraries had a large peak at 78 bp suggesting primer 
dimer. The occurrence of the primer dimers decreased the number of final reads that 
were mapped to the genome, so the higher the ratio of CAGE peak vs primer peak, the 
better was the outcome of the number of final reads used in the analysis. The reason 
for the difference in the amount of primer contamination in each run is unknown, as 
all libraries used the same quantity of RNA per sample. However, another CAGE 
preparation in the laboratory showed that using 1 µg of RNA per sample produced a 
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large amount of primer contamination (Dr Sara Clohisey, personal correspondence, 
2017). Even though the protocol is optimised for 1-5 µg of RNA per sample 
(Takahashi et al., 2012), the use of primers in samples in the lower range of RNA 
might have to be optimised in future studies. There were also larger peaks (> 100 bp) 
present in CAGE libraries, which were of unknown origin (Figure 3-7). After several 
libraries were sequenced, all enzyme stocks (particularly restriction endonuclease 
EcoP15I) were replaced to rule out enzyme degradation, but the presence of the larger 
peaks was not significantly reduced. 
 
Another hindrance in the analysis of the CAGE sequences was the low number of 
mapped reads on average in certain samples with the CTT barcode (Figure 3-9). As 
the problem was discovered during the process of making the later libraries, new 
barcodes were produced from a frozen master stock of oligonucleotides. This 
improved the number of mapped reads, but it is unclear why the CTT barcode was so 
unstable. The first four barcodes (ACG, GAT, CTT and ATG) were created about a 
year before the start of the CAGE library production for this project. The rest were 
produced at the start of the project. All barcodes were frozen and aliquoted to prevent 
excessive amount of freeze-thaw cycles, but that did not prevent the malfunction. It 
might be that CTT sequence (the only difference among the barcodes) is particularly 
unstable or the oligonucleotides were incorrectly manufactured. Future work should 
be focused on testing the performance of all barcodes before any other large-scale 
project is initiated.  
 
It was found that there was a large variability in the number of reads between different 
samples, from 33 million of mapped reads to just below 3 million (Figure 3-10). 
Barcode occurrence, quality and quantity in samples with small or large number of 
reads were checked, but no obvious differences were detected. This difference might 
be due to chance, which could be tested by running the same CAGE library on two 
lanes of the Illumina sequencing flow cell.  
 
Analysis of CAGE data was made easier by using the CAGEr package, which also 
removes the G-nucleotide bias introduced at the beginning of reads by CAGE primers 
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(Haberle et al., 2015). The normalised CTSS reads were then uploaded to Zenbu for 
convenient visualisation of individual genes. For further analysis, it was decided to use 
this package to group the individual CTSS into ‘clusters of CTSS’ based on CTSS 
distance (max distance 20 bp). The number of CTSS clusters was then reduced to about 
half (from around 30,000 CTSS groups in each sample to 15,341 overall) when 
aggregating all CTSS groups for each of the 66 samples into a single file of non-
overlapping CTSS clusters. This was due to the more stringent conditions, when only 
CTSS groups in which at least one sample contained TPM of at least 5 were included. 
This ensured that only the most significant results were considered, and the amount of 
possible transcriptional noise was kept to minimum. FANTOM4 identified 29,857 
promoters and 14,607 wider promoter regions substantially expressed at least once 
(Suzuki et al., 2009); which is around the same number as the number of aggregated 
clusters in this study. Further comparison with FANTOM4 promoter region is needed 
to complete the analysis. 
 
CAGE technology was chosen, as opposed to RNAseq or microarray analysis, to allow 
for precise comparison with FANTOM4 data and primary cell data from FANTOM5. 
CAGE deep sequencing is also sensitive enough to look for novel transcriptomic 
features, such as enhancers and shifting promoters, which technology such as 
microarray is unable to do. Analysis for CAGE data is also easier due to the fact that 
each capped mRNA only produces one CAGE read, as opposed to RNAseq, where the 
number of reads is dependent on the length of the transcript. On the other hand, 
RNAseq is able to look for new splicing variants. The cost of making the CAGE library 
and sequencing 8 samples on one lane of the Illumina 2500 flow cell was lower than 
that of RNAseq or expression microarray (Prof Kim Summers, personal 
correspondence, 2016), which allowed a substantial number of samples to be analysed 
with a limited budget. 
 
3.4.6 Waves of gene repression and activation during the THP-1 time course 
Sample to sample correlation data showed that there were at least two samples which 
did not correlate at all with their biological replicates (Figure 3-15). These two 
samples, both for the 4 hour time point, were shown to be most similar to much later 
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time points in the differentiation. When these two samples were removed, the resulting 
sample-to-sample correlation showed clearer progression of the time point samples 
from 0 hour to 96 hours (Figure 3-16). Thus, these two samples were excluded from 
further cluster analysis. All 66 samples were used in other analyses, but the results 
were investigated with caution. FANTOM4 expression measurements were stated to 
be ‘noisy’ (Suzuki et al., 2009), which could be seen by expression analysis of few 
genes (e.g. section 1.4.1). The samples in this study were correlated comparably, but 
there were still certain inconsistent results for the set of 64 samples, such as the 8 hour 
time point being most correlated to the 16 hour time point. It is not clear why these 
samples have such a poor outcome in the correlation graphs, as not all of them had low 
number of mapped reads (as stated in section 3.3.3) and the quality of starting RNA 
was similarly good for all reads used in CAGE sequencing.  
 
Network analysis of CTSS expression patterns was performed with Pearson’s 
correlation coefficient of 0.75. Higher correlation coefficients were examined, as 
genes within the clusters were more highly correlated but they excluded many CTSS 
(nodes). For example, some chromatin modifying enzymes analysed in section 3.3.6 
were omitted from the analysis at higher coefficients. Clusters formed with a higher 
correlation coefficient were similar in various expression patterns to the clusters 
presented in this study (section 3.3.3 and Appendix 8.4), but subsequent GO term 
annotation by DAVID resulted in higher p-values due to their small size. The network 
analysis at 0.75 also showed a main element with the two largest clusters (Clusters 1 
and 2) being apart.  
 
Eight different clusters were chosen for further analysis as they represented the 
transition in gene expression during THP-1 differentiation (Figure 3-17 and Figure 
3-18). This analysis showed a clear progression from Cluster 1 (least differentiated) to 
Cluster 7 (most differentiated), consistent with the notion that clusters were at the 
opposite ends of the differentiation spectrum (Figure 3-17). As the pattern of activation 
progressed through the time course, it can be clearly seen that firstly early response 
genes such as various transcription factors were activated, which in turn would 
stimulate the transcription of macrophage-specific genes responsible for functions 
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such as phagocytosis and lysosome activity. These detailed transcriptional waves 
could only be detected by a tight time course. The next steps in analysis would be to 
study these transcription factors, compare them with already known networks from 
FANTOM4 and match them with possible gene targets.  
 
Further investigation is needed for other interesting clusters not currently included in 
the analysis, for example clusters with genes that are downregulated by the PMA 
stimulation, but returning back to the basal pre-stimulation level of expression by the 
end of the 4 day period. Other clusters recognised by Miru usually included sample-
specific gene expression, which was not replicated in the other samples of the same 
time point. Cluster 23, which was included in the analysis due to its high GO 
enrichment, has this problem, as the replicates show different levels of expression. 
Investigation into the reasons for this high GO enrichment for antiviral defence could 
help to understand why a well-established cell line such as THP-1 can produce such 
variable results.  
 
3.4.7 Novel features of THP-1 differentiation found by CAGE 
3.4.7.1 Enhancers 
As detailed in Andersson et al. (2014), deep CAGE sequencing is able to detect 
enhancer activity. The example presented in this study shows the enhancers for the 
transcription factor gene MYB. One of the enhancers near the MYB promoter was 
annotated in FANTOM5, but there were bidirectional transcripts located further along 
the gene, for which expression was correlated to the main MYB promoter. The positive 
strand transcript was annotated in the Ensembl database, as a MYB transcript targeted 
by nonsense mediated decay. When checking the expression for these transcripts, the 
positive strand transcript was most highly upregulated in various cancers and 
leukaemia. This transcript could therefore be cancer-specific and could potentially be 
a therapeutic target for RNAi use or as a diagnostic marker.  
 
Further analysis of all enhancers in the time course will be continued, firstly by finding 
a way to correctly annotate them as enhancers (based on the study of Andersson et al 
(2014)), and then by comparing the expression with the target in the time course. These 
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potential enhancers can only be detected because of the tight time course and deep 
sequencing, as their expression is low and may be quite transient during the 
differentiation process, as demonstrated for other time course data by Arner et al. 
(2015). Enhancers could be further validated by intersection with publicly available 
data sets of transcription start sites and chromatin marks, such as FANTOM5 and 
ENCODE (ENCODE, 2012, Arner et al., 2015, Forrest et al., 2014). 
 
3.4.7.2 Shifting promoters 
As mentioned above, one of the advantages of using CAGE sequencing is that it very 
precisely determines where transcription starts. As documented in Haberle et al. 
(2014), promoters have various structures and can use different regions of the DNA 
upstream of the coding sequence at different times. Using CAGE technology in a tight 
time course such as this one, allows the discovery of finer differences in gene 
expression and promoter usage, than, for example, comparing static samples of widely 
different developmental origin (Arner et al., 2015, Forrest et al., 2014). Information 
about promoter switching could be potentially useful in determining a drug target, 
which might give specificity to the cancer cells without impacting normal expression 
in primary cells. Using the CAGEr programme to look at different start sites of the 
same promoter area was quite effective, as multiple sites were flagged by the software. 
In this study, three interesting areas were chosen. 
 
There was a difference in the promoter usage by the ARHGAP30 gene between 
undifferentiated and differentiated THP-1. Further analysis showed that the main area 
of the promoter, which codes for the longer ARHGAP30 transcript, was ubiquitously 
expressed throughout the differentiation, but there was a spike of expression of the 
ARHGAP30 shorter transcript, which was only expressed at the end of the time course, 
in macrophage-like THP-1 cells. Little is known about this gene (there were only 5 
articles on Pubmed as of November 2017), but it codes for a Rho GTPase, a family of 
genes which are important in signal transduction pathways that control cell migration, 
proliferation adhesion and other functions (Naji et al., 2011). ARHGAP30 also 
promotes p53 acetylation and thus is a possible prognostic marker in colorectal cancer 
(Wang et al., 2014). This acetylation of p53 is highly specific for the full length 
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isoform, not the shorter one without the glutamate-rich region. This seems to be the 
only functional difference between these two transcripts. However, THP-1 cells do not 
express p53 (Sugimoto et al., 1992), so it is not currently clear whether the 
differentiation-dependent expression of the shorter transcript is due to the p53 
interaction. Interestingly, the ARHGAP30 longer transcript was mostly expressed in 
immune cells (such as T-cells), but these cells with high expression levels do not 
produce the shorter transcript at the same levels. However, the expression of the 
shorter transcript was abundant in another time course in FANTOM5, monocyte-
derived macrophages and their response to LPS. This could imply that this shorter 
transcript has a similar role in LPS treatment as in THP-1 differentiation. Further 
research is needed to unravel the difference between these two transcripts and why 
their expression is tightly regulated in the differentiation study. 
 
Two other examples of shifting promoters were in the TMEM70 and PLAGL1 genes. 
TMEM70 is mutated in mitochondrial complex V (ATP synthase) deficiency (OMIM 
614052; (Cizkova et al., 2008)), associated with lactic acidosis, cardiovascular 
abnormalities, dysmorphic features and death in the neonatal period. TMEM70 may 
be important for cells’ survival, although there is no clear link with macrophage 
function. The TMEM70 promoter had two areas with differential expression – P1 
which was at the beginning of the transcripts, and did not change throughout 
differentiation, and P2 which was found at the beginning of the translated region, and 
was upregulated few hours after PMA stimulation following which its expression 
decreased to almost pre-differentiation levels. No alternative transcripts based on the 
genomic region position of P2 area have been identified.  
 
For PLAGL1 the P2 area, where expression was also differentiation-specific, was 
outside the annotated transcript region so there were no known transcripts initiating 
from this promoter. PLAGL1 is an imprinted gene (Kamiya et al., 2000), which codes 
for a transcription factor that acts as a tumour suppressor (Spengler et al., 1997, 
Varrault et al., 1998, Bilanges et al., 2001), and has at least 5 other promoters found 
to date (Smith et al., 2017). There are alternately spliced transcripts which use different 
promoters and vary in the 5 untranslated region and whether coding exon 7 is included 
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in the transcript (Valleley et al., 2007). This plasticity of transcript structure suggests 
that P2 identified here could be a real variant. 
 
In both cases, TMEM70 and PLAGL1, the differentiation-specific area of the promoter 
region was also expressed in other FANTOM5 samples, so the presence of two 
promoter regions is unlikely to be due to the incorrect mapping of the sequences. In 
fact, both of the regions which are specific for differentiating THP-1 cells (plus the P2 
area of ARHGAP30), were upregulated in time course samples of immune cells, both 
primary cells and cell lines. It might be that these new transcripts are highly immune-
cells specific and thus had not been annotated at the time of writing. The P2 area was 
of TMEM70 was identified as a second promoter in FANTOM5 database, but PLAGL1 
P2 region was not annotated as a promoter. Further analysis of these transcripts and 
TSS could uncover specific monocyte/macrophage transcriptional activity controlled 
by differential promoter usage, which could not be easily found by RNAseq. Since 
PLAGL1 has been identified as a tumour suppressor further investigation of this gene 
and the alternative promoter could lead to a possible tumour specific drug target.  
 
One of the disadvantages of this analysis is that the programme only compares CTSS 
usage within already defined clusters. These clusters of CTSS were aggregated with 
the distance apart set at a maximum of 100 bp (see section 2.5.4). Thus, if there is a 
different CTSS of the same gene which is further away than 100 bp, it is flagged as a 
different CTSS cluster and its expression is not compared with other promoters for 
that gene. For example, the distance between p1@BAP1 and p2@BAP1 of BAP1 as 
shown by FANTOM5 database is over 4000 bp, therefore the p2@BAP1 would not be 
identified as a shifting promoter. Further analysis could include CTSS clustering in a 
different way or with longer distance between the CTSS, but this could produce more 
false positives. The other method is to annotate the promoters the same way as 
FANTOM5 did, with assigning promoter numbers to all genes, as the analysis in this 
study did not use this approach to look at shifting promoters. The next step would be 
to compare the usage of promoters between individual time points, although this 
process is more time consuming than using the CAGEr method.  
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3.4.8 Role of chromatin modifying enzymes – epigenetic regulation  
The expression of five genes, three encoding H2A deubiquitinases USP12, USP16 and 
BAP1; and two encoding H3K27me3 demethylases KDM6B and (potentially) UTY 
was analysed in the tighter time course. More time points have shown higher resolution 
of gene expression patterns, for example BAP1 transcription exhibits cyclical 
behaviour not previously noticed. qRT-PCR was also used to validate the results of 
the two upregulated genes from FANTOM4, KDM6B and USP12, but USP12 qRT-
PCR did not show the same trend as in CAGE, where only a very small upregulation 
after few hours was seen. qRT-PCR of KDM6B also showed high variability between 
replicates. All qPCR results were also normalised against a housekeeping gene, ACTN, 
so the results should be comparable to normalised CAGE data. It could be due to the 
fact that CAGE picks up all 5’ ends of the transcripts, but qRT-PCR primers were 
selected for the middle of the gene. As mentioned in section 3.4.4, the qRT-PCR 
graphs contain all samples, even those for the time points not chosen for CAGE and 
samples with low RNA quality, which could affect the results.  
 
USP16 expression did not change throughout the differentiation, and thus it was not 
correlated with other genes and the Miru programme did not include the gene in any 
cluster. Other genes, however, were included in various clusters. UTY was found to be 
upregulated at the end of the time course, and thus it belonged to Cluster 2 (Figure 
3-18). BAP1 was included in Cluster 15, which shows an oscillating expression pattern 
but has low expression in the 12th hour, which looks like a sequencing artefact. The 
other genes’ clusters (KDM6B and USP12) also seem to be influenced more by high 
expression in a few samples, which may be due to technical problems rather than real 
biological issues.  
 
Further investigation of genes co-expressed with these genes in the clusters could 
provide clues to whether the difference in biological replicates were technical errors. 
Differential expression of chromatin modifying enzymes could rapidly change the 
transcription of other genes and thus increase the variability in biological replicates. 
Expanding knowledge about how these processes can occur can help in battling cancer 
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heterogeneity and metastasis formation. The analysis of expression of these chromatin 
modifying enzymes inspired further studies of their functional roles in later chapters.  
 
3.4.9 Conclusions and further work 
It is not a simple and straightforward process for a cell to change cell type during 
differentiation to perform different functions. The transition from primary monocyte 
to macrophage takes multiple days and, the same is true for the THP-1 model. 
However, as is shown by the data in this chapter, and supported by multiple 
publications as discussed above, there is an almost immediate change of transcriptomic 
expression after stimulation. The FANTOM4 consortium made a major contribution 
characterising a transcription factor network and regulatory site prediction given the 
limited time points used in the study (Suzuki et al 2009). However, further work 
characterising the transcriptomic changes in detail is needed for precise understanding 
how the activation and repression of gene expression is regulated. The role of 
chromatin modifying enzymes in this change should be further emphasized and 
explored. This study lays the ground work for further bioinformatic analysis of the 
deepCAGE sequencing, which could help also help find new targets for leukaemia 
therapy. Due to the fact that CAGE sequencing picks up all transcripts which contain 
capped mRNA, this data is also suitable for further investigation of the role of long 
non-coding RNAs and miRNAs in monocyte to macrophage differentiation, as has 











Chapter 4: Deubiquitinases BAP1, USP12 and USP16 
and their functional role in macrophage differentiation 
and monocytic leukaemia  
 
4.1 Introduction 
The previous chapter described the genome-wide changes that occur during THP-1 
differentiation. This chapter will focus on particular chromatin-modifying enzymes, 
H2A deubiquitinases, which remove the PRC1 repressive mark and pave the way to 
activation of gene expression. As mentioned in Chapter 1 section 1.2.2, there are 
multiple deubiquitinases, but this study concentrated on three – BAP1, which has been 
implicated as a tumour suppressor, USP12, which appeared to be regulated in the 
earlier FANTOM4 study of THP-1 cells, and USP16, with a role in haematopoiesis. 
These are discussed in more detail below. 
 
As discussed in the Introduction (section 1.2.2.1), BAP1 (BRCA1-associated protein 
1) is a tumour suppressor gene mutated in various cancers, most relevantly to the 
project in chronic myeloid leukaemia (Dkhissi et al., 2015). BAP1, as noted from the 
name, interacts with BRCA1, a tumour suppressor most famously known for its 
involvement in human breast cancer. BAP1 has various other roles, ranging from 
regulating cell cycle progression, to promoting DNA double strand break repair (Yu 
et al., 2014). The Bap1 knockout allele in mice associates with lethality around 
embryonic days E9.5/E8.5 (Dey et al., 2012). Conditional knockouts in 
haematopoietic lineages exhibit features of human myelodysplastic syndrome, a group 
of cancers where bone marrow cells do not mature properly, plus there is an increase 
in number of monocytes (Dey et al., 2012). BAP1 only contains one recognised protein 
domain, peptidase C12, a ubiquitin carboxyl-terminal hydrolase which is the catalytic 
domain for removing ubiquitin (Figure 4-1).  
 
Unlike BAP1, USP12 and USP16 are not well studied proteins, with only 30 and 31 
published publications cited on PubMed to date (accessed October 2017, 
https://www.ncbi.nlm.nih.gov/pubmed/).  
 102
As mentioned in section 1.2.2.2, USP12 was found to have various roles, including 
activating androgen receptors (Burska et al. 2013), as a negative regulator of NOTCH 
signalling  (Moretti et al. 2012), as a cell cycle regulator (Tang et al., 2016). Most 
importantly, it was also found to deubiquinate H2A and H2B in vivo and its deficiency 
was found to have detrimental effects on the developing Xenopus embryo (Joo et al., 
2011). The MGI (Mouse Genome Informatics) database reports that homozygote 
knockouts of Usp12 (via insertion of the neo cassette into the gene) are viable but have 
reduced growth, some immune deficiencies and cardiovascular abnormalities 
(accessed on 21st October 2017, 
http://www.informatics.jax.org/marker/phenotypes/MGI:1270128). Until recently, 
there was no study looking at USP12 in macrophages. Consistent with human 
macrophages stimulated with LPS in the FANTOM5 results described in Chapter 1, a 
study by Nayak et al. (2017) found Usp12 to be upregulated in a mouse macrophage 
cell line in response to LPS stimulation, and its knock down showed that Usp12 might 
be needed for the activation of the NF-κB pathway. USP12 is a small protein (Figure 
4-1), with only one domain identified by bioinformatic tools, the same C19 ubiquitin 
carboxy-terminal domain found in USP16. USP12 needs several other proteins to 
perform its deubiquitinating function to the full extent (Joo et al., 2011, McClurg et 
al., 2015). Thus, USP12 may be a catalytic protein, which requires other compounds 
and co-factors to guide it to specific targets.   
 
USP16 has so far been found to have three independent functions (see section 1.2.2.3): 
cell cycle progression (Xu et al., 2013), DNA damage repair (Zhang et al., 2014) and 
gene activation by removal of H2A ubiquitins (Yang et al., 2014). Usp16 knockout 
mice are embryonically lethal (Yang et al., 2014), and in conditional bone marrow 
knockout mice, the haematopoietic stem cells were reduced in maturity and lineage 
commitments and there were less mature cells in peripheral blood (Gu et al., 2016). 
No studies in macrophages or leukaemic cells have been reported to date. USP16 
protein contains two domains; a zinc finger, UBP type domain (also called BUZ 
domain), which is also found in histone deacetylase 6 (HDAC6); and a catalytic site 
in the C19 ubiquitin carboxy-terminal domain (Figure 4-1). The UBP type domain 
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contains three zinc-binding sites consisting of 12 residues (Pai et al., 2007), which 
facilitate protein-protein and DNA-protein interactions. 
 
Figure 4-1 Protein domains of three H2A deubiquitinases studied in this chapter. The main transcripts 
and their translated protein domains as identified by SMART, Pfam and Prosite tools are shown. 
Information downloaded from Ensembl database. All three proteins have a catalytic ubiquitin hydrolase 
domain, USP16 also has a Zinc finger domain. Scale shows the length of the proteins in amino acid 
residues. 
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4.1.1 Aims of this chapter 
This chapter deals with the roles of three H2A deubiquitinases in the human acute 
myelocytic leukaemia cell line THP-1 and how depletion of these enzymes affects 
differentiation into macrophages. siRNA for BAP1, USP12 and USP16 was used to 
reduce the levels of mRNA for these genes. Genome-wide analysis of gene expression 
of the siRNA treated cells was analysed using CAGE sequencing (described in Chapter 
3). Overall, this chapter provides insights into the role of these three deubiquitinases 




4.2 Materials and methods 
4.2.1 Gene and protein structures and phylogenic analysis of deubiquitinase 
family 
Information about protein and gene structures was taken from the Ensembl database: 
https://www.ensembl.org (Yates et al., 2016). Information was correct as of 
September 2017. Transcription Start Site (TSS) information was taken from the 
FANTOM 5 database (Forrest et al., 2014) visualised on the Zenbu hg19 genome 
viewer (http://fantom.gsc.riken.jp/zenbu/gLyphs/) (Severin et al., 2014). 
 
4.2.2 RNA interference 
siRNA pools (GE Dharmacon) against BAP1, USP12 and USP16 were used as 
described in Chapter 2 section 2.3. All three siRNA pools were used in the initial 
experiment to test the efficacy of the siRNA, as well as the 6-well experiments set up 
for CAGE. 
 
4.2.3 CAGE library preparation and bioinformatics analysis 
Libraries were prepared and sequenced as specified in Chapter 2 section 2.2.6 together 
with processing the sequencing reads, and mapping to hg38 genome (section 2.5.1). 
Results for 38 samples (together with samples for Chapter 6) were uploaded into the 
CAGEr programme (Haberle et al., 2015) (Table 4-1, Appendix 8.3). All samples were 
normalised with CAGEr using the power law with alpha of 1.19, with results being in 
Tags per million (TPM). Data was analysed as specified in Chapter 2 section 2.5 using 




Sample Time point Number of biological 
replicates 
Wildtype (from Chapter 3)  0 hours 6 
 24 hours 4 
Non-targeting control 0 hours 2 
 24 hours 2 
BAP1 siRNA 0 hours 2 
 24 hours 2 
USP12 siRNA 0 hours 2 
 24 hours 2 
USP16 siRNA 0 hours 2 
 24 hours 2 
Table 4-1 CAGE samples used in the analysis in this chapter. All samples had two time points, 0 and 24 
hours.  
 107 
4.3 Results  
4.3.1 Bioinformatics analysis of H2A deubiquitinases 
Human BAP1, USP12 and USP16 gene structures were compared based on the 
Ensembl database to gain more knowledge about these genes, which would be needed 
for genetic editing at the later stage of the project (Chapter 6). 
 
BAP1 gene has six different protein-coding transcripts, one product predicted to 
undergo nonsense mediated decay and four products with retained introns not 
producing any protein according to Ensembl database. The BAP1 protein contains 
peptidase C12, a ubiquitin carboxyl-terminal hydrolase domain, which catalyses the 
ubiquitin removal. Only four genes in the human genome have been found to contain 
this domain; BAP1, UCHL5, UCHL1 and UCHL3. The principal transcript isoform 
used for this is ENST00000460680.5, which is 3937 bp long and codes for 729 amino 
acids. As seen from FANTOM5 data (Figure 4-2), the BAP1 primary promoter 
p1@BAP1, which initiates the principal transcript, is expressed ubiquitously 
throughout various tissues. The second promoter p2@BAP1 is located in the middle 
of the gene, producing smaller transcripts and expressed mainly in neural tissues, and 
not at all in monocytes. Thus, the principal isoform ENST00000460680.5 was used 
for further research in the THP-1 cell line. 
 
Figure 4-2 BAP1 transcription start sites as identified in FANTOM5. Image taken from Zenbu viewer. The 
primary promoter (p1@BAP1) for BAP1 is identified by red arrow. The second, tissue-specific promoter 
p2, is identified by black arrow. BAP1 is transcribed from the reverse strand, reading from right to left 
across the image. 
USP12 is a gene with large introns, which has 3 different protein coding transcripts. 
The principal transcript of USP12 (ENST00000282344.10) is also the longest at 4511 
 108
bp and codes for a peptide only 370 amino acids long. USP12 protein contains a single 
catalytic domain, which is very common among ubiquitin specific peptidases, called 
the ubiquitin specific protease domain (according to Prosite database) and peptidase 
C19, another ubiquitin carboxyl-terminal hydrolase (according to Pfam database). 
FANTOM5 results show a very simple promoter architecture (Figure 4-3) with a single 
TSS region. 
 
Figure 4-3 USP12 transcription start sites as identified in FANTOM5. Image taken from Zenbu viewer. 
The primary promoter (p1@USP12) for USP12 is identified by a red arrowhead. USP12 is transcribed 
from the reverse strand, reading from right to left across the image. 
 
The USP16 gene produces for 4 different protein-coding transcripts, and 2 retained 
intron, non-protein coding transcripts. USP16 protein contains the same 
deubiquitinase catalytic domain as USP12, but it also contains a zinc finger UBP type 
domain for DNA binding. This type of zinc finger domain has only been found in 14 
human genes at present. Three of the 4 USP16 protein-coding transcripts code for 
peptides with very similar length (two for 823 amino acids and one for 822 amino 
acids). The main difference between these three transcripts are the different lengths of 
the 5’ untranslated regions (UTR), due to variable non-coding exon usage; they all 
appear to use the same promoter region based on FANTOM5 and Ensembl data. The 
small protein-coding transcript (ENST00000399973.1) shares the same TSS as other 
transcripts based on FANTOM5 data (Figure 4-4), but codes for the zinc finger domain 
only. Thus, the longest transcript (ENST00000399973.1) of 3004 bp coding for 823 
amino acids was further used in the THP-1 study. 
 109 
 
Figure 4-4 USP16 transcription start sites as identified in FANTOM5. Image taken from Zenbu viewer. 
Primary promoter (p1@USP16) for USP16 is identified by a red arrowhead. USP16 is transcribed from 
the forward strand, reading from left to right across the image. 
 
4.3.2 Using siRNA technology to knock down the expression of BAP1, USP12 
and USP16 in THP-1 cells 
4.3.2.1 Preliminary experiments assessing the siRNA efficiency shows 
sufficient knock down for all three genes 
 
siRNA was used to knock down the deubiquitinase transcripts and to determine what 
happens to these THP-1 cells during macrophage differentiation. 
 
A pool of 4 different siRNAs was ordered (Chapter 2 section 2.3) for each gene (BAP1, 
USP12, and USP16) and their efficiency was tested using an 8-day time course (Figure 
4-5). Lipofection of the THP-1 cell line with siRNA was carried out on day -1, and 
cells were stimulated by PMA to differentiate into macrophages on day 0 (section 2.3). 
RNA was taken on day -1, 0, 1, 2, 3 and 7. 
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Figure 4-5 Diagram of the preliminary siRNA experiment assessing siRNA efficiency. siRNA was added 
at day -1, differentiation of THP-1 was started by PMA at day 0. RNA was collected at day -1, day 0, day 
1, day 2, day 3 and day 7. 
 
The BAP1 siRNA pool of 4 oligonucleotides knocked down the expression of BAP1 
to the lowest levels among all samples (Figure 4-6). Some level of BAP1 knock down 
lasted till at least day 3, compared to all other controls in this experiment – Non-
targeting siRNA pool control, Lipofectamine only control and wildtype THP-1 
differentiation control.  
 
The Non-targeting control (NT siRNA) and Lipofectamine only control 
(Lipofectamine) showed almost identical levels of BAP1 expression. The wildtype 
THP-1 (Control) closely followed their expression levels until day 7, where its BAP1 
expression was lower, and similar to day -1 and 0 (before differentiation). Unlike the 
Control, the NT siRNA and Lipofectamine controls had the highest levels of BAP1 at 
day 7. BAP1 siRNA knock down did not affect the THP-1 macrophage morphology 
compared to the condition without treatment. BAP1 siRNA pool was deemed suitable 




Figure 4-6 qRT-PCR results of an initial siRNA experiment. Pictured here is the BAP1 expression 
normalised to ACTN expression and error bars showing standard error (calculated by the by Roche 
LightCycler 480 software). Day -1 is the same for all treatments. 0 means day 0, 1 is day 1 and etc. 0 
BAP1 siRNA stands for day 0 sample with BAP1 siRNA, 1 NT siRNA stands for day 1 with Non-targeting 
control siRNA, 2 Lipofectamine stands for day 2 cells with Lipofectamine only, and 3 Control stands for 
day 3 wildtype THP-1 differentiation. 
 
A USP12 siRNA pilot experiment was carried out in the same way as BAP1 pool, 
except there was no Lipofectamine control. USP12 levels were knocked down by 
siRNA to less than half of controls (Non-targeting siRNA pool and wildtype THP-1 
differentiation) at day 0 and day 1 (Figure 4-7). The USP12 siRNA pool seemed to 
considerably downregulate the USP12 transcript levels longer than for BAP1, until day 
3 or even day 7. The Non-targeting siRNA control pool caused the USP12 levels to 
rise to higher levels than in the wildtype THP-1 differentiation control (probably due 
to the lipofection process itself (Fiszer-Kierzkowska et al., 2011)). USP12 siRNA 
knock down did not affect the THP-1 macrophage morphology compared to without 
treatment. Knock down of USP12 by USP12 siRNA pool was also deemed sufficient 
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Figure 4-7 qRT-PCR results of an initial siRNA experiment. Pictured here is the USP12 expression 
normalised to ACTN expression and error bars showing standard error (calculated by the by Roche 
LightCycler 480 software). Day -1 is the same for all treatments.0 means day 0, 1 is day 1 and etc. 0 
USP12 siRNA stands for day 0 sample with USP12 siRNA, 1 NT siRNA stands for day 1 Non-targeting 
control siRNA, and 2 Control stands for day 2 wildtype THP-1 differentiation. Y axis is in logarithmic scale 
(base 10). 
 
USP16 siRNA pool efficiency was also tested the same way as the BAP1 siRNA pool 
(Figure 4-8). USP16 expression was knocked down by siRNA to less than half of the 
controls in day 0, and even more in day 1. The mRNA levels of USP16 were 
considerably lower in the siRNA treated samples than the controls for the duration of 
the experiment. The experiment controls (Non-targeting siRNA pool, Lipofectamine 
only and wildtype THP-1 differentiation) all exhibited similar levels of USP16 mRNA 
for the duration of the time course. USP16 siRNA knock down did not affect the THP-
1 macrophage morphology compared to without treatment. Knock down of USP16 by 
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Figure 4-8 qRT-PCR results of an initial siRNA experiment. Pictured here is the USP16 expression 
normalised to ACTN expression and error bars (calculated by the by Roche LightCycler 480 software). 
Error bars show standard error. Day -1 is the same for all treatments.0 means day 0, 1 is day 1 and etc. 
0 UTY siRNA stands for day 0 sample with UTY siRNA, 1 NT siRNA stands for day 1 Non-targeting 
control siRNA, 2 Lipofectamine stands for day 2 cells with Lipofectamine only, and 3 Control stands for 
day 3 wildtype THP-1 differentiation. 
 
4.3.2.2 siRNA experiments for CAGE sequencing 
The purpose of these experiments was to harvest enough good quality RNA from THP-
1 cells treated with siRNA pools to perform CAGE sequencing. It was decided that 
only day 0 (24 hours after adding siRNA pools) and day 1 (48 hours after adding 
siRNA pools and 24 hours after adding PMA and starting macrophage differentiation) 
would be used in CAGE sequencing studies. All experiments were carried out four 
times to select the best 2 biological replicates with good quality and quantity of RNA, 
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Figure 4-9. qRT-PCR results of BAP1 expression in four siRNA experiments for CAGE sequencing. 
Pictured here is the BAP1 expression normalised to ACTN expression and error bars showing standard 
error (calculated by the by Roche LightCycler 480 software). 0 NT is Non-targeting siRNA pool at day 0, 
1 BAP1 is BAP1 siRNA pool at day 1. 
 
 
% of BAP1 expression after knock down 
Experiment day 0 day 1 
1 31% 22% 
2 28% 20% 
3 32% 29% 
4 32% 19% 
Table 4-2 BAP1 expression after knock down by siRNA pools compared to NT control levels (% of control 
level). Calculated with qRT-PCR levels normalized to ACTN by Roche LightCycler 480. 
 
As seen in Figure 4-9, BAP1 downregulation by siRNA compared to the Non-targeting 
control (NT) was consistent between all four replicates. Calculating efficiency of the 
knock down (Table 4-2) shows that most replicates had BAP1 levels downregulated 
to about 30% of the control at day 0 and around 20% for day 1. Any of these replicates 
would be suitable for further analysis, but due to the varying quantity of RNA (at least 
5 µg is needed for CAGE seq), experiments 1 and 3 were selected for CAGE. In 
Experiment 4, BAP1 day 0 total RNA was less than 5 µg, and the same for Experiment 
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Figure 4-10 qRT-PCR results of USP12 expression in four siRNA experiments for CAGE sequencing. 
Pictured here is the USP12 expression normalised to ACTN expression and error bars showing standard 
error (calculated by the by Roche LightCycler 480 software). 0 NT is Non-targeting siRNA pool at day 0, 
1 USP12 is USP12 siRNA pool at day 1. 
 
 
% of USP12 expression after knock down 
Experiment day 0 day 1 
1 30% 13% 
2 36% 9% 
3 36% 41% 
4 29% 25% 
Table 4-3 USP12 expression after knock down by siRNA pools compared to NT control levels (% of 
control level). Calculated with qRT-PCR levels normalized to ACTN by Roche LightCycler 480. 
 
USP12 downregulation by siRNA pools at day 1 was not as consistent in replicates as 
for BAP1 (Figure 4-10). USP12 gene expression levels for the Non-targeting control 
at day 1 (1 NT) varied across the replicates as well. Nevertheless, USP12 siRNA pools 
managed to knock down the expression of USP12 to around 30% of the control for 
day 0 and from 9% to 41% for day 1 (Table 4-3). Due to poor quantity and quality of 
RNA for replicates 1 and 4, the replicates chosen for RNA sequencing were from 
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Figure 4-11 qRT-PCR results of USP16 expression in four siRNA experiments for CAGE sequencing. 
Pictured here is the USP16 expression normalised to ACTN expression and error bars showing standard 
error (calculated by the by Roche LightCycler 480 software). 0 NT is Non-targeting siRNA pool at day 0, 
1 USP16 is USP16 siRNA pool at day 1. 
 
% of USP16 expression after knock down 
Experiment day 0 day 1 
1 36% 19% 
2 40% 25% 
3 32% 73% 
4 28% 45% 
Table 4-4 USP16 expression after knock down by siRNA pools compared to NT control levels (% of 
control level). Calculated with qRT-PCR levels normalized to ACTN by Roche LightCycler 480. 
 
USP16 siRNA experiment replicates also showed inconsistency in the USP16 levels 
(Figure 4-11). However, most samples showed reduction of mRNA levels of USP16 
to about 30% of the control for day 0 (Table 4-4). Day 1 expression levels were highly 
varied, from 19% of Non-targeting control in experiment 1 to 73% in experiment 3. 
For further CAGE sequencing, replicates from experiments 1 and 2 were selected due 
to the best quality and quantity of RNA and also highest levels of downregulation in 
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4.3.3 CAGE sequencing 
As discussed in Chapter 3, all CAGE reads were mapped to hg38 and normalised 
between each other using power law distribution. The 26 CAGE samples included in 
the analysis for this chapter were all siRNA samples and controls, and wildtype 
controls from THP-1 differentiation from Chapter 3 for 0 hours and 24 hours.  
 
Figure 4-12 Sample-sample correlation of correlation coefficient of 0.88 derived from Miru programme. 
Samples are nodes and edges are connections between them with a correlation coefficient of 0.88 or 
greater, i.e. how closely correlated the expression patterns are to each other across all samples. Nodes 
which are close are highly correlated. Each sample type is different colour: wildtype – blue, Non-targeting 
siRNA control – black, BAP1 siRNA – aquamarine, USP12 siRNA – green and USP16 siRNA - orange. 
Day 0 is bolder colour, Day 1 paler. 
 
All samples were then correlated to each other with Pearson’s correlation coefficient 
of 0.88 (Figure 4-12) using Miru software. From the Figure 4-12, it is clearly seen that 
the most important divide between the samples is the differentiation status. All 
undifferentiated samples (Day 0; bolder colours) are on the left of the figure and their 
expression correlates between each other more than the differentiated samples (Day 1; 
paler colours), which are primarily on the right. The greatest difference between Day 
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0 and Day 1 was in the wildtype, indicating that the treated samples all had some 
response to the treatment (including the Non-targeting control). All the treated samples 
showed a similar shift in expression to the NT control, suggesting that much of the 
observed difference may be due to non-specific effects following transfection of RNA 
using lipofectamine. 
 
The question that was considered was whether the siRNA knock down of USP12, 
USP16 and BAP1 also had an effect on THP-1 gene expression. The sample-to-sample 
correlation in Figure 4-12 shows that the biological replicates of many time points 
were not strongly correlated. For example, for BAP1 at day 0 or USP12 at day 1 
(though these had a different levels of knock down), replicates were quite distant in 
the network layout. It was noted that the two USP12 Day 1 replicates had very different 
reductions in mRNA levels measured by qRT-PCR (9% compared with 41% of NT 
control; Table 4-3), while the two BAP1 Day 0 replicates chosen had very similar 
levels (Table 4-2), so the distance between replicates is not entirely due to differential 
knock down.  
 
The gene expression levels of the three deubiquitinases detected by CAGE in each of 
the knock downs were assessed using Zenbu genome viewer. BAP1 levels at day 0 
were knocked down on average to 45% of the Non-targeting control, and 46% for day 
1 in the BAP1 knock down cells (Figure 4-13). In the USP12 knock down, BAP1 levels 
were higher than in the NT control and in the USP16 knock down, BAP1 levels were 
similar to the NT controls. This indicates that BAP1 may compensate for USP12 knock 
down.  
 
USP12 expression was knocked down on average to 45% of the Non-targeting control 
(NT) at day 0 (Figure 4-14). At day 1, Non-targeting control and USP12 siRNA values 
for USP12 expression were more variable in the biological replicates. Nevertheless, 
on average, the expression was lowered to 47% of the Non-targeting control. In the 
BAP1 and USP16 knock downs, USP12 levels were similar to Non-targeting control 
at day 0. USP12 levels were marginally lower than Non-targeting control at day 1 of 
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the USP16 knock down, but the levels in the BAP1 knock down were variable with 
one replicate much higher and one lower than the Non-targeting control. 
 
 
Figure 4-13 BAP1 expression in siRNA experiments assessed by CAGE sequencing. The gene 
expression levels are normalised and in Tags per million (TPM). Samples are Non-targeting control (NT 
siRNA), and treatment with BAP1 siRNA. USP12 siRNA and USP16 siRNA. Two biological replicates 
are shown. 
 
Unlike the initial qRT-PCR experiment (Figure 4-11). USP16 expression detected by 
CAGE did not seem to decrease after treatment with USP16 siRNA either for day 0 or 
day 1 in the samples sent for CAGE sequencing (Figure 4-15).  
 
CSF1R and MYB expression levels were similar to those of the Non-targeting control 
at both day 0 and day 1, so there is no indication that THP-1 cells subjected to siRNA 
treatment to reduce USP12 and BAP1 deubiquitinases were different from untreated 
cells, in their differentiation state.  
 
USP12 downregulation was found to increase expression of USP46 (Joo et al., 2011), 
but the level of USP46 was not found to be affected by any siRNA samples in both 
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Figure 4-14 USP12 expression in siRNA experiments assessed by CAGE sequencing. The gene 
expression levels are normalised and in Tags per million (TPM). Samples are Non-targeting control (NT 




Figure 4-15 USP16 expression in siRNA experiments assessed by CAGE sequencing. The gene 
expression levels are normalised and in Tags per million (TPM). Samples are Non-targeting control (NT 
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Figure 4-16 USP46 expression in siRNA experiments assessed by CAGE sequencing. The gene 
expression levels are normalised and in Tags per million (TPM). Samples are Non-targeting control (NT 
siRNA), and treatment with BAP1 siRNA. USP12 siRNA and USP16 siRNA. Two biological repeats are 
shown. 
 
All siRNA samples were also analysed using Miru with Pearson’s correlation 
coefficient of 0.95 (Figure 4-17). The two biggest clusters were similar to those seen 
for the wildtype samples (Chapter 3) and USP16 knockout samples (Chapter 6) – a 
cluster of monocyte markers with high expression at the beginning of the time course 
and one of macrophage markers with high expression after treatment with PMA, which 
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Figure 4-18 Interesting clusters from Miru software comparing all siRNA samples with Pearson's 
correlation ≥ 0.95. Cluster 18 contains CTSS which were only upregulated in macrophages treated with 
USP16 siRNA and cluster 36 which are upregulated in USP16 siRNA treated monocytes before 
differentiation.  
 
The two interesting clusters found were clusters 18 and 36, which, were only expressed 
in USP16 knock down samples - one in monocytes and one in macrophages (Figure 
4-18). Cluster 18 (high after PMA treatment) was significantly enriched in GO terms 
relating to alternative splicing, whereas cluster 36 (high before treatment) was 
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enriched in GO terms relating to ATP-binding. Since USP16 knock down did not 
reduce USP16 levels (measured by CAGE), these results possibly indicate an off-
target effect of the siRNA pool. 
 
No USP12 or BAP1 specific clusters were found, possibly because the biological 
replicates did not correlate well, or due to the different levels of knock down. Most 
clusters contained genes that were highly expressed in one of the replicates and not the 
other. While these clusters might have revealed the reasons for the lack of replication, 
the data could not be used to study the effects of the knock down and were not analysed 
further. 
 
Differential expression in siRNA-treated samples was also assessed using the EdgeR 
package (Table 4-5). There were only 30 CTSS that were significantly (p-value < 0.01) 
dysregulated between Non-targeting control and wildtype in non-differentiated state 
(day 0). There were more CTSS on day 1 (507 CTSS) which were up or down 
regulated than before differentiation, and the sample-sample correlation graph (Figure 
4-12) shows that the Non-targeting control was more similar to other siRNA samples 
than to wildtype.  
 
Possibly due to the lack of replication in the two samples (as seen by Miru clustering), 
there was a very small number of CTSS changed in BAP1, USP12 or USP16 siRNA-
treated samples. Most CTSS which were differentially expressed in BAP1 or USP12 





NT 0 - WT 0 NT 1 - WT 1 BAP1 0 - NT 0 BAP1 1 - NT 1 
-1 2 181 1 0 
1 28 326 2 19 
     
 
USP12 0 - USP12 1 USP12 1 - NT 1 USP16 0 - NT 0  USP16 1 - NT 1 
-1 2 48 6 81 
1 0 32 35 9 
Table 4-5 Number of CTSS which were upregulated (1) or downregulated (-1) in comparison between 
Non-targeting control (NT)or wildtype (WT) or BAP1 siRNA (BAP1) or USP12 siRNA (USP12) or USP16 
siRNA (USP16) on day 0 (0) or day 1 (1) with smaller p-value than 0.01 as calculated by EdgeR package. 
 
To make sure no important clusters were missing from the analysis, all 26 samples 
from this chapter were clustered using Miru with Pearson’s correlation threshold of 
greater than or equal to 0.93. Aside from the obvious clusters of monocytic or 
macrophages markers present in all relevant samples, the most interesting cluster was 
Cluster 32, which contained 24 CTSS that were lower in all Lipofectamine-treated 
(with siRNA) differentiated macrophages at day 1 (Figure 4-19) than in wildtype or 
genome edited cells at day 1. Significant GO annotation enrichment for this cluster 
included protein transport and splice/sequence variant.  
 
 
Figure 4-19 Cluster 32 from comparing all Chapter 4 samples in Miru software with Pearson's correlation 
≥ 0.93.  
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4.4 Discussion 
4.4.1 Chapter overview 
Histone H2A deubiquitinases remove the repressive ubiquitin mark on Lysine 119 and 
thus pave the way for the activation of gene expression during differentiation or in 
response to stimuli. In this chapter, depletion of three H2A deubiquitinases, BAP1, 
USP12 and USP16 in acute monocytic leukaemia THP-1 cells was examined using 
siRNA technology. Knock down of these three genes in THP-1 cells was analysed 
using CAGE technology. CAGE libraries were successfully created. Unfortunately, 
biological replicates for USP12 and BAP1 siRNA samples did not correlate with each 
other and thus not many genes were significantly affected by BAP1 or USP12 
depletion. The discrepancy between the qRT-PCR results and CAGE quantification of 
mRNA levels for USP16 made it difficult to interpret the impact of USP16 knock 
down. 
 
4.4.2 Using siRNA to knock down deubiquitinases in THP-1 cells did not yield 
any significant results 
siRNA was used to knock down the level of these chromatin modifying enzymes. 
Lipofectamine2000 was chosen as a mode of delivery into the cells due to its previous 
use in FANTOM4 (Suzuki et al., 2009), although other lipofection reagents have been 
tried in THP-1 with very similar delivery efficiency (not shown). ON-TARGETplus 
SMARTpool siRNA was chosen, as it contains 4 different siRNAs to maximise the 
knock down and had been tried before in monocytic cells (Troegeler et al., 2014). 
 
BAP1 siRNA and USP12 siRNA pools successfully downregulated the mRNA levels 
of BAP1 and USP12 respectively, according to both qRT-PCR and also CAGE 
sequencing. However, even though USP16 siRNA downregulated USP16 according 
to qRT-PCR (with primers in exons 15 and 16), this was not shown by CAGE 
sequencing. This discrepancy might be due to CAGE only picking up the 5’ end of 
mRNA, not anywhere else. The 4 siRNAs in the pool targeting USP16 bind to exons 
8+9, 15 and 17, but the siRNAs for BAP1 and USP12 target exons much earlier – 
exons 4 and 3, respectively (section 2.3.1). However, due to the mechanism of siRNA 
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silencing, the 5’end of mRNA would be immediately targeted for degradation and the 
remnants of functional mRNA would have a very transient lifespan. The way to solve 
this question is to either perform qRT-PCR with primer sets mapping to other exons 
(and see if the USP16 expression truly goes down) or perform western blotting on the 
samples.  
 
Even though both BAP1 and USP12 siRNA biological replicates had similar levels of 
downregulated transcripts, they did not correlate closely with each other and all 
replicates had variable global gene expression (as seen in Figure 4-12). This is in 
contrast with the Non-targeting control, where replicates did group together well. Miru 
did not find any relevant clusters which were either upregulated or downregulated in 
both biological replicates for BAP1 or USP12; most of genes were differentially 
expressed in one replicate, but not the other. This can also be seen in the very small 
number of differentially expressed genes found by EdgeR. It could be due to the nature 
of siRNA knock down, when different amounts of protein might be made. Knock 
downs should therefore be validated by western blotting as well as measurement of 
mRNA. Without protein validation, it can be only speculated why the two replicates 
were so variable. Both targets are chromatin modifying enzymes and thus their 
deficiency might result in different responses in cells – especially in cells which were 
not synchronised in cell cycle phases. These replicates were done on different days, 
and even though every precaution was taken to preserve the same experimental 
variables, cells might have behaved differently. Another explanation is that because 
BAP1 expression is upregulated in USP12 siRNA samples, BAP1 or other 
deubiquitinase might have compensated differently for this loss in different 
experiments.  
 
4.4.2.1 Limitations of siRNA use 
Using siRNA technology to reduce mRNA translation levels and therefore study the 
protein function in cells had been widely reported, as it is simple to do. siRNAs are 
smaller than plasmid DNA and therefore are easier to deliver to cells. However, 
knocking down gene expression using siRNA also has its disadvantages. First, the 
reduction in mRNA level is transient and therefore does not permanently affect protein 
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levels, especially in proliferating cells. Lipofectamine was found to stimulate 
proliferation in immune cells (Przybylski et al., 2017), which is then stopped by 
addition of PMA in THP-1 cells. However, there have also been reports of 
Lipofectamine slowing down cell proliferation in HeLa cells (Zhang et al., 2011). 
There are genes which are affected by the Lipofectamine treatment itself (like genes 
in Cluster 32, Figure 4-19) and thus proper controls (like the Non-targeting control 
sample) are needed.  
 
The use of Lipofectamine might interfere with various macrophage responses, for 
example response to LPS (Leon-Ponte et al., 2005). Monocytic cells also do not 
respond well to foreign nucleic acid, since one function is to detect viral infections 
which can be indicated by the presence of viral DNA or RNA. Nucleic acids can induce 
cell death (Paijo et al., 2016). Optimisation of siRNA delivery methods into THP-1 
which do not interfere with macrophage function might be required (as seen for 
lipofection of primary monocytic and macrophage cells (Troegeler et al., 2014)). 
 
4.4.3 Conclusions and future directions 
In the USP12 siRNA samples, when the levels of one deubiquitinase was lower, gene 
expression of other deubiquitinases was upregulated. This has been documented 
previously by literature – for example USP12 downregulation results in USP46 
upregulation (Joo et al., 2011). However, USP46 gene expression was not significantly 
affected by downregulation deubiquitinases in this study. As documented in the 
introduction, there are various deubiquitinases that might share redundant function. 
Future knockdowns or knockouts of multiple deubiquitinases might answer this 
question. The use of CRISPR-Cas9 technology to knockout the deubiquitinase genes 
is explored in Chapter 6. 
 
To properly distinguish between different roles of H2A deubiquitinases and 
concentrate on the regulation of gene expression, ChIP-seq against these H2A 
deubiquitinases could be performed during wildtype THP-1 differentiation to analyse 





Chapter 5: Demethylases KDM6A, KDM6B and UTY 
and their functional role in macrophage differentiation 
and monocytic leukaemia  
 
5.1 Introduction 
The previous chapter described a study of several deubiquitinase enzymes during the 
transition of THP-1 monocytes to macrophages. As mentioned in Chapter 1, 
demethylase enzymes are also important in chromatin modification during cell state 
changes and the present chapter examines the impact of several of these enzymes on 
THP-1 differentiation. There are at least two demethylases containing a Jumonji C 
(JmjC) catalytic domain (described further in section 1.2.3.1 and 1.2.3.2), which are 
known to be responsible for removing the di-and trimethyl groups on H3K27 (Hong 
et al., 2007). These are KDM6A also known as Ubiquitously Transcribed 
Tetratricopeptide Repeat on chromosome X (UTX) and KDM6B which was first 
described as the Jumonji domain containing protein 3 (JMJD3) (Van der Meulen et 
al., 2014, Hong et al., 2007). Ubiquitously Transcribed Tetratricopeptide Repeat 
Containing, Y-Linked (UTY) is a third protein which contains JmjC domain (Figure 
5-1) but is frequently overlooked as a non-functional Y-chromosome-encoded 
counterpart of KDM6A. UTY is also known as KDM6C (Allis et al., 2007). 
 
KDM6B, unlike KDM6A or UTY, lacks the tetratricopeptide repeats (TPRs) (Figure 
5-1). TPRs are important for protein-protein interactions (Van der Meulen et al., 
2014), and the fact that KDM6B does not have them might suggest a lack of redundant 
functions between KDM6A and KDM6B. The KDM6A gene is located on 
chromosome X in eutherian mammals. Although not located in the pseudoautosomal 
region, KDM6A escapes X-inactivation (Greenfield et al., 1998). Eutherian females 
therefore have higher levels of this dosage-sensitive protein than eutherian males. 
However, eutherian males have a gene called UTY, the homologue of KDM6A on the 
Y chromosome, which shows similar patterns of expression to KDM6A (Xu et al., 
2008). The UTY protein was thought to be enzymatically inactive (Shpargel et al., 
2012) but recent studies suggest it may have some residual activity. 
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Figure 5-1 Protein domains of H3K27 demethylases. The main transcripts and their translated protein 
domains as identified by SMART, Pfam and Prosite tools are shown. Information downloaded from 
Ensembl database. KDM6A and UTY both have TPR domains and all three proteins have a catalytic 
JmjC domain. Scale shows the length of the proteins in amino acid residues. 
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As mentioned briefly in section 1.2.3.1, complete deletion of Kdm6a in mice results in 
fully penetrant embryonic lethality (Welstead et al., 2012). Shpargel et al. (2012) 
described Kdm6a-/- embryos at E10.5 stage to display severe deformities of neural 
tube, yolk sac and heart, and  their entire development was delayed. These embryos 
were dead and reabsorbed by stage E12.5. Surprisingly, there was a subset of Kdm6a-
null male mice (~25%) who survive to adulthood. These mice were smaller with 
reduced lifespan, but they were fertile and viable. This disparity was thought to be due 
to compensation for the absence of Kdm6a by Uty. Further experiments generated 
Kdm6a- Uty- male mice, which shared the fate of female homozygous Kdm6a-/- mice 
and died in utero with heart deformities.  
 
Thus, although UTY was previously thought to be catalycally inactive (Shpargel et al., 
2012), these results indicate that UTY performs some function. Indeed, Walport et al. 
(2014) found that human UTY does have a low level of H3K27me3 demethylase 
activity in vitro. Together with the knockout mouse studies, this suggests that UTY 
might be functionally redundant with KDM6A at least in some cells and tissues. 
However, it is not certain whether this depends on its demethylase activity or its 
protein-protein interactions.  
 
A recent study identified KDM6B as an oncogene and KDM6A as a tumour suppressor 
gene in T-cell acute lymphoblastic leukaemia (T-ALL), but did not completely address 
the role of UTY in T-ALL  (Ntziachristos et al. 2014). Further understanding of the 
activity of these enzymes, particularly UTY, in acute monocytic leukaemia cell lines 
would potentially be helpful for cancer treatments and improvement of outcomes.  
 
5.1.1 Aim of this chapter 
The aim of this chapter was to assess the importance of these three demethylase 
enzymes in the monocytic leukaemia cell line THP-1, and their impact on cell viability 
and ability to differentiate these cells into macrophages using a range of bioinformatics 
analysis tools and experimental approaches. 
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The focus of the bioinformatic investigation was on the relationship between KDM6A 
and UTY due to their localisation on sex chromosomes and the possibility that they 
might have complementary roles. The expression of KDM6A and UTY was assessed 
using FANTOM 5 datasets and available genome data from the Ensembl browser (see 
Methods below). The THP-1 cell line was used to experimentally test how perturbing 
gene expression or the catalytic function of these demethylases influenced the viability 
of the leukaemic cells and/or their competence in cell differentiation. THP-1 cells 
contain a deletion of the first exons (1 to 16) in KDM6A, and do not produce KDM6A 
protein at all (van Haaften et al., 2009). Consequently, studying THP-1 cell line helps 
to find more clues about UTY functionality. As mentioned in previous chapters, 
KDM6B expression is upregulated during early stages of THP-1 differentiation to 
macrophages and this enzyme thus might be one of the key factors that control changes 
in cell state and/or cell lineage definition. Perturbing the expression of KDM6B and 
UTY was attempted by silencing their expression by RNAi and using specific 





5.2 Materials and methods 
5.2.1 Bioinformatic analysis of KDM6A, KDM6B and UTY genes 
Gene structure, protein sequences and other gene information if not mentioned 
otherwise were taken from Ensembl database (https://www.ensembl.org; (Yates et al., 
2016). Data is up to date as of September 2017. Protein sequences were aligned using 
MegAlign and MegAlign Pro; sequences were visualised using SeqBuilder (Lasergene 
suite 14, DNASTAR, Inc, Madison, Wisconsin, USA). Domains in protein sequences 
were determined using ScanProsite (http://prosite.expasy.org/scanprosite/) (de Castro 
et al., 2006). Human FANTOM 5-time course and baseline data was downloaded from 
http://fantom.gsc.riken.jp\zenbu (Severin et al., 2014). TPM for KDM6A and UTY 
were determined by highlighting the entire promoter region of the genes. Samples with 
UTY gene expression of 0 TPM were filtered to remove female samples; where 
available the sex of the sample was confirmed from sample information 
(http://fantom.gsc.riken.jp/5/sstar/Main_Page). For the remaining samples TPM for 
UTY and KDM6A were plotted against each other. Cancer samples were separated 
manually from tissue samples based on information at 
http://fantom.gsc.riken.jp/5/sstar/Main_Page. A full list of sample names and their 
respective TPM used for this study is found in Appendix 8.6. The KDM6B, KDM6A 
and UTY promoter structures were also assessed using FANTOM 5-time course and 
static datasets (Arner et al., 2015, Forrest et al., 2014). Transcription factor binding 
sites associated with KDM6A, UTY and KDM6B were discovered using Harmonizome 
available at http://amp.pharm.mssm.edu/Harmonizome/ (Rouillard et al., 2016). 
 
5.2.2 RNA interference 
siRNA pools (GE Dharmacon) against UTY and KDM6B were used as described in 
section 2.3. Both UTY and KDM6B siRNAs were employed in initial experiment to 
test the efficacy of siRNA pools and for validating their mRNA expression silencing 
capacity for the subsequent 6-well CAGE experiments. 
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5.2.3 Inhibition KDM6A, KDM6B and UTY enzymatic activity 
GSK-J4 and GSK-J5 (Cayman chemicals, Ann Arbor, MI, USA) were diluted in 
DMSO (Sigma-Aldrich) at a stock concentration of 1 mg/ml (2.2 mM) and frozen at  
-20 ºC in aliquots. The stock was then diluted to the desired concentration in THP-1 
media and added to cells. Cytotoxicity of different concentrations of both, GSK-J4 and 
GSK-J5, was tested using the MTT assay (as described in section 2.4.1). For cell 
adherence assays, THP-1 cells were seeded in 6-well plates at a density of 5x105 cells 
per plate. Cells were differentiated with 30 ng/ml PMA as described in section 2.1, 
with the inhibitor added at the same time. Non-adherent cells, collected by removing 
the medium without lifting the adherent cells, were counted with a haemocytometer 
after 24 and 48 hours post differentiation and treatment with inhibitors. DMSO without 
PMA control was included to see if DMSO concentration alone could trigger THP-1 
differentiation. The cell permeable isomer of GSK-J4, GSK-J5 was used as an inactive 
control of GSK-J4 (Kruidenier et al., 2012).  
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5.3 Results 
5.3.1 H3K27 demethylases – a bioinformatics study 
5.3.1.1 Genes, transcripts and protein comparison 
Firstly, human KDM6A, KDM6B and UTY gene structures were compared based on 
the Ensembl database and FANTOM 5 data to gain more knowledge about these genes 
which would be needed for genetic editing at the later stage of the project. 
 
KDM6B gene has 6 different splice variants, with only different 3 protein-coding 
transcripts (Table 5-1). The shortest protein-coding transcript (203, 
ENST00000570632.1) does not code for the KDM6B catalytic domain, whereas the 
other two do. These two long transcripts (6713 bp and 5422 bp) code for similarly long 
proteins (1682 amino acids and 1643 amino acids, respectively). Out of these two, the 
longer transcript (201, ENST00000254846.9) was selected from Ensembl using 
APPRIS bioinformatic tools (Rodriguez et al., 2013) as a candidate principal isoform, 
which was used for further analysis. 





1 201 ENST00000254846.9 Protein-coding 6713 1688 JmjC 
2 202 ENST00000448097.6 Protein-coding 5422 1643 JmjC 
3 203 ENST00000570632.1 Protein-coding 1339 361 none 
4 205 ENST00000572030.1 Processed transcript 432 NA NA 
5 204 ENST00000571047.5 Processed transcript 362 NA NA 
6 206 ENST00000575521.1 Processed transcript 219 NA NA 
Table 5-1 KDM6B and its transcripts and encoded proteins as identified by Ensembl datasets. 
 
Examination of the KDM6B promoter region in humans revealed a more complex 
picture (Figure 5-2). Looking at FANTOM 5 data, which show transcription start sites 
(TSS), the highest number of TSSs for KDM6B seem to be in an area within the first 
intron of the 201 transcript, not at the beginning of the identified transcripts. This 
region is annotated as a CpG island, and three different enhancers have also been 
identified in this region through bioinformatics analysis (Andersson et al., 2014). 
FANTOM 5 has identified the main promoter p1 for KDM6B in the centre of the gene 
(labelled as p1@KDM6B in intron 1/2), which is not consistent with the Ensembl and 
Gencode gene models (Figure 5-2). For further KDM6B gene expression analysis, the 
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region from the beginning of the gene to the end of the CpG island (boxed in Figure 
5-2) was taken into consideration.  
 
Figure 5-2 KDM6B gene structure and its TSS. Image taken from FANTOM5 genome viewer Zenbu 
(section 5.2.1). Upper tracks show the position, extent of the locus as determined by Ensembl, gene 
models are from Gencode data, enhancers are from FANTOM5 data and identified CpG islands from 
UCSC data. Lower tracks show the number of tags at the TSS detected in the FANTOM5 study and the 
promoters identified after clustering of TSS (Forrest et al 2014). Green indicates transcription from the 
forward strand; purple indicates transcription from the reverse strand. TSS associated with KDM6B are 
shown by the box and p1@KDM6B is indicated by the arrow. 
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According to Ensembl, the KDM6A gene has 14 different transcripts, 10 of which are 
predicted to be protein encoding (Table 5-2). The transcripts range from lengths of 
5924 bp to 671 bp. Some shorter protein-coding splice variants do not code for 
KDM6A JmjC or TPR functional domains (for example transcripts 205, 203, 206 and 
214). Interestingly, Ensembl has flagged the second longest protein-coding transcript 
rather than the longest one as its principal candidate isoform by the bioinformatics 
method APPRIS (Rodriguez et al., 2013). The principal isoform (currently named 
KDM6A-201), which codes for a 1401 amino acid long protein, has been chosen for 
further analysis in this study. The FANTOM 5 study identified only the main promoter 
(p1@KDM6A) at the start of the gene, no other alternative promoters can be detected 
or have been described (Figure 5-3). 
 
  TRANSCRIPT ENSEMBL ID TYPE LENGTH (BP) PROTEIN 
LENGTH (AA) 
DOMAINS 
1 201  ENST00000377967.8 Protein-
coding 
5438 1401 TPR, 
JmjC 
2 213  ENST00000611820.4 Protein-
coding 
5924 1429 TPR, 
JmjC 
3 202  ENST00000382899.8 Protein-
coding 
5789 1384 TPR, 
JmjC 
4 212  ENST00000543216.5 Protein-
coding 
5655 1269 TPR, 
JmjC 
5 211  ENST00000536777.5 Protein-
coding 
5633 1332 TPR, 
JmjC 
6 205  ENST00000433797.5 Protein-
coding 
4324 1044 JmjC 
7 203  ENST00000414389.5 Protein-
coding 
4189 999 JmjC 
8 214  ENST00000621147.4 Protein-
coding 
2876 224 TPR 
9 204  ENST00000431196.2 Protein-
coding 
735 161 none 
10 206  ENST00000451692.5 Protein-
coding 
671 224 TPR 
11 208  ENST00000479423.1 Processed 
transcript 
768 NA NA 




640 NA NA 
13 207  ENST00000475233.1 Processed 
transcript 
612 NA NA 
14 210  ENST00000485072.5 Processed 
transcript 
382 NA NA 




Figure 5-3 KDM6A gene structure and its TSS. Image taken from FANTOM5 genome viewer Zenbu 
(section 5.2.1). Upper tracks show the position, extent of gene determined by Ensembl, gene models 
from Gencode data, enhancers from FANTOM5 data and identified CpG islands from UCSC data. Lower 
tracks show the number of tags at the TSS detected in the FANTOM5 study and the promoters identified 
after clustering of TSS (Forrest et al., 2014). Green indicates transcription from the forward strand; purple 
indicates transcription from the reverse strand. 
 
Similarly to KDM6A, UTY has 16 transcripts the in Ensembl database, 13 of them are 
protein-coding (Table 5-3), with various transcript and peptide lengths. Some splice 
variants do not contain the JmjC domain or full length TPR domains. None of the 
transcripts have been verified as a principal isoform by APPRIS for this gene based on 
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protein structural information, cross-validation from other species and important 
protein residues (Rodriguez et al., 2013). For further analysis, the longest transcript 
(currently UTY-212, as of August 2017) was chosen (6817 bp, which encodes a 1444 
amino acid protein). FANTOM 5 transcription start site database did not show any 
alternative promoters to the main promoter named p1@UTY (Figure 5-4).   
 
Figure 5-4 UTY gene structure and its TSS. Image taken from FANTOM5 genome viewer Zenbu (section 
5.2.1). Upper tracks show the position, extent of the locus as determined by Ensembl, gene models are 
from Gencode data, enhancers are from FANTOM5 data and identified CpG islands from UCSC data. 
Lower tracks show the number of tags at the TSS detected in the FANTOM5 study and the promoters 
identified after clustering of TSS (Forrest et al 2014). Green indicates transcription from the forward 
strand; purple indicates transcription from the reverse strand. P1@UTY is the main promoter identified 
by FANTOM5 (red arrowhead), and no other TSS were found to be expressed at high rate. 
 140




1 212 ENST00000545955.5 Protein-coding 6817 1444 TPR, JmjC 
2 214 ENST00000617789.4 Protein-coding 6682 1399 TPR, JmjC 
3 205 ENST00000382896.8 Protein-coding 6661 1392 TPR, JmjC 
4 211 ENST00000540140.5 Protein-coding 6652 1389 TPR, JmjC 
5 213 ENST00000612274.4 Protein-coding 6586 1667 TPR, JmjC 
6 210 ENST00000538878.5 Protein-coding 6574 1363 TPR, JmjC 
7 202 ENST00000331397.8 Protein-coding 6529 1347 TPR, JmjC 
8 209 ENST00000537580.5 Protein-coding 6490 1335 TPR, JmjC 
9 215 ENST00000618474.4 Protein-coding 6277 1264 TPR, JmjC 
10 203 ENST00000362096.8 Protein-coding 4990 1240 TPR, JmjC 
11 201 ENST00000329134.9 Protein-coding 4325 1079 TPR 
12 216 ENST00000624098.3 Protein-coding 3636 1211 TPR, JmjC 
13 204 ENST00000382893.2 Protein-coding 1539 207 TPR 
14 206 ENST00000474365.1 Processed transcript 1387 NA NA 
15 207 ENST00000478900.5 Processed transcript 747 NA NA 
16 208 ENST00000479713.1 Processed transcript 686 NA NA 
Table 5-3 UTY and its 16 transcripts according to the Ensembl database. 
 
Human KDM6A and UTY show up to 88% cDNA homology and up to 86% amino 
acid homology (Appendix 8.7, Ensembl database, accessed November 2016). KDM6B 
showed only 29% cDNA homology with both KDM6A and UTY, and even less for the 
protein. KDM6A and UTY proteins look very similar, which is consistent with their 
amino acid sequence homology (Figure 5-1). Unlike KDM6B, both contain 7 TPR 
domains. However, all three proteins contain a catalytic JmjC domain, which is 
conserved across all members of the KDM family (Klose et al., 2006). 
 
Because of the high similarity between the KDM6A and UTY proteins, their amino 
acid sequences were compared further using the MegAlign programme. The results 
show that the sequences of the TPR and JmjC functional domains are highly 
homologous between both proteins (Figure 5-5, Figure 5-6). The catalytic residues 
(red asterisks in Figure 5-6) in their JmjC domains are also sequence conserved. 
Walport et al. (2014) reported that a G -> S substitution in the JmjC domain (green 
rectangle in Figure 5-6) reduces the UTY demethylase activity compared to KDM6A. 
The linker sequence between the domains is not as highly conserved compared to both 




Figure 5-5 MegAlign CLUSTAL W comparison between Ensembl predicted amino acid sequences of the 
KDM6A and UTY main transcripts. 7 TPR domains are boxed in blue. Highlighted yellow residues 
indicate sequence conservation. 
 
Figure 5-6 MegAlign CLUSTAL W comparison between Ensembl amino acid sequences of KDM6A and 
UTY main transcripts. JmjC domain is boxed in red. Highlighted yellow residues indicate sequence 
conservation between both proteins. Red asterisks denote catalytic sites in the JmjC domains. The green 
rectangle points to the amino acid change that has been previously reported to be associated with a 
reduction of the catalytic activity of UTY (Walport et al, 2014). 
 
5.3.1.2 Investigating co-regulation of UTY and KDM6A 
Due to the similarity of the UTY and KDM6A proteins, the vast FANTOM5 dataset 
was analysed to determine whether or not the genes were expressed at the same time 
in the same tissues (suggesting co-regulation) or with opposite expression patterns 
(suggesting functional redundancy in different tissues). An initial survey showed that 
most samples did not express UTY (Table 5-4). However, all testes and prostate 
samples did express UTY (Appendix 8.6), suggesting that those not expressing UTY 
were from female donors. Where possible this was validated using the metadata for 
samples available as part of the FANTOM5 data set (section 5.2.1). All samples with 
UTY TPM = 0 were excluded from further analysis (Table 5-4) to properly assess the 
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gene expression correlation of KDM6A and UTY. KDM6A and UTY TPM values were 
positively correlated (Pearson’s correlation = 0.720, Figure 5-7). These results show 
that UTY probably does not substitute for KDM6A in KDM6A low expression cells, 
since when there is a high UTY expression, there is also high KDM6A expression. 
However, there seems to be less correlation between UTY and KDM6A expression 
levels in cancerous tissue as further analysed below. 
 




ALL Together 1829  
 UTY TPM = 0 1312  
 UTY TPM > 0 517 0.720 
TISSUES Together 1358  
 UTY TPM = 0 919  
 UTY TPM > 0 439 0.727 
CANCER Together 471  
 UTY TPM = 0 393  
 UTY TPM > 0 78 0.322 
Table 5-4 FANTOM5 static and time course samples. Pearson's correlation coefficient between 
expression in non-zero UTY samples and KDM6A was calculated in Microsoft Excel. 
 
 
Figure 5-7 Correlation of mRNA expression of UTY versus KDM6A for all male FANTOM5 human 
samples. Samples which had no expression of UTY were taken out to accurately assess the correlation 


















Figure 5-8 Correlation of mRNA expression of UTY versus KDM6A for all male tissues and non-
cancerous cell samples. Pearson’s correlation coefficient =0.727, N= 439. 
 
 
Figure 5-9 Correlation of mRNA expression of UTY versus KDM6A for all cancer samples. Samples with 
no UTY expression were removed. Pearson’s correlation coefficient = 0.322, N= 78. 
Interestingly, comparing tissue only data (Figure 5-8) to cancer samples (Figure 5-9), 
the high correlation in tissues did not apply to cancerous samples (Pearson’s 
correlation 0.727 vs 0.322). There were fewer cancer samples than tissue samples, but 
modelling using a simulated larger dataset with the same distribution of expression 
levels did not change the correlation coefficient. KDM6B expression did not have a 
































COMPARISON SAMPLE SIZE CORRELATION 
COEFFICIENT 
KDM6B VS KDM6A 1829 0.469 
KDM6B VS UTY (UTY 
TPM > 0) 
517 0.261 
Table 5-5 FANTOM 5 samples comparison for KDM6B with UTY and KDM6A. 
Next, potential co-regulation of KDM6A and UTY by the same transcription factors 
was assessed. Alignment analysis of promoter regions of KDM6A and UTY in human 
sequences (where the transcription factors would bind) downloaded from FANTOM 5 
dataset, using MegAlign Clustal W, showed the sequences were not strikingly similar 
(data not shown).  
 
Using protein and gene database Harmonizome, different predicted transcription factor 
binding sites (TF) for KDM6A, UTY and KDM6B were identified. Various databases 
for transcription factors binding sites were used such as TRANSFAC, JASPAR, 
CHEA and ENCODE (Matys et al., 2003, Matys et al., 2006, Mathelier et al., 2014, 
Sandelin et al., 2004, Lachmann et al., 2010, ENCODE, 2004). TRANSFAC and 
JASPAR predict TF binding using known binding site motifs, whereas CHEA and 
ENCODE use ChIPseq data. The TRANSFAC dataset also provided curated data, 
which were manually selected from low-throughput or high-throughput TF functional 
studies. The data from these five different sources gave very variable results, with very 
few TF appearing in more than 2 studies (all TF tables are available in Appendix 8.8).  
 
Figure 5-10 TRANSFAC predicted and curated transcription factor binding sites in KDM6A, KDM6B and 
UTY promoters. Data taken from Harmonizome. 
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Figure 5-11 JASPAR predicted transcription factor binding in KDM6A, KDM6B and UTY promoters. Data 
taken from Harmonizome.  
 
A number of TF binding sites appeared common to KDM6A and UTY, especially in 
TRANSFAC curated dataset (Figure 5-10), where all 10 UTY TF were shared by 
KDM6A. Fewer TF sites were shared between KDM6A and KDM6B or UTY and 
KDM6B in all three datasets, with no TF shared by all three gene promoters (Figure 
5-10, Figure 5-11) 
 
Figure 5-12 CHEA and ENCODE transcription factor binding based on ChIPseq studies in KDM6A, 
KDM6B and UTY promoters. Data taken from Harmonizome. 
This trend is different in ChIP-seq based data (Figure 5-12) where the UTY promoter 
does not have as many TF binding sites as the other two. In both CHEA and ENCODE 
datasets KDM6A and KDM6B have a number of TF binding sites in common, unlike 
UTY. The ENCODE dataset also shows 32 different TF sites which are common to all 
three gene promoters. 
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Using Harmonizome and its pathway commons protein-protein interactions database, 
KDM6A and UTY share a higher number of common protein interaction partners, 
even though KDM6B has a higher number of targets overall (Figure 5-13). This 
database also shows that UTY and KDM6A interact together (Appendix 8.8). 
 
 
Figure 5-13 Pathway Commons protein-protein interactions of KDM6A, KDM6B and UTY. Data taken 
from Harmonizome. 
 
5.3.1.3 Evolutionary analysis of UTY and KDM6A 
Surveying orthologues of genes in other species provides clues about evolutionary 
constraints and thus the importance and possible function of a gene itself. In this 
section, the evolutionary relationships of the demethylases are examined, with the 
emphasis on the KDM6A and UTY genes.  
 
According to Ensembl database, the KDM6B gene has 82 orthologues, KDM6A has 90 
and UTY 51 orthologues in different species. Placental mammal orthologues are most 
similar to the human ones, but depending on the evolutionary distance of other species 
from humans, the less clear become the available annotations. However, even in 
animals with distant shared ancestors, for example in C. elegans, there is a gene 
encoding a JmjC domain, however, based on the available information of the protein 
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structure and its encoded domains this gene is probably not a homologue or paralogue 
of mammalian KDM6A, KDM6B or UTY as its protein structure is much less complex.  
KDM6A is located on human chromosome band Xp11.3 and at a syntenic region in 
other eutherian mammals, whereas it is located on an autosome (chromosome 4) in 
opossum (a marsupial) according to Ensembl database and UltraContig222 and is 
predicted to be located on chromosome 18p in platypus (a monotreme) (Veyrunes et 
al., 2008). KDM6A is also located on autosomes in birds and fish (Ensembl database). 
This would suggest that the KDM6A gene became associated with the sex chromosome 
with a block of other genes, somewhere at the time when the common ancestor for all 
eutherian mammals evolved. Therefore, only eutherian males do not have two 
expressing alleles of KDM6A, as KDM6A escapes X inactivation in human females 
(Greenfield et al., 1998).  
 
UTY lies on the mammalian Y chromosome, right next to two other genes with X 
chromosome equivalents, USP9Y and DDX3Y and a testis specific non-coding element 
TTTY15. KDM6A also neighbours the X-equivalent genes, USP9X and DDX3X, 
although not as close by. There was only moderate correlation when comparing 
TTTY15 gene expression with UTY or DDX3Y in the FANTOM5 human dataset 
(Figure 5-14, Figure 5-15). There are almost no gene expression data for USP9Y in the 
FANTOM5 results, and the reason for this lack of data is not clear. According to data 





Figure 5-14 Correlation of RNA expression of TTTY15 versus UTY for all FANTOM5 human samples, 
including time courses. Pearson’s correlation coefficient = 0.358, N= 1829. 
 
Figure 5-15 Correlation of RNA expression of TTTY15 versus DDXY3 for all FANTOM5 human samples. 
Pearson’s correlation coefficient = 0.409, N= 1829. 
 
5.3.1.4 Conclusions of bioinformatics analyses 
In conclusion, analysis of available data for KDM6A and UTY shows that they share 
many similarities, in both amino acid sequence homology (Figure 5-5, Figure 5-6) and 
regulation of gene expression or common protein interactions (Figure 5-10, Figure 
5-13). In contrast, KDM6B shows only a low level of similarity to either KDM6A or 
UTY. 
 
Perturbing the gene expression or inhibiting the demethylase activity of these enzymes 






































of leukaemic cell lines and their differentiation from monocyte-like cells into 
macrophages. The next section reports the results of experiments changing expression 
of these genes through the use of RNAi as well as using an inhibitor of the catalytic 
activity of their JmjC domains. 
 
5.3.2 The inhibitor GSK-J4 does not prevent THP-1 cells from differentiating 
into adherent macrophage-like cells 
The inhibitor GSK-J4 has been found to specifically inhibit the demethylase activity 
of both KDM6B and KDM6A, with no data available of testing its effect on UTY 
(Kruidenier et al., 2012, Heinemann et al., 2014). To assess whether the ability of 
THP-1 cells to differentiate into macrophages is dependent on the demethylase activity 
of KDM6B or UTY, adherence assays were performed. 
 
Firstly, an MTT assay of inhibitor toxicity was carried out on THP-1 cells. Identical 
numbers of THP-1 cells were cultured in varying concentrations of both GSK-J4 
(inhibitor) or GSK-J5 (control) for 48 hours, and then their metabolic activity was 
measured by a colorimetric MTT assay. Results showed (Figure 5-16) that GSK-J4 
had higher toxicity effect on THP-1 cells at lower concentrations than the control 
GSK-J5. Both inhibitors did not affect THP-1 viability and metabolic activity up to a 
concentration of 5 µM. However, from 10 µM upwards GSK-J4 decreased THP-1 
viability to ~50% of THP-1 without inhibitor. GSK-J5 did not reach 50% viability 




Figure 5-16 MTT assay results for THP-1 cells treated with varying concentrations of GSK-J4 and GSK-
J5. Results after 48 hours in culture are shown. Results were measured at 570 nm, samples were 
quadruplicate. Blank measurement (only medium) was subtracted from the mean of samples. Error bars 
show standard deviation (SD).  
 
A known number of THP-1 cells were then subjected to an adherence assay, where 
different concentrations of the inhibitors were added together with the differentiating 
agent PMA and adherence and morphology of the cells were assessed after 24 and 48 
hours. Adherence of the cells indicates that they have differentiated towards 




























Figure 5-17 Summary of four different experiments testing the adherence of THP-1 cells 24 hours after 
adding PMA and varying concentrations of inhibitors. Control is THP-1 cells without any additions, DMSO 
is THP-1 cells with DMSO (the carrier of the inhibitors) to test whether DMSO itself make the cells 
differentiate. 
 
The results of four replicates of the adherence assays (Figure 5-17, Figure 5-18,  
Table 5-6, Figure 5-19) are quite variable. THP-1 cells without any treatment (Control) 
and with control amount of the vehicle (DMSO) seemed to not differentiate and adhere 
to the plate in 24 or 48 hours. Control differentiation of THP-1 (PMA, without 
inhibitors) proceeded successfully and more than 90% of cells were adherent after 48 
hours. Therefore, if the inhibitors were suppressing differentiation, the proportion of 






































Inhibitor summary after 24 hours
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Figure 5-18 Summary of four different experiments testing the adherence of THP-1 cells 48 hours after 
adding PMA and varying concentrations of inhibitors. Control is THP-1 cells without anything, DMSO is 
THP-1 cells with DMSO (the carrier of the inhibitors) to test whether DMSO itself make the cells 
differentiate. 
 
Each replicate of the assay for inhibitor GSK-J4 and the control inhibitor GSK-J5 
showed different results and the average of these four replicates has a very high 
standard deviation ( 
Table 5-6, Figure 5-19). Nevertheless, a consistent finding was that a larger population 
of cells seemed to be non-adherent after 24 or 48 hours in high concentrations of GSK-
J4 than for GSK-J5. The non-adherent cells counted were always viable, as dead cells 
were excluded by Trypan Blue staining, so it is not clear whether the inhibitor actually 
killed the cells or just stopped their metabolic activity (as detected by MTT assay) at 












































Inhibitor summary after 48 hours




Average values  24 h 24 h SD 48 h 48 h SD 
Control 1.290 0.50 1.683 0.59 
DMSO 1.385 0.35 1.365 0.38 
0µM + PMA 0.065 0.05 0.015 0.01 
          
2µM GSK-J4 +PMA 0.065 0.02 0.013 0.01 
5µM GSK-J4+PMA 0.083 0.03 0.040 0.01 
10µM GSK-J4+ PMA 0.318 0.25 0.165 0.18 
15µM GSK-J4+ PMA 0.493 0.14 0.275 0.23 
20µM GSK-J4+ PMA 0.703 0.26 0.520 0.18 
          
2µM GSK-J5 +PMA 0.075 0.04 0.030 0.01 
5µM GSK-J5+PMA 0.060 0.04 0.025 0.01 
10µM GSK-J5+ PMA 0.388 0.23 0.130 0.15 
15µM GSK-J5+ PMA 0.195 0.10 0.168 0.13 
20µM GSK-J5+ PMA 0.473 0.16 0.210 0.23 
 
Table 5-6 Average values of percentage of non-adherent THP-1 cells (compared with initial number 
seeded into plates) after being treated with inhibitors for 24 hours (24 h) and 48 hours (48 h). Average 





Figure 5-19 Average values of non-adherent THP-1 cells after being treated with inhibitors for 24 hours 
(24 h) and 48 hours (48 h). Average values of 4 different technical replicates. Error bars represent 
standard deviation (SD), which was calculated from these 4 technical replicates. 
5.3.3 Using siRNA technology to knock down the expression of UTY and 
KDM6B in THP-1 cells 
5.3.3.1 Preliminary experiments assessing siRNA knock down 
efficiency showed no effect on UTY, and moderate effect on 
KDM6B  
RNAi was used to knock down expression of these UTY and KDM6B. A pool of four 
different siRNAs was ordered (Chapter 2 section 2.3) for each gene and their 
efficiency was tested using an 8-day time course. Lipofection with siRNA of the THP-
1 cell line was carried out on day -1, and cells were stimulated by PMA to differentiate 
into macrophages on day 0 (section 2.1). RNA was taken on day -1, 0, 1, 2, 3 and 7.  
 
For KDM6B, a Non-targeting control (NT) and normal THP-1 differentiation assay 
without lipofection or siRNA (control) were included. For UTY there was also a 
lipofection-only control, without any siRNA (Lipofectamine). The Non-targeting (NT) 
siRNA pool is specially designed to not bind anywhere specifically in the human 









































Figure 5-20 qRT-PCR results of an initial siRNA experiment for KDM6B. Pictured here is the KDM6B 
expression normalised to ACTN expression and error bars (calculated by the by Roche LightCycler 480 
software). Error bars show standard error. Day -1 is the same for all treatments.0 means day 0, 1 is day 
1 and etc. 0 KDM6B siRNA stands for day 0 sample with KDM6B siRNA, 1 NT siRNA stands for day 1 
Non-targeting control siRNA, and 2 Control stands for day 2 wildtype THP-1 differentiation. 
KDM6B was expressed at low levels at day -1 and 0 in control differentiation 
experiment (Control), but it increased 9-fold from day 0 to day 1, and then stabilised 
its expression for the rest of time course by day 2 (Figure 5-20). The Non-targeting 
control (NT) followed the pattern of the Control time course for days 0 and 1, but 
KDM6B expression continued to increase up to day 3.  
 
siRNA pool (KDM6B siRNA) knocked down the expression of KDM6B in day 0 to 
about half the value of NT. The values were around the same level as the Control 
experiment for day 0. KDM6B expression at day 1 was knocked down to up to ~50% 
of NT or Control expression using the siRNA pool. Some level of knock down was 
maintained until around day 3, if compared to Control, and throughout the whole time 
course if compared to NT control. The cells exhibited the same macrophage 



























KDM6B expression in siRNA pilot experiment
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Figure 5-21 qRT-PCR results of an initial siRNA experiment for UTY. Pictured here is the UTY expression 
normalised to ACTN expression and error bars (calculated by the by Roche LightCycler 480 software). 
Error bars show standard error. Day -1 is the same for all treatments.0 means day 0, 1 is day 1 and etc. 
0 UTY siRNA stands for day 0 sample with UTY siRNA, 1 NT siRNA stands for day 1 Non-targeting 
control siRNA, 2 Lipofectamine stands for day 2 cells with Lipofectamine only, and 3 Control stands for 
day 3 wildtype THP-1 differentiation. 
 
The UTY siRNA pilot experiment also included a third control – Lipofectamine 2000 
used on day -1, without siRNA (Lipofectamine) (Figure 5-21). Generally, UTY 
expression did not change much throughout the normal time course of THP-1 
differentiation (Control), with similar values for also Lipofectamine and NT controls. 
The only exception was day 7 for both Lipofectamine and NT control, where 
expression was almost twice as high as for the Control. Other than that, Lipofectamine 
or Non-targeting siRNA pool did not affect the UTY expression during THP-1 
differentiation. 
 
UTY siRNA pool only reduced UTY expression to ~70% of the NT control on day 0. 
On day 1, UTY siRNA pool expression was higher than NT. UTY siRNA did not 
prevent THP-1 differentiating into macrophages, as they became adherent to the 
surface and exhibited a macrophage-like morphology. It can be concluded that UTY 
siRNA pool did not knock down the expression of UTY to a sufficient level at day 0, 
and not at all after start of the differentiation, so the impact of reducing UTY mRNA 



































































































































































































UTY expression in pilot siRNA experiment
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5.3.3.2 siRNA experiment harvesting RNA for proposed CAGE 
sequencing did not show a satisfactory knock down for KDM6B 
and almost none for UTY 
The siRNA experiments were carried out again, aiming to harvest sufficient RNA for 
CAGE sequencing.  
 
 
Figure 5-22 qRT-PCR results of KDM6B expression in four siRNA experiments for CAGE sequencing. 
Pictured here is the KDM6B expression normalised to ACTN expression and error bars (calculated by 
the by Roche LightCycler 480 software). Error bars show standard error. 0 NT is the Non-targeting siRNA 
pool at day 0, 1 KDM6B is KDM6B siRNA pool at day 1. 
 
KDM6B siRNA pool experiment was repeated 4 times, with lipofection of siRNAs on 
day -1, harvesting RNA and simultaneously adding PMA at day 0, and harvesting 
RNA on day 1 again. Only Non-targeting control (NT) was used in this instance 
(Figure 5-22). Replicates seem to have similar levels of KDM6B expression on day 0, 
with more variation at day 1. This might be due to the greater biological variability of 
the cells after differentiation, as also seen in FANTOM4 (Suzuki et al., 2009). 
 
KDM6B expression level was only reduced to around half in all four cases for day 0 
(Table 5-7) and remained at more than 70% on day 1. This was deemed an 
unacceptable level of knock down to properly assess the effect of change in gene 






























KDM6B expression in siRNA CAGE experiments
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% of KDM6B expression after knock down 
Experiment number day 0 day 1 
1 59% 75% 
2 57% 70% 
3 57% 70% 
4 44% 90% 
Table 5-7 KDM6B expression after knock down by siRNA pools compared to NT control levels (% of 
control level). Calculated with qRT-PCR levels normalized to ACTN by Roche LightCycler 480. 
 
Because UTY knock down was not very efficient in the pilot experiment, UTY siRNA 
pools were only repeated twice in the siRNA experiments for possible CAGE 
sequencing. UTY siRNA pools did not knock down the UTY expression to less than 
65% in any sample (Figure 5-23, Table 5-8). In the second experiment day 1, UTY 
expression with the UTY siRNA was even higher than the control (Figure 5-23, Table 
5-8). 
 
Figure 5-23 qRT-PCR results of UTY expression in four siRNA experiments for CAGE sequencing. 
Pictured here is the UTY expression normalised to ACTN expression and error bars (calculated by the 
by Roche LightCycler 480 software). Error bars show standard error. 0 NT is Non-targeting siRNA pool 
at day 0, 1 UTY is UTY siRNA pool at day 1. 
 
 
% of UTY expression after knock down 
Experiment number day 0 day 1 
1 68% 65% 
2 71% 146% 
Table 5-8 UTY expression after knock down by siRNA pools compared to NT control levels (% of control 
































Thus, it was not appropriate to continue with CAGE sequencing for any demethylase 
siRNA treated samples.  
 160
5.4 Discussion 
5.4.1 Overview of this chapter  
H3K27 demethylases perform an important catalytic function in mediating change in 
gene expression, whether it is cell differentiation or activation, because they remove 
repressive marks from histones which opens the chromatin and facilitates 
transcription. In this chapter, functional roles of H3K27 demethylases were more 
closely studied using widely available open source databases like Ensembl and 
FANTOM5, and also using the THP-1 monocyte to macrophages experimental 
system. 
 
Looking at bioinformatics analysis of KDM6A, UTY and KDM6B showed that 
KDM6A and UTY genes are very similar in structure and their regulation, and thus 
potentially their function as well. KDM6A and UTY expression was found to be co-
regulated, but this seemed to diminish in cancerous samples. Using the THP-1 
experimental system, which contains a mutation deleting KDM6A expression, allows 
exploration of the function UTY and KDM6B in leukaemic monocytic cells and in the 
monocyte to macrophage transition. Demethylase-specific inhibitor GSK-J4 prevented 
THP-1 differentiation, consistent with these enzymes being important in removing 
repressive marks from key genes. It was hoped to study this effect by targeting each 
demethylase specifically. Unfortunately, treatment with RNAi was not able to knock 
down the expression of KDM6B and UTY sufficiently to have an impact on enzyme 
function.  
 
5.4.2 Bioinformatics study of H3K27 demethylases 
5.4.2.1 Structural differences between H3K27 demethylases 
Analysis of the different transcripts, proteins, promoter structure and gene expression 
of KDM6A, KDM6B and UTY demethylases showed that KDM6B is quite different 
from the other two. As mentioned in section 5.1, UTY has been frequently overlooked 
as a catalytically inactive member of this protein family, with much more focus 
directed at its X chromosome paralogue, KDM6A. Even though the protein structure 
of KDM6B lacks the TPR domains found in KDM6A, there is functional catalytic 
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redundancy between these two proteins in some instances (Manna et al., 2015). 
However, KDM6B expression did not have a high positive correlation with UTY or 
KDM6A expression in the comprehensive FANTOM5 data (Table 5-5), suggesting a 
weak link between gene regulation and function of KDM6B and KDM6A/UTY. 
 
KDM6B was shown to have quite a complex promoter structure based on expression 
data from FANTOM5 (Figure 5-2). There was no main TSS peak as seen in other 
simpler promoter structures (Figure 5-3 or Figure 5-4). Instead, there are multiple TSS 
for transcription from both strands, which is a sign for enhancers (Arner et al., 2015). 
The enhancer area actually comprised of one of the most expressed KDM6B TSS, 
whereas the areas where the two main protein-coding transcripts should start, had very 
low transcript levels. Enhancers having higher levels than the promoters they regulate 
is unusual, and it might be possible that this enhancer region interacts with another 
promoter. However, the highest TPMs of this region (KDM6B), reflecting gene 
expression, were found in stimulated immune cells (for example monocyte-derived 
macrophages stimulated with LPS) which is highly documented by literature (De Santa 
et al., 2009). The KDM6B promoter 1 annotated by FANTOM5 (p1@KDM6B) is 
found in the middle of the gene, where none of the known transcripts have start sites, 
and this position was not used as the promoter region for further analysis. Instead, the 
whole CpG region was used to determine expression for KDM6B, which could mean 
that some enhancer activity was included. However, Ensembl lists this whole region 
as promoter flanking region, with two promoters, either at the beginning of the two 
long protein-coding transcripts, or further away, at the beginning of the short protein-
coding transcript. All in all, it seems that even though the CpG region taken for 
consideration does include some expression associated with enhancers, it is also 
identified as a promoter for the short transcript (Ensembl ID ENST00000570632.1). It 
is therefore possible that most of the expression for KDM6B detected in the 
FANTOM5 samples codes for the short transcript without the JmjC catalytic domain. 
However, for example, KDM6B activity in monocyte-derived macrophages stimulated 
with LPS depends on its demethylase activity (Kruidenier et al., 2012) and thus it is 
highly improbable that these transcripts would be without the catalytic domain. Further 
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investigation by looking at RNAseq data would be able to confirm or to deny this 
hypothesis. 
 
UTY and KDM6A did not have the complex promoter structure of KDM6B (Figure 5-3, 
Figure 5-4). However, UTY has been reported as having a huge frequency of 
alternative splice forms (Laaser et al., 2011). They found as many as 284 new 
transcripts, but these findings have not been validated by other reports. Thus, only the 
16 validated transcripts from Ensembl were included in this project to elucidate the 
role of UTY in THP-1 cells. As described in the results section, a few of the protein-
coding transcripts do not code for UTY or KDM6A functional domains. It is not clear 
whether these incomplete peptides are able to carry out the functional role of these two 
enzymes.  
 
5.4.2.2 Co-regulation of demethylase gene expression 
KDM6A and UTY were analysed in detail to observe the level of similarity between 
these two genes, and assess the importance of UTY in cells due to its frequent neglect 
in publications about demethylases. Several lines of evidence suggested that UTY 
might have some function in cells. For example, while Kdm6a-/- female mice die in 
utero, a proportion of Kdm6a-/Y male mice, which have a normal Uty gene on the Y 
chromosome, survive. In addition, THP-1 cells, which have a deletion of KDM6A 
which renders it non-functional, are also able to survive in culture, possibly due to the 
presence of a functional UTY gene. 
 
Firstly, it was hypothesized that UTY might compensate for KDM6A in tissues where 
there is low KDM6A expression. In this case, there would be an inverse correlation 
between expression of KDM6A and UTY. Instead, these results showed that UTY and 
KDM6A gene expression are positively correlated (Figure 5-7), suggesting that the two 
genes are co-regulated and that UTY might be a mechanism to compensate in males 
for the single copy of KDM6A (which is not inactivated in females who therefore have 
expression from both chromosomal gene copies).  
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This positive correlation was shown to be disrupted in cancer-only cells (Figure 5-9). 
KDM6A is a known tumour suppressor gene, so the disruption could contribute to the 
malignancy of cancerous cells. For example, Ahn et al. (2016) reported that both UTY 
and KDM6A enhance proliferation of two male urothelial bladder cancer cell lines. 
UTY knockout increased cell proliferation to the same rate as KDM6A knockout, 
whereas double knockout of KDM6A and UTY increased it even more. The authors 
argue this is due to the loss of dosage-dependent suppression effect of KDM6A/UTY 
in urothelial cancer. KDM6A, like other developmentally important chromatin 
modifying genes and tumour suppressor genes, is tightly regulated in most tissues 
(Bellott et al., 2014). Unlike other genes on the chromosome X, X genes with a Y 
chromosome paralogue have even been mostly found to have a role in transcription, 
translation and nucleic acid binding (Bellott et al., 2014). There is a strong assumption 
that these genes (many of them coding for chromatin-modifying enzymes) are needed 
for proper gene regulation and thus are more sensitive to the altered dosage. 
Perturbation of this fine balance of regulation of demethylase activity might result in 
cancer or developmental issues. 
 
KDM6A missense, nonsense and deletion mutations were found to cause Kabuki 
syndrome (KS, OMIM #147920) (Miyake et al., 2013), which is a rare multi-systemic 
disorder first reported in Japan by two research groups (Kuroki et al., 1981, Niikawa 
et al., 1981). Patients with KS have an unusual facial appearance, resembling the 
traditional make up by Japanese Kabuki artists. However, the majority of cases were 
found by whole-genome sequencing to have mutations in KMT2D (histone lysine N-
methyltransferase 2D, also known as MLL2), not KDM6A. KMT2D is part of a 
complex involved in methylating H3K4 (and thus activating gene expression), which 
also includes KDM6A (Cho et al., 2007). So far, 33 germline mutations in KDM6A 
gene have been found in a comprehensive study of KS mutations (Bogershausen et al., 
2016). No mutations have been reported in UTY.  
 
Some patients with Turner syndrome (TS) were found to have KS like features 
(Rodriguez et al., 2008). TS is a 45,X monosomy and is the only human chromosomal 
haploinsufficiency where affected individuals survive after birth. Nevertheless, it 
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significantly affects foetal mortality as only 1% of 45X monosomy foetuses survive to 
term (Hook and Warburton, 2014). TS patients surviving to adulthood are most 
probably mosaic cases (Hook and Warburton, 2014) where some cells have two X 
chromosomes or an X and a Y chromosome. 
 
Trolle et al. (2016) hypothesized that KDM6A is a potential candidate gene for 
premature ovarian failure in TS. KDM6A was found to be more highly expressed in 
46XX karyotype than in 45X karyotype, which is consistent with the observation that 
KDM6A escapes X-inactivation (Greenfield et al., 1998). However, they found that 
KDM6A was expressed at the same level in 46XX females as in 46XY males. If UTY 
is also active, this should mean that males have much higher levels of demethylase 
activity (from KDM6A and UTY) than females with just KDM6A. These results are 
also not consistent with other findings in mouse (Xu et al., 2008), where higher levels 
of KDM6A in liver and brain in females than in males were reported. Xu et al. (2008) 
postulated that even though Kdm6a does escape X inactivation, its expression from the 
inactivated X is lower than from the active X chromosome. 
 
Miyake et al. (2013) created a hypothesis for the KDM6A abnormality observed in KS 
and TS. They ascertain that a certain level of KDM6A/UTY gene expression is needed 
for proper developmental function, either two copies of KDM6A or one copy of 
KDM6A and one of UTY. This threshold level is higher than that coming from one 
copy of KDM6A, as TS patients have one copy of KDM6A and may manifest a KS-
like phenotype (discussed above). KS syndrome female patients also can have skewed 
inactivation of the X chromosome for the KDM6A mutation (Lederer et al., 2012), 
which could bring the overall level of KDM6A (one X active copy) higher than in 
males with KDM6A mutation, but still less than the expression level reached with two 
KDM6A copies (one X active copy and one X inactive less expressing copy). Thus, 
this hypothesis needs to be investigated further by assessing absolute levels of 
KDM6A and UTY in the same male and female tissues. 
 
Analysis of potential TF binding on KDM6A, UTY and KDM6B promoters either by 
motif predicting (Figure 5-10, Figure 5-11) or various ChIPseq data (Figure 5-12) gave 
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very variable results. More validation would be needed, especially by ChIPseq in the 
same cell type, but the present results indicate that KDM6A and UTY have a higher 
number of common TF than either with KDM6B.  
 
According to the database Common Pathways protein-protein interactions, UTY 
protein interacts with KDM6A (Appendix 8.8), but with also other parts of the H3K4 
methylation complex such as KMT2B, KMT2C and RBBP5, just like KDM6A. This 
suggests that UTY binds to the same complex as KDM6A and also performs 
demethylation functions. It is not clear whether UTY binds to this complex 
independently or only with KDM6A present, so it still might have a catalytically 
autonomous function and could therefore target different substrates. Further 
investigation into protein-protein interactions with KDM6A should prove interesting. 
 
Although UTY may serve a separate male specific function, for example in testes, it 
appears to be expressed globally (Appendix 8.6). The findings presented in this section 
suggest that in general KDM6A and UTY have shared regulation, which may allow for 
survival of males by compensating for the haploinsufficiency of KDM6A. In contrast 
KDM6B appears to have very different regulation and showed little redundancy with 
KDM6A and UTY, indicating that this protein likely has an independent role. 
 
5.4.2.3 Evolutionary consequences of KDM6A position on X 
chromosome 
Despite recent advances in high throughput sequencing of genomes of various 
organisms, Y chromosome sequence has been frequently overlooked, which makes it 
more difficult to examine UTY sequences in other organisms and its evolutionary 
history. Most genome releases in Ensembl did not include Y chromosomes, probably 
due to its small size, its presumed low gene content and a huge number of repetitive 
sequences which hinder scaffold assemblies (Li et al., 2013a). However, from the 
limited reports of Y chromosome sequencing it appears that UTY is one of the few Y 
chromosome genes that is present as a functional gene in all species studied so far (Li 
et al., 2013a). 
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The original placental and marsupial (therian) Y chromosome, containing the sex-
determining gene SRY, emerged approximately 180 million years ago (Cortez et al., 
2014). UTY is located in a Y chromosome region that stopped recombining 
approximately 100 million years ago (Lahn and Page, 1999), together with other Y-
chromosome genes such as ZFY, USP9Y, DDX3Y and TMSB4Y (Cortez et al., 2014), 
just as KDM6A emerged on the X chromosome. As mentioned in the results section, 
UTY has always clustered together in a male-specific Y chromosome region (MSY) 
with two other Y-linked genes, USP9Y and DDX3Y, throughout eutherian Y 
chromosome evolution despite rampant rearrangements of Y chromosome (Li et al., 
2013a). The high microsyntenic conservation of this cluster of genes 
UTY+USP9Y+DDX3Y suggests that they might be co-regulated. Li et al (2013) 
speculate that they could be regulated by the ‘testis-specific’ non-coding element 
TTTY15. However, expression was not correlated with either of these genes in the 
extensive FANTOM5 results (Figure 5-14, Figure 5-15) so this hypothesis was not 
confirmed.  
 
Gerrard and Filatov (2005) reported findings of positive directional selection on 
human genes UTY and USP9Y, unlike their X chromosome paralogues which are under 
a strong purifying (negative) selection. This means that any KDM6A mutation 
negatively affects the cell, but UTY mutations may have been encouraged in evolution 
and they might be beneficial with a male-specific function. The question arises 
whether the loss of the larger part of the sequence encoding the demethylase / 
hydroxylase function of UTY was driven by positive selection or was an unfortunate 
consequence of evolutionary processes acting on the Y chromosome. Nevertheless, it 
seems that, despite the tight regulation of KDM6A and UTY gene expression, UTY with 
lower demethylase activity seems sufficient to rescue the embryonically lethal Kdm6a-
/- genotype.  
 
5.4.3 Inhibition of KDM6A, KDM6B and UTY  
Initially, the effect of perturbing demethylase function on THP-1 differentiation was 
assessed using an H3K27 demethylase specific inhibitor. GSK-J4 is a cell permeable 
H3K27 demethylases inhibitor, which binds to the catalytic centre of JmjC domain 
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(Kruidenier et al., 2012). It was originally thought to bind only to KDM6A and 
KDM6B, but later was proved to bind weakly to other demethylases such as KDM5B 
and KDM5C (Heinemann et al., 2014). Neither of these papers show whether GSK-J4 
has an effect on UTY demethylase activity. Kruidenier et al. (2012) also showed that 
GSK-J4 successfully inhibits LPS stimulation of human monocyte-derived 
macrophages, and decreases typical LPS response-related gene expression. Control for 
this experiment was GSK-J5, a cell permeable compound similar to GSK-J4, but 
without any inhibitor activity (Kruidenier et al., 2012). The half-maximum inhibitory 
concentration (IC50) of GSK-J4 effect on KDM6B in unnamed cell based assays was 
3.1 µM (Heinemann et al., 2014), whereas IC50 for GSK-J4 in TNFα blockade was 9 
µM (Kruidenier et al., 2012). 
 
The MTT results (section 5.3.2) show that viability/metabolic activity or proliferation 
of THP-1 decreased to about 50% at 10 µM GSK-J4 inhibitor. Other research projects 
used GSK-J4 at much lower dose in THP-1 cell line (1 and 2 µM) (Ha et al., 2017, 
Ntziachristos et al., 2014). Together with the MTT results, it seems that the reason 
why cells do not differentiate and adhere to the bottom of the well is due to the lethality 
or effect on metabolic activity of the inhibitor. Because GSK-J5 decreases cells’ 
viability/metabolic activity at a lower rate than GSK-J4, it can be concluded that 
demethylase activity of KDM6 proteins is important for the cells’ survival or 
metabolic activity. GSK-J4 only binds to the catalytic centre of the JmjC fold, so 
specific protein-protein interactions of KDM6B and UTY might be still active.  
 
The adherence assay also had high variability of the results, suggesting that THP-1 
cell populations were not completely uniform in response to the inhibitor, something 
else is affecting the differentiation or the methods of quantifying the results need to be 
improved. Counting cells with haemocytometer is not time effective nor precise. 
Establishing clear boundary between THP-1 monocytes and macrophages using 
macrophage markers such as CD11b for flow cytometry would be helpful. 
Unfortunately, an initial attempt showed that this approach needed to be optimised 
extensively and it was not possible to achieve this due to time constraints. Another 
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way would be to take the two populations of adherent and non-adherent cells and 
investigate gene expression levels of monocyte and macrophage markers.  
 
MTT results suggest that the non-adherent cells present at >10 µM concentration levels 
are dead/metabolically inactive cells. However, due to using Trypan blue during 
counting, only living cells were included. It might be suggested that high 
concentrations of GSK-J4 only slow down the differentiation process, since, when 
these non-adherent cells were replated onto a fresh plate, they did appear to 
differentiate after few days (only repeated once, not shown). GSK-J4 might therefore 
slow down or pause the differentiation process, but it is not known how long GSK-J4 
stays active in the cell. The differentiation adherence assay was also only performed 
at 24 and 48 hours post-differentiation, making it possible to miss the window at which 
differentiation of THP-1 cells affected by GSK-J4 is slowed down. As only a fraction 
of cells at 10 and 20 µM were adherent after 24 and 48 hours, it seems that perhaps 
the cells are not uniform in their response to the inhibitor. It might be useful to use 
lower passage number of THP-1 cells to assess whether passaging and time in culture 
affects this response. These experiments with inhibitor against KDM6B in THP-1 cells 
raised interesting questions about THP-1 uniformity. Further research could include 
gene expression analysis and assessing global H3K27me3 levels in THP-1 following 
the use of the inhibitor. 
 
Since the results with the demethylase inhibitor suggested that KDM6B and possibly 
UTY were involved in the transition from monocyte to macrophage, other approaches 
to perturb the level of these proteins in THP-1 cells were then explored.  
 
5.4.4 siRNA silencing efficiency for KDM6B and UTY in THP-1 cells 
Next, silencing of the genes was attempted using RNAi in THP-1 cells. The pools of 
four different siRNA provide complete silencing of the gene according to the 
manufacturer (GE Dharmacon website, 2016). The mode of delivery chosen was 
lipofection by Lipofectamine 2000, following the procedure in the FANTOM4 project 
(Suzuki et al., 2009). THP-1 monocyte cells were hard to transfect with plasmids 
(discussed further in Chapter 6), it was easier to introduce siRNAs, as described in 
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previous chapter (Chapter 4). It might have been possible to achieve higher level of 
transfection using siRNA-specialised Lipofectamine reagents (for example 
Lipofectamine RNAiMAX, Thermo Fisher Scientific), but as shown in Chapter 4, 
where the level of BAP1 expression was knocked down to less than 20% of the control 
expression, the problem of low efficiency of KDM6B and UTY knock down was not 
in the lipofection itself.  
 
KDM6B expression was knocked down by siRNA to around 50% at day 0, which was 
not as low as required to explore the effects of the gene/protein (Chapter 5.3.3.2). At 
day 1 the knock down is even less at only around 30% reduction in mRNA level. As 
KDM6B expression levels before differentiation are very low and dramatically rise 
during first hours of differentiation (as seen in Chapter 3), it might be possible that the 
amount of siRNA present in the cell did not manage to degrade all the KDM6B 
transcripts at the peak of expression. However, the final concentration of siRNA used 
was higher than the minimum amount suggested by manufacturer (50 nM vs 20 nM) 
for all siRNAs. 
 
It seems that lipofection itself increases the KDM6B levels, as the cells are in stress 
(Figure 5-20). All the comparisons between siRNA and control were therefore made 
using Non-targeting siRNA control (NT). This might explain why KDM6B knock 
down did not have an effect on THP-1 differentiation, as the absolute levels of KDM6B 
transcript in cells with KDM6B siRNA and Lipofectamine might have been around 
the same as in control THP-1 cells without Lipofectamine.  
 
The UTY siRNA pool did not downregulate the amount of UTY transcripts in THP-1 
cells at any point. The best knock down out of all repeats was around 30% reduction 
in mRNA level, and at one point the UTY mRNA level increased above the control 
level with the addition of UTY siRNA. It is unclear why the siRNA pool did not 
decrease UTY levels. The primer set used to quantify the UTY levels by qRT-PCR was 
designed specifically to detect only UTY transcripts (exon 16). This primer set was 
used in preliminary absolute expression qRT-PCR experiment comparing U937 cell 
line (with no UTY and with KDM6A expression) with THP-1, where the expression 
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was only found in THP-1 cells (not shown). The most similar transcript to UTY is 
KDM6A, which is not expressed at all in THP-1 in FANTOM5 data and very small 
amount in FANTOM4. Looking at THP-1 clone 5 genome using microarray-based 
comparative genomic hybridization, there is a deletion in X chromosome which also 
includes KDM6A (Adati et al., 2009). van Haaften et al. (2009) states that the deletion 
occurs precisely at exons 1 to 16 in KDM6A in THP-1 cells. It can therefore be 
concluded that this UTY primer set used in the qRT-PCR cannot pick up KDM6A 
contamination in THP-1 cells.  
 
To ensure higher knock down of UTY and KDM6B using siRNA different sets of 
siRNAs for KDM6B and UTY could be designed and tested. Transcript levels could 
also be assessed by various sets of primers, and the protein levels should be checked 
by western blotting.  
 
5.4.5 Conclusions and future directions 
This chapter has shown that UTY, despite its low demethylase activity, should share 
some of the activities of KDM6A. This functionality is worth further investigation, 
either by assessing the levels of KDM6A and UTY in the same male and KDM6A in 
female tissues to see whether KDM6A and UTY expression together in males equates 
to KDM6A expression in females. The present study failed to knock down UTY using 
siRNA in THP-1 cells, but other options include using primary cells from male and 
female donors to see whether UTY has an effect on cell survival. A further possibility 
is to use other leukaemia cell lines and primary cells with or without UTY and KDM6A 
genes to elucidate the UTY function by adding exogenous WT or mutated KDM6A or 
UTY proteins or overexpression the genes. KDM6B gene expression was shown to 
rapidly increase during early monocyte to macrophage differentiation (Chapter 3). 
Thus, it is reasonable to assume that it is important in changing gene expression. It 
would be interesting to find out whether cells would change gene expression if more 
KDM6B protein was added or the gene was overexpressed. The use of CRISPR-Cas9 
technology to knockout the demethylases’ genes is explored in Chapter 6. 
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 In summary, studying demethylases KDM6A, KDM6B and tentative demethylase 
UTY brings us more clues about how chromatin modifying enzymes orchestrate the 
change in gene expression and how their dosage is important in development and 





Chapter 6: Genome editing of chromatin modifying 
enzymes using CRISPR-Cas9 
 
6.1 Introduction 
As discussed in Chapters 4 and 5, perturbing the expression of the chromatin 
modifying genes using inhibitors and siRNA showed variable results. Knocking down 
a gene using siRNA never brought its expression down to zero per cent, with protein 
still being made. Even though the dosage of chromatin modifying enzymes is 
extremely important in healthy cells (as discussed in Chapter 5), transient lower levels 
of these enzymes in leukaemic cell lines such as THP-1 might still permit their 
immediate survival. Therefore, attempts were made to generate stable mutations in 
these chromatin modifying genes using genome editing technology.   
 
CRISPR (clustered regularly interspaced short palindromic repeats) - Cas9 is a new 
genome editing technology which utilises a bacterial system of recognition of 
sequences against viruses, such as bacteriophages and other genetic mobile elements 
(as reviewed by Doudna and Charpentier (2014)). This method is extremely efficient, 
versatile and easy to design, as to create a new target, only a 20 nucleotide guide 
sequence, which leads the endonuclease Cas9 to the desired place, needs to be 
provided (Ran et al., 2013). Cas9 creates a double strand break, which can be repaired 
by non-homologous end joining (NHEJ), if no template is present, creating an insertion 
or a deletion (indel) (Ran et al., 2013).  In the present project, the 20 nt guide sequence 
has been inserted into a plasmid containing Cas9 nuclease and GFP genes, so that 
successfully transfected cells express GFP and are easily recognisable (Ran et al., 
2013). 
 
High levels of Cas9 activity or guide sequences which are highly complementary to 
multiple places in the genome might lead to off-target effects. Most researchers have 
found that CRISPR-Cas9 is an extremely precise technology, with minimum off target 
effects (Iyer et al., 2015), and the ones reporting extortionate high numbers of off 
target effects are currently being investigated (Schaefer et al., 2017). 
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At the start of this project, no genome editing employing CRISPR-Cas9 had been used 
in THP-1 cells. Since then, only two reports have been published (Goetze et al., 2017, 
Schmidt et al., 2016), with THP-1 cells declared to be difficult to transfect with 
CRISPR-Cas9 plasmid. Nevertheless, generating a stable knockout THP-1 cell line 
with multiple passage numbers in culture and thus diminishing the probability of 
functional protein being present in the cell after multiple cell divisions might give more 
information about the functional role of these enzymes in leukaemia.  
 
6.1.1 Aims of this chapter 
In this chapter attempts to edit the five chromatin modifying genes in THP-1 cells are 
described. As THP-1 cells have a deletion of the first exons (1-16) of KDM6A (van 
Haaften et al., 2009), these represent a natural knockout of this gene with no KDM6A 
expression found in FANTOM5 data (Chapter 3 and 5), and further manipulation was 
not necessary.  
 
Initially bioinformatics analysis using Ensembl and FANTOM5 databases was done 
in Chapters 4 and 5 to decipher which transcripts and transcription start sites are used 
in BAP1, USP12 USP16, KDM6B and UTY. This knowledge was used to design 
CRISPR-Cas9 guides to efficiently knockout these five enzymes. The USP16 gene 
was successfully altered by insertion of an adenine nucleotide causing a frameshift 
mutation. USP16 knockout THP-1 clone proliferation, cell cycle progression and 
macrophage phagocytosis were assessed. The effect of USP16 deficiency on THP-1 






6.2 Materials and methods 
6.2.1 CRISPR-Cas9 editing of target genes 
CRISPR sequence guides were designed using an online website tool 
(http://crispr.mit.edu), where the desired sequence to be edited was queried, and then 
good quality guides were selected based upon their base chemistry and possible off-
target effects (Table 6-1). Information about protein and gene structures was taken 
from the Ensembl database: https://www.ensembl.org (Yates et al., 2016). Information 
was correct as of September 2017. Translation of altered USP16 DNA exonic sequence 
into protein was provided by the online ExPaSy tool available at 
http://web.expasy.org/translate/. Transcription Start Site (TSS) information was taken 
from the FANTOM 5 database (Forrest et al., 2014) visualised on the Zenbu hg19 
genome viewer (http://fantom.gsc.riken.jp/zenbu/gLyphs/) (Severin et al., 2014). The 
oligonucleotides were ordered through Sigma-Aldrich (0.025 µmol, DST purification) 
based on the protocol from Ran et al. (2013). 
 
The guide sequences were initially phosphorylated and annealed together by adding 1 
µl of 100 µM TOP sgRNA, and 1 µl of 100 µM BOTTOM sqRNA together with 1 µl 
of T4 PNK ligase 10X Buffer (NEB), T4 PNK (10 U/ µl, NEB) and 6 µl of water (total 
10 µl per guide). The mixture was incubated at 37°C for 30 minutes, 95°C for 5 
minutes and then cooled down to 25°C at 5°C per minute. The phosphorylated and 
annealed oligonucleotides were diluted 1:200 by adding 1 µl of annealed and 
phosphorylated oligonucleotide mix to 199 µl water. The sgRNA oligonucleotides 
were then cloned into a plasmid vector containing a Cas9 open reading frame sequence 
(pX458 from Addgene, plasmid#48138, kindly provided by Dr Peter Hohenstein, The 
Roslin Institute) in one step. Cutting and ligation was done by adding together 100 ng 
of pX458, 2 µl of the diluted annealed oligonucleotide, 2 µl of 10X T4 ligase buffer 
with 10mM ATP (NEB), 1 µl of BbsI restriction endonuclease (10 U/ µl , NEB), 0.5 
µl of ligase from Quick Ligation kit (NEB) made up to 20 µl water. The mixture was 
incubated for 6 cycles of 37°C for 5 min and 21°C for 5 min. 
 
Next, the cloned plasmids with sgRNA sequences were treated by Plasmid Safe 
Exonuclease kit (Epicentre, Madison, WI, USA) which digests any residual linear 
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DNA. 11 µl of ligation reaction was mixed with 1.5 µl of Plasmid safe buffer 10X, 1.5 
µl of 10 mM ATP and 1 µl of Plasmid Safe Exonuclease (10 U/ µl), and incubated at 
37°C for 30 min, then 70°C for 30 min.  
 
Afterwards, DH5α strain E. coli bacteria were transformed with these plasmids as 
follows. 20-30 µl of DH5α bacteria per reaction were thawed on ice, mixed with 2 µl 
of plasmid and left on ice for 20-40 min. The bacteria were then heat-shocked by 
incubating in a water bath for 30-60 s at 42°C and left on ice for 2 min. Next, 100 µl 
of SOB (Super Optimal Broth, provided by the Roslin Institute core services) was 
added and the bacteria were streaked on an ampicillin plate (100 µg/ml ampicillin in 
LB (Lysogeny Broth) agar, provided by the Roslin Institute core services). After 
leaving the plate overnight at 37°C, there were around 50-100 colonies on the plate, 
no colonies on a no plasmid control and no colonies for a no oligonucleotide control.  
 
Two colonies per plate were picked into 5 ml LB (provided by the Roslin Institute core 
services) + 100 µg/ml ampicillin and left overnight in a shaker at 37°C and 200 rpm. 
The plasmid DNA was extracted using the Qiagen MiniPrep kit (Qiagen) according to 
manufacturer’s instructions. The right DNA sequence was validated by sequencing 
using U6 FWD primer at Edinburgh Genomics (see 6.2.3.2).  
 
Once the sequences were validated, 5ml of LB with ampicillin was inoculated with the 
cell suspension from the previous step, and left in the shaker for 6-8 hours at 37°C and 
200 rpm. In the evening, 500 µl of the growing colony was put into 250 ml of LB with 
ampicillin and left incubating overnight at 37°C and 200 rpm. In the morning, the 
bacteria were spun down at 3200 x g, 30 min at 4°C. The plasmid DNA was extracted 
using the Endo-free Maxi Prep (Qiagen) according to manufacturer’s instructions. It 
was important to use endotoxin-free (Endo-free) reagents to avoid activating the cells 
during the transfection step. The final plasmid was resuspended in 500 µl of Endo-free 





Gene Location Name sgRNA sequence Score Off-target sites  - in genes 
BAP1 Before exon 4 g1 TTTGCACTGCGTCATCACTC 84 79 6 
    g2 TGAGTGATGACGCAGTGCAA 83 114 15 
  After exon 4 g1 AGTTCAGTTCGTTCTGCCAG 76 124 12 
    g2 TCAGATATCCAGTGGGTATT 72 199 8 
USP12  Exon 2 g1 CCGGTCAATGAGCACTATTT 78 60 5 
  Exon 3 g2 ATCTTGTGATGAACTTCTTA 64 235 24 
  Exon 4 g3 CAAAATGGTCGTTTACCTAA 73 144 14 
              
  Before exon 3 g1 AGAGAGAAATTCCCGGTATA 85 187 11 
  After exon 3 g1 AAGAGGCACTCGTTTAGTGA 84 111 14 
USP16  Exon 5 g1  TGGCGTCAGATAGTGCTTCA 79 89 7 
    g2  AAGATCTGAACCTCACTGTC 70 188 15 
       
KDM6B Exon 11 g1 CCATTACCAAACTCCCGCGC 96 24  0 
              
  Before exon 4 g1 CGAGCTGGCTGGATGTACAC 84 79 8 
  After exon 4 g1 GTCTGTTATATACGGCAAAA 85 114 10 
              
  Before exon 17 g1 CGGTGCGGAAGTGCGACGAG 95 42 14 
    g2 GCTGCTAGGACCTCGTGGCG 90 108 24 
  After exon 17 g1 CGGGGATCGCAGTTCCGACC 95 29 8 
    g2 CTTCCAGCATCAGCGCGCAC 92 93 24 
UTY Exon 1 g1 GGTAGTGAGCGACACTGCGC 92 46 11 
    g2 GTCTGTTAGCCTGACAGTCG 87 77 9 
              
  Exon 2 g1 GCCTAGTAGGGTCTTCGTTC 92 40  0 
    g2 GCCTCACGAACCCGAAGAGA 88 88 15 
              
  Exon 3 g1 AGAGGTTGAAGTGACCTAAT 73 184 10 
              
  Exon 24 g1 ACTTCCTGCTTTTGCGCGTG 90 103 13 
              
  Before exon 6 g1 TATATCTCACTTGATAGTAT 64 278 10 
              
  After exon 6 g1 TTAATGTCACTGAGAAGCGT 77 173 19 
    g2 AAATTGAGGATATGACCTAA 67 287 14 
Table 6-1 CRISPR-Cas9 sgRNAs designed and scored using http://crispr.mit.edu page from 0-100 (100 
most likely to give the appropriate result) based on the chemical structure of the sgRNA sequence and 
the number of potential off-target sequences in the human genome. 
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6.2.2 THP-1 nucleofection of CRISPR-Cas9 plasmids  
The best rate for plasmid transfection efficiency in THP-1 was obtained using the 4D 
Nucleofector kit (Lonza, Germany), with a following optimised Lonza protocol for 
THP-1 cells. 1x106 cells per sample were centrifuged at 400 x g for 5 minutes, the 
pellet resuspended in 100 µl of SG 4D Nucleofector solution with added supplement 
(SG Cell line 4D Nucleofector solution X kit, Lonza). Then, 0.5 µg of Endotoxin-free 
plasmid (section 6.2.1, 0.5 µg of DNA total) was mixed in per sample. The cell 
suspension was transferred to the Nucleocuvette vessels and the programme FF-100 
was executed on the 4D Nucleofector. Afterwards, 500 µl of pre-warmed THP-1 media 
was added using the supplied pipettes and the cell suspension was transferred to a 12-
well plate with 1 ml of THP-1 media already in each well. Next day (~24 hours after 
nucleofection), the cells were spun down at 400 x g for 5 min at room temperature, 
and the pellet resuspended in 300 µl of 10% FBS in PBS and passed down through the 
filter tube for FACS (flow cytometry assisted cell sorting). Single GFP+ cells were 
sorted into 96-well plates of 200 µl THP-1 media using BD FACS Aria IIIu (service 
provided by Flow Cytometry unit in the Roslin Institute). 
 
6.2.3 Validation of knockout cell lines 
The single cell clones were left to grow for multiple weeks in 96 well plate until there 
were enough of them to passage into a bigger vessel. These potential knockout cell 
lines were tested for an insertion or deletion by DNA extraction (section 6.2.3.1), 
sequencing (section 6.2.3.2), qRT-PCR (section 2.2.4) and western blotting (section 
6.2.3.3). 
 
6.2.3.1 DNA extraction 
The THP-1 cells were spun down, and the pellet was resuspended in 500 µl of DNA 
buffer (100 mM Tris-HCl pH 8.5, 0.2% SDS, 200 mM NaCl and 5 mM EDTA) and 
10 µl of Proteinase K (20mg/ml, Qiagen). The samples were incubated at 56-60°C for 
1-2 hours. Then, phenol-chloroform extraction was performed to isolate the DNA from 
protein and RNA. 500 µl of Phenol-Chloroform-Isoamyl alcohol (25-24-1, Sigma-
Aldrich) was added to the sample (1 volume), then the layers were thoroughly mixed 
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by vortexing. The mixture was centrifuged at 16,000 g for 5 min at room temperature. 
The upper layer containing DNA was transferred to a new 1.5 ml Eppendorf tube. 
After that, 500 µl of chloroform (1 volume) was added and thoroughly mixed again. 
Samples were centrifuged at 16,000 x g for 5 min at room temperature. The upper 
layer containing DNA was again transferred to a new 1.5 ml Eppendorf tube. The DNA 
was precipitated by adding 50 µl of sodium acetate 3 M (1/10 volume) and 1 ml of 
100% ethanol (2 volumes) and left at -20°C overnight or for at least an hour. 
Afterwards, the sample was spun at 16,000 x g for 5-10 min at room temperature to 
form a pellet. This pellet was washed using 70% ethanol and air-dried. DNA was 
resuspended using a suitable volume of TE or water. 
 
6.2.3.2 PCR and sequencing  
The polymerase chain reaction used High Fidelity Q5 Polymerase (NEB) according to 
manufacturer’s instructions. For a 25 µl reaction, 5 µl of 5X Q5 reaction buffer, 0.5 µl 
of 10 mM dNTPs, 1.25 µl of 10 µM Forward primer, 1.25 µl of 10 µM Reverse Primer, 
1 µl of 100 ng/µl DNA, 0.25 µl of Q5 Polymerase and 15.75 µl of water were mixed 
together. For primer sequences see Table 2-1 together with estimated melting 
temperature (Tm) for each primer pair, which was calculated using NEB Tm Calculator 
(http://tmcalculator.neb.com). The samples were initially denatured at 98°C for 30 s, 
then incubated for 35 cycles of 98°C for 10 s, Tm (normally 65-68°C) for 30 s and 
72°C for 30 s. The final extension was at 72°C for 2 minutes.  
 
The PCR product was run on an agarose gel (1.5% of Agarose Ultrapure (Invitrogen) 
in 1X TAE (provided by the Roslin Institute core services) with 1X of Sybr Safe DNA 
stain (Invitrogen) and results viewed using a transilluminator. 20 µl of the PCR product 
was purified using Charge Switch PCR clean-up kit (Invitrogen) according to 
manufacturer’s instructions.  
 
For sequencing, 3 µl of water, 2 µl of the purified PCR product and 1 µl of 3.2 µM 
primer was mixed and sent for chain termination (Sanger) sequencing at Edinburgh 
Genomics. The results were viewed using FinchTV programme (Geospiza, Perkin 
Elmer, Waltham, MA, USA). 
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Gene Oligo name  Sequence Q5 Tm 
BAP1 BAP1_ex4_site_F AGGCCACTTCAGACACAGTG 68 
  BAP1_ex4_site_R AGTCACCCATACACAGCACC   
USP12 USP12_ex2g1site_F AAAGACGCACCTGTGTAGGG 68 
  USP12_ex2g1site_R AGGCAGACGTTGCAGTGAG   
  USP12_ex3g2site_F GCAGTTTGGGAATACCTGCT 62 
  USP12_ex3g2site_R AAAAGCCAAGCAAGCAAAAA   
  USP12_ex4g3site_F GGTTTTGCCCTTTTCTCAGG 65 
  USP12_ex4g3site_R TTCATCTTCCATTCTGTCTTTCTCA   
USP16 USP16 crispr site F CCTAGCGAGTGCATGGTTTT 65 
  USP16 crispr site R ACCCAAGAGGCAGAGGAACT   
    
KDM6B KDM6B_ex11_F2 TGGAGCTTGTCTTGAGGCAG 64 
  KDM6B_ex11_R2 GGGTCCCTCAGTCCCAAAGA   
  KDM6B_ex4_site_F GGGTAGCGGGCACTCTTATC 69 
  KDM6B_ex4_site_R CCTTACCTCCCACTCCCAGA   
  KDM6B_ex17_site_F GTTCCTGCTTCCTTCCCCTC 68 
  KDM6B_ex17_site_R AGAAAGCGCTGATGGTCTCC   
UTY UTY_ex1+2_F TGGTGCTGGCAAAGTTTGTG 68 
  UTY_ex1+2_R GGGCCTTGGTAGAGCAAAGT   
  UTY_ex3_F TCCTCTCTGAAATGCCGAATT 65 
  UTY_ex3_R ACAAGGGCAAGCAAAATAGC   
  UTYbefex6_F GTGAGCTGTGATTGTCCTGC 68 
  UTYbefex6_R TCGACAAAAGCTGGGGTCAA   
  UTYaftex6_F TTGACCCCAGCTTTTGTCGA 68 
  UTYaftex6_R GGCAGTCCAAAAGCCTTAGA   
  UTY_bothex6_F CCTGCTGTTCTTCCTTGAATGT 65 
  UTY_bothex6_R TCTCTCTTTGGTGGCAGACA   
  UTY_ex24_F AAGAAAACCAAAGTACCCTCTCT 64 
  UTY_ex24_R2 TGCTCTCTATGCCTGCTCC   
Table 6-2 Primers used to validate the CRISPR-Cas9 targetting, together with the annealing temperature 
(Q5 Tm) used for genotyping with Q5 High Fidelity Polymerase (NEB). 
 
6.2.3.3 Western blot 
2x106 cells per sample were resuspended in 50 µl PBS (provided by the Roslin Institute 
core services), then 50 µl of 2X Laemmli loading buffer with 50 mM DTT (BioRAD, 
Hercules, CA, USA, prepared by mixing 950 µl Laemmli loading buffer + 50 µl 1M 
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DTT (NEB) in water), was added and mixed thoroughly. Samples were then incubated 
at 95°C for 5 minutes and stored at -20°C until needed. 
 
Samples stored in buffer as described above were run on a precast Mini-Protean TGX 
4-15% 12-well gel (BioRAD), in a tank with running buffer (25 mM Tris (Fisher 
Scientific), 192 mM Glycine (Sigma-Aldrich) and 0.1% w/v SDS (Fisher Scientific)) 
at 100V for 5 min and then 120V till the end of the gel. The gel was then rinsed in 
water. 
 
To blot the protein onto PVDF membrane (Immobilon-P, Sigma-Aldrich), the 
membrane and the gel were activated by soaking in 100% methanol. The western 
blotting apparatus was then assembled as follows: black side down, sponge, 2 pieces 
of Whatman paper (GE Healthcare, Little Chalfont, UK), gel, PVDF membrane, 2 
pieces of Whatman paper, sponge and red/white side up (BioRAD). The apparatus was 
closed, making sure there were no bubbles between the gel and membrane and that it 
was completely soaked in the transfer buffer (25 mM Tris, 192 mM Glycine, 20% (v/v) 
Methanol). The blotting was run at 50 V for 1 hour at initial current of 400 mA.  
 
Afterwards, the membrane was blocked for 1 hour in 5% milk powder (Marvel Dried 
Milk, Premier Foods Group Ltd, London, UK) in PBS-T (0.05% Tween in PBS, PBS 
was provided by the Roslin Institute core services). Then, primary anti-human 
antibodies (dilution of 1:1000 for rabbit anti-USP16 (ab121650, Abcam, Cambridge, 
UK); and 1:2000 dilution for mouse anti-ß-actin (C4) monoclonal IgG1 (sc-47778, 
Santa Cruz Biotech, Dallas, TX, USA)) were diluted in 5% milk powder in PBS-T and 
the membrane immersed rotating overnight at room temperature. The next day, the 
membrane was washed six times for 5 min in PBS-T, and then secondary antibodies 
were diluted at 1:2000 in 5% milk powder in PBS-T (horse anti-mouse HRP-linked 
for β-actin and goat anti-rabbit HPR-linked for USP16; both from Cell Signalling 
Technology, Danvers, MA, USA), and the membrane immersed rotating for 1 hour at 
room temperature. The membrane was again washed six times for 5 min in PBS-T, 
and then Pierce ECL western blotting substrate (Thermo Scientific) was applied 
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according to manufacturer’s instructions. The image was developed onto Amersham 
Hyperfilm (GE Healthcare). 
 
6.2.4 Phagocytosis assay 
A phagocytosis assay was performed by incubating THP-1 macrophages, that had been 
differentiated with PMA for two days, with Zymosan A particles (Life 
Technologies, Z2841) coated with fluorescein isothiocyanate (FITC), at a ratio of 100 
particles per cell; for 1 hour at 37°C. Cells were washed five times with cold PBS and 
fixed with 4% paraformaldehyde (PFA, WVR, Radnor, PA, USA) for 10 min at room 
temperature and washed twice with PBS. Images were viewed using a fluorescent 
microscope (Zeiss Vert.A.1, Carl Zeiss Limited, Cambridge, UK). 
 
6.2.5 MTT assay and cell cycle analysis 
MTT assays were performed as in section 2.4.1 to assess cell viability, and cell cycle 
analysis was conducted as in section 2.4.2 to determine the stages of the cell cycle. 
 
6.2.6 CAGE library preparation and bioinformatics analysis 
Libraries were prepared and sequenced as specified in section 2.2.6, together with 
processing the sequencing reads, and mapping to hg38 genome (section 2.5.1). Results 
for 38 samples (samples for this chapter and Chapter 4) were uploaded into the CAGEr 
programme (Haberle et al., 2015) (Appendix 8.3). The CAGE samples were 
normalised together with CAGEr using the power law with alpha of 1.19, with results 
being in Tags per million (TPM) (section 2.5.2). Samples’ data (Table 6-3) was 







Sample Time point Number of biological 
replicates 
Wildtype (from Chapter 3)  0 hours 6 
 24 hours 4 
USP16 homozygote knockout clones 0 hours 4 
 24 hours 4 
USP16 heterozygote knockout clones 0 hours 2 
 24 hours 2 
Table 6-3 CAGE samples used in the analysis in this chapter. All samples had two time points, 0 and 24 
hours.  
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6.3 Results  
6.3.1 CRISPR guide design for BAP1, USP12, USP16, KDM6B and UTY  
Two guides were designed to make an indel in exon 5 of USP16, creating an out of 
frame mutation. Exon 5 (coding exon 3) is at the start of the transcript and codes for 
part of the zinc finger domain. Insertion or deletion of one or two nucleotides would 
create an out of frame mutation, which creates a wrongly translated amino acid 
sequence, with possible multiple stop codons along the way. This shortened peptide 
would not have a catalytic deubiquitinase domain, and thus would be unable to 
perform the function of USP16. Transcripts with multiple stop codons are sometimes 
degraded by the cell’s nonsense-mediated mRNA decay mechanism and thus the 
production of USP16 mRNA and resulting peptide would be reduced. 
 
BAP1 CRISPR guides were designed to work in pairs to create two double strand 
breaks in the DNA on the opposite ends of an exon and therefore delete the whole 
exon. Deletion of a large segment of the gene makes it easier to screen the THP-1 
clones by a simple PCR rather than having to sequence the product. Generally, deletion 
of a section of the genome, rather than creating a single base indel, would be preferred, 
as it is easier to screen the THP-1 clones by a simple PCR rather than more expensive 
Sanger sequencing. Exon 4 was selected, which is in the beginning of the gene and is 
133 nucleotides long, so its deletion would create a shift in the reading frame 
downstream and introduce stop codons. 
 
USP12 CRISPR guides were designed to both make an indel in the USP12 coding 
sequence and also delete whole exons. The first few exons did not have multiple guides 
available with good scores (not pictured), so only one guide was designed for exon 2, 
exon 3 and exon 4 each to generate an indel which would create a frameshift mutation. 
Later, when a deletion of whole exon strategy was deemed more suitable, guides to 
delete exon 3 were designed. Exon 3 is 214 nucleotides long and its deletion would 
also shift the reading frame in subsequent exons.  
 
CRISPR-Cas9 target sites were designed to make an indel inside the open reading 
frame of KDM6B which according to the design should result in a frameshift mutation 
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(single guide) or deletion of a whole exon from the locus by using two sgRNA guides 
in combination together. It was decided to create an indel in exon 11 (the longest exon), 
and to delete exons 4 (containing the start of the coding sequence) and exon 17 (which 
encodes the start of the JmjC domain coding sequence). Exons 4 and 11 start and end 
with a different reading frame, thus the deletion would also create a frameshift 
mutation with stop codons along the way. Exon 4 is also present in all protein-coding 
transcripts (Figure 6-1), so knocking out this exon should abolish all functional 
translation of KDM6B by disrupting the reading frame of all transcripts. To explore 
possible non-catalytic activity of KDM6B, guides which should result in deletion of 
exon 17 were designed. This mutation would produce a truncated KDM6B without the 
JmjC catalytic domain, if the transcript was not degraded. In either case the strategy 
chosen would allow assessment of the importance of the underlying demethylase 
activity in macrophage differentiation.  
 
UTY CRISPR-Cas9 guides were designed similarly to KDM6B, to produce frameshift 
mutations using a single guide (for exons 3 and 24) and deletion of exons using two 
guides (exons 1+2 and exon 6). For indel-inducing single guides relying on non-
homologous end joining to produce an imperfect repair of a break in DNA, exon 3 and 
exon 24 were chosen. Exon 3 codes for the start of TPR domains, and exon 24 starts 
the coding sequence for the JmjC domain. Exons 1 and 2 sit very close together (Figure 
6-2), and there were no high score guides available for the intron before or after, so it 
was decided to use the guides which match the coding sequence inside the exons. 
Based on 4 different combinations of 2 guides for each exon, it would be possible to 
determine which guide pair was most efficient in creating a frameshift mutation. 
According to the Ensembl website, exon 6 is one of the few exons present in all UTY 
transcripts. It is also 121bp long (that is, not a multiple of three), so successful deletion 
would shift the reading frame and create multiple stop codons thereafter (not shown).  
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Figure 6-1 Six splice variants of KDM6B and chosen exons for CRISPR-Cas9 genome editing. Image 
adapted from Ensembl website. Three transcripts are protein coding (gold and red), the other three are 
not (blue). Depicted here are exons chosen for CRISPR-Cas9 editing. JmjC domains are shown as 
predicted by Prosite, Pfam and SMART domains. 
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Figure 6-2 Location of CRISPR guides in exons 1 and 2 in UTY. Figure made from SeqBuilder, 
Lasergene suite. 5’ UTR is pictured as red arrow, exons are shown as green arrows.  
 
 
Figure 6-3 Location of CRISPR guides for deletion of exon 6 in UTY. Figure made from SeqBuilder, 
Lasergene suite. Exons are shown as green arrows. 
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6.3.2 Knockout of USP16 in THP-1 cells was successful 
Use of the USP16 guides resulted in insertion of a single nucleotide. USP16 g1 plasmid 
was nucleofected into THP-1 cells with low passage number, and GFP positive cells 
were single cell sorted into 96-wells. Out of two plates, 15 clones survived the sorting 
and 3 clones proved to be heterozygous for a one nucleotide insertion (A) (Figure 6-4).  
No homozygotes were present at the first targeting, so two of the heterozygotes were 
used for targeting the second time with the same guide (USP16 exon 5 g1). Out of 3 
plates for each heterozygous parental cell line, 67 clones survived the sorting (Table 
6-4). 13 clones (19%) had reverted back to the wildtype sequence and 4 clones (6%) 
were homozygous for the same adenine insertion in exon 4 (Figure 6-4). One clone 
(hereafter named as Hom 1) was derived from a different parental heterozygote (Het 
C) than the other three (Hom 2, Hom 3, Hom 4) which came from another heterozygote 
not featured in the further experiments.  
 
 
Figure 6-4 Sanger sequencing of exon 4 of USP16 clones. All three founder heterozygous clones had 
the same insertion of adenine (A) in one allele (indicated by arrow). Four final homozygous USP16 -/- 
clones had the same insertion of one additional adenine, but on both alleles (indicated by red box). The 




 Number of clones % of all clones 
Wildtype 13 19 
Heterozygotes 50 75 
Homozygotes 4 6 
All 67 100 
Table 6-4 Results of the second targeting of USP heterozygotes. Clone genotypes verified by Sanger 
sequencing. 
To determine the impact of the genetically edited transcript, the sequence was 
translated by bioinformatics tools (Figure 6-5). The insertion site of the adenine in 
exon 4 codes for the amino acid alanine in the zinc finger domain of USP16. When 
this single additional nucleotide is present, a further string of incorrect amino acids is 
abruptly terminated by a stop codon ten amino acids downstream. The transcript also 
has numerous other stop codons along the way, ensuring that the resulting peptide is 
small and contains only the start of the protein sequence and no functional domains 
(Figure 6-5). 
 
To further validate the knockout of USP16 in the homozygous clones, their RNA was 
extracted and cDNA synthesised (section 2.2). The cDNA was subjected to Sanger 
sequencing and the insertion was confirmed to be present in the transcribed RNA. All 
four putative homozygous clones had the extra adenine inserted in their cDNA.  
 
The next step was to find out whether the level of USP16 transcripts was lowered in 
the edited lines, potentially due to nonsense mediated decay. Quantitative reverse 
transcriptase PCR experiments were conducted with the four homozygotes, two 
heterozygotes and wildtype THP-1 cells for 3 sets of primers, each set in a different 
exon along the transcript. The results show that USP16 homozygous clones had 
decreased level of expression compared to wildtype THP-1 cells (Figure 6-6, Figure 




Figure 6-5 Translation of edited USP16 in homozygous clones by the ExPaSy tool (single letter code). 
Insertion of the single nucleotide induces a frame shift mutation, which introduces multiple stop codons 
in the translated sequence. The insert is present in the middle of the zinc finger domain, in codon 91 for 
the amino acid alanine (pictured here framed by yellow box). Ten amino acids later, translation would be 
terminated by an in frame stop codon. Met indicates potential start codons (amino acid methionine), and 
highlighted sequences show open reading frames. The first grey sequence up to the yellow box is the 
correct amino acid sequence. 
 
 
Figure 6-6 qRT-PCR results of USP16 knockout clones and wildtype THP-1. Pictured here is Roche ratio 
of USP16 exon 4-5 primers normalized by ACTN expression with error rates calculated by Roche 
LightCycler480 software (see section 2.2.4). Het E result (asterisk) had a technical failure. The Y-axis is 
in logarithmic scale. Hom = Homozygote for USP16 knockout, pictured in red, Het = Heterozygote for 
































Expression of USP16 exon 4-5 in THP-1 cells
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Figure 6-7  qRT-PCR results of USP16 knockout clones and wildtype THP-1. Pictured here is Roche 
ratio of USP16 exon 15-16 primers normalized by ACTN expression with error rates calculated by Roche 
LightCycler480 software (see section 2.2.4). The Y-axis is in logarithmic scale. Hom = Homozygote for 
USP16 knockout, pictured in red, Het = Heterozygote for USP16 knockout, pictured in purple, and WT = 
wildtype THP-1 cells, pictured in blue. Error bars show standard error.  
 
 
Figure 6-8 qRT-PCR results of USP16 knockout clones and wildtype THP-1. Pictured here is Roche ratio 
of USP16 exon 17-18 primers normalized by ACTN expression with error rates calculated by Roche 
LightCycler480 software (see section 2.2.4). The Y-axis is in logarithmic scale. Hom = Homozygote for 
USP16 knockout, pictured in red, Het = Heterozygote for USP16 knockout, pictured in purple, and WT = 
wildtype THP-1 cells, pictured in blue. Error bars show standard error. 
 
The final validation of the USP16 knockout was to see whether the altered (and 


























































Expression of USP16 exon 17-18 in THP-1 cells
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western blotting (Figure 6-9). In the figure, the lower actin bands, identified by an 
arrow, shows that the loading of protein lysates was constant for all samples. This actin 
antibody did not produce any other bands in these protein samples (not pictured), so 
all other bands were detected by anti-USP16 antibody. Various bands were present, 
but the one around 120 kDa (red box in the figure) was absent in homozygous clones, 
whereas it was the strongest one for wildtype and heterozygotes. Predicted size of 
USP16 according to ab121650 datasheet is 94 kDa, but Xu et al. (2013) confirmed the 
size of their USP16 to be 110 kDa and Joo et al. (2007) found the peptide to be 120 
kDa in SDS-PAGE. It can be therefore concluded that USP16 KO homozygotes do 
not produce a correct USP16 protein.  
 
 
Figure 6-9 Western blotting for USP16 and actin in extracts of THP-1 clones. Ladder sizes are in kDa. 
Lanes 1, 2, 3, 4 are USP16 KO homozygotes; D, E are USP16 KO heterozygotes, and WT denotes 
wildtype THP-1 cell line. Actin loading control bands of size of 42 kDa are indicated by an arrow. All other 
bands are detected by USP16 antibody (ab121650), bands around 120 kDa (present in heterozygotes 
and wildtype) are not present in four homozygous knockout USP16 THP-1 clones. 
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6.3.3 Deletion of USP16 in THP-1 cells did not prevent macrophage 
differentiation 
After establishing that the homozygous knockout clones did not produce a functional 
USP16 protein, the first experiment was to determine whether USP16 protein 
deficiency interrupts the monocyte to macrophage differentiation of THP-1 cell line.  
 
Knockout clones were treated with the differentiation agent PMA, and exhibited the 
same differentiation pattern as wildtype THP-1 after 48 hours (Figure 6-10). The next 
step was to see whether USP16 homozygous clones’ ability to phagocytose (one of the 
key functions of macrophages) would be impaired. THP-1 macrophages (derived by 
treatment with PMA) were exposed to Zymosan A particles for an hour, the excess of 
particles was washed away and then macrophages were viewed on a fluorescent 
microscope. The results showed that USP16 clones were able to phagocytose the 




Figure 6-10 Brightfield and FITC signal overlay of phagocytosis assay (phagocytosis beads are FITC +) 
of USP16 clones and wildtype macrophages (2 days post- PMA treatment). Scale bar is 100 µm. 
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6.3.4 Deletion of USP16 in THP-1 cells affected proliferation and cell cycle 
progression during differentiation 
To see whether knockout of USP16 affects THP-1 monocyte proliferation rate, MTT 
assays were conducted at multiple times throughout the culturing of these cells. Cells’ 
metabolic activity was measured by this colorimetric assay at day 0 (the time of 
seeding) and after two days of culture (day 2). Two results from two assays are 
presented, one from the beginning of the project (I) and the other from the end (II).  
 
The first MTT assay reading (Figure 6-11) was used to calculate the difference in 
metabolic activity over the two days, which should show the proliferation rate of the 
different clones (Figure 6-12). Wildtype (WT) had the highest rate of proliferation 
(three-fold increase in metabolic activity measured by MTT in two days), followed by 
heterozygotes and homozygote clonal line 1. USP16 knockout clonal lines 2, 3, and 4 
had smaller increase in metabolic activity compared to WT and the other clones. One 
sample t-test showed that homozygous cell lines proliferated more slowly than 
wildtype (p-value = 0.032). 
 
 
Figure 6-11 MTT assay USP16 knockout clones vs wildtype THP-1 cells, Experiment I, from early in the 
project. Day 0 is symbolized by bolder colour, day 2 by paler colour. Hom = Homozygote for USP16 
knockout are pictured in red, Het = Heterozygote for USP16 knockout are pictured in purple, and WT = 






















MTT assay USP16 clones Expt I




Figure 6-12 Rate of growth of USP16 clones calculated from MTT assays at the beginning of the project. 
Hom = Homozygote for USP16 knockout, Het = Heterozygote for USP16 knockout, WT = wildtype THP-
1 cells. 
 
To minimise technical errors and random biological variation and to assess any drift 
in clone phenotype over time, this experiment was repeated multiple times throughout 
the clones’ time in culture. Figure 6-13 shows a different reading from the end of the 
project, where the clones had been in culture for multiple passages. At this time, the 
parental heterozygote cell line (Het C) for homozygous clone 1 (Hom 1) was included. 
Comparing the change in metabolic activity over two days for these clones (Figure 
6-14), it seems that cells maintained a similar rate of proliferation as in the beginning 
of their time in culture (Figure 6-11, Figure 6-12). It was noted that the parental 
heterozygote for homozygous clone 1 (Het C) had similar rate of change of metabolic 
activity to the homozygous clone 1, which was at similar level to wildtype.  








Change in metabolic activity
Rate of growth over 2 days Expt I
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Figure 6-13 MTT assay USP16 knockout clones vs wildtype THP-1 cells. Experiment II, from the end of 
the project. Day 0 is symbolized by bolder colour, day 2 by paler colour. Hom = Homozygote for USP16 
knockout are pictured in red, Het = Heterozygote for USP16 knockout are pictured in purple, and WT = 
wildtype THP-1 cells are pictured in blue. Error bars represent standard deviation of the readings. 
 
Figure 6-14 Rate of growth of USP16 clones calculated from MTT assays at the end of the project. Hom 
= Homozygote for USP16 knockout, Het = Heterozygote for USP16 knockout, WT = wildtype THP-1 
cells. 
Calculating statistical significance using two-sample t-test between wildtype and 
homozygous clones using data from both MTT assays show that the rate of growth of 
homozygous USP16 clones over two days was significantly slower than that of 
wildtype (p-value = 0.004). However, the difference in rate of growth over 2 days for 
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To find out whether the deficiency of USP16 protein in THP-1 cells has a role in cell 
cycle progression, USP16 homozygous and heterozygous knockout clones, together 
with wildtype THP-1, were differentiated into macrophages with PMA, over the 
course of 3 days, checking the proportions of cells in different phases of the cell cycle 
every day by propidium iodide staining.  
 
This experiment was repeated four times. Before differentiation, the USP16 
homozygous clones behaved similarly to the wildtype (Figure 6-15). Around 20% cells 
were in the S-phase, which number should decline after differentiation as proliferation 
stops. Indeed, as seen on day 2, the proportion of cells in S-phase was drastically 
reduced to around 10%, while gaining G1 phase cells in wildtype and heterozygotes 
(Figure 6-16). However, in 3 of the homozygous knockout clones (Hom 2, Hom 3 and 
Hom 4) there was no change in percentage of cells in S-phase, whereas the G2 
proportion of cells had more than doubled. Hom 1 follows similar pattern to wildtype 
(WT) progression.  
 
 
Figure 6-15 Cell cycle phases for non-differentiated THP-1 monocytes at day 0. DNA was stained by 
propidium iodide, detected by Flow Cytometry and cell cycle phases were assigned by FlowJo (See 
section 2.4.2). Homozygous clones for USP16 knockout are Hom 1, Hom 2, Hom 3 and Hom 4. 
Heterozygous clones for USP16 knockout are Het D and Het E. Double-targeted wildtype clone (which 
reverted to wildtype after the second targeting with USP16 g1) is dT WT. For wildtype THP-1 (WT), the 
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Figure 6-16 Cell cycle phases for differentiated THP-1 monocytes at day 2. DNA was stained by 
propidium iodide, detected by Flow Cytometry and cell cycle phases were assigned by FlowJo (See 
section 2.4.2). Homozygous clones for USP16 knockout are Hom 1, Hom 2, Hom 3 and Hom 4. 
Heterozygous clones for USP16 knockout are Het D and Het E. Double-targeted wildtype clone (which 
reverted to wildtype after the second targeting with USP16 g1) is dT WT. For wildtype THP-1 (WT), the 
passage number was 11. 
 
These results were not replicated in a consistent manner in the next three experiments. 
All replicates had the four homozygous clones and wildtype present, but the 
heterozygous clones and double targeted wildtype clone were not always included. 
Looking at the average values for cell cycle phases at day 0 (Figure 6-17), the results 
show quite high standard deviation and standard error across S phase and G2 phase 
(Table 6-5). The percentage of cells which were in S-phase was around the same for 
all clones before the differentiation (day 0, around 30%). However, Hom 2 and WT 
had a higher number of cells in G2 phase than other clones; and also lower number of 
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Figure 6-17 Average values at day 0 for each phase of the cell cycle for 4 USP16 homozygous clones 
(N=4 each), one parental heterozygous clone (Het C, N=3), one double targeted heterozygous clone 
(Het dE2, N=2) and wildtype (WT, N=4). Sum of three cell cycle phases G1, S, G2 equals 100%. SD and 




As mentioned previously, Hom 1 seems to behave differently to other homozygous 
clones after differentiation. Average values for day 2 (Figure 6-18) show that Hom 1 
has very similar profile to its parental clone, Het C. The results indicate that Hom 2 is 
the most different to other homozygous clones (and also wildtype), with the highest 
number of cells in S and G2 phase. The standard deviation and standard error for day 
2 were also quite high (Table 6-6), which suggest that the results were not consistent 












Hom 1 Hom 2 Hom 3 Hom 4 Het C Het dE2 WT
Average values Cell Cycle day 0
G1 S G2
Day 0        
Standard deviation Hom 1 Hom 2 Hom 3 Hom 4 Het C Het dE2 WT 
G1 0.06443 0.05404 0.07792 0.07551 0.02744 0.08212 0.03478 
S 0.06059 0.02149 0.07317 0.05566 0.03247 0.08160 0.04885 
G2 0.00777 0.04421 0.02335 0.02783 0.01952 0.00051 0.01691 
        
Standard error Hom 1 Hom 2 Hom 3 Hom 4 Het C Het dE2 WT 
G1 0.03221 0.03120 0.03896 0.03775 0.01585 0.05806 0.01739 
S 0.03029 0.01241 0.03659 0.02783 0.01875 0.05770 0.02442 
G2 0.00388 0.02552 0.01167 0.01391 0.01127 0.00036 0.00846 
Table 6-5 Standard deviation and standard error calculated for Cell Cycle day 0 values, 1 = 100%. 
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Taking all biological replicates together, the difference in the proportion of cells in G2 
or S phase between homozygotes and wildtype samples was not significantly different 
either on day 0 or on day 2 (two-sample t-test, p-value > 0.25 in all cases). 
 
 
Figure 6-18 Average values at day 2 for each phase of the cell cycle for 4 USP16 homozygous clones 
(N=4 each), one parental heterozygous clone (Het C, N=3), one double targeted heterozygous clone 
(Het dE2, N=2) and wildtype (WT, N=4). Sum of three cell cycle phases G1, S, G2 equals 100%. SD and 
SE are given in Table 6-6. 
 
Day 2 
       
Standard deviation Hom 1 Hom 2 Hom 3 Hom 4 Het C Het 
dE2 
WT 
G1 0.0636 0.0846 0.0895 0.1097 0.0693 0.1155 0.0714 
S 0.0330 0.0591 0.0255 0.0464 0.0230 0.0581 0.0773 
G2 0.0398 0.1072 0.0799 0.0883 0.0631 0.0574 0.0377 
        
Standard error Hom 1 Hom 2 Hom 3 Hom 4 Het C Het 
dE2 
WT 
G1 0.0318 0.0423 0.0447 0.0548 0.0400 0.0817 0.0357 
S 0.0165 0.0295 0.0127 0.0232 0.0132 0.0410 0.0387 
G2 0.0199 0.0536 0.0399 0.0441 0.0364 0.0406 0.0188 
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Average values Cell Cycle for day 2
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In order to find out more about these USP16 homozygous and heterozygous clones, 
their RNA at day 0 and 24 hours post differentiation was selected for CAGE 
sequencing.  
 
6.3.5 CAGE sequencing of USP16 clones 
As discussed in Chapter 3, all CAGE reads were mapped to hg38 and normalised 
between each other using power law distribution. The 22 CAGE samples included in 
the analysis for this chapter were all knockout samples (homozygotes and 
heterozygotes for USP16) and wildtype controls from THP-1 differentiation from 
Chapter 3 for 0 hours and 24 hours.  
 
Figure 6-19 Sample-sample correlation of correlation coefficient of 0.88 derived from Miru programme. 
Samples are nodes and edges are connections between them with a correlation coefficient of 0.88 or 
greater, ie how closely correlated the expression patterns are to each other across all samples. Nodes 
which are close are highly correlated. Each sample type is different colour: wildtype – blue, USP16 
heterozygotes – purple, USP16 homozygotes – red. Day 0 is bolder colour, Day 1 paler. 
 
All samples were then correlated to each other with Pearson’s correlation coefficient 
of 0.88 (Figure 6-19) using Miru software. From the Figure 6-19, it can be seen that 
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all samples changed in expression pattern between Day 0 and Day 1. All 
undifferentiated samples (Day 0, bolder colours) are on the left of the figure and their 
expression correlates between each other more than the differentiated samples (Day 1, 
paler colours), which is primarily on the right. The greatest difference between Day 0 
and Day 1 was in the wildtype and one Day 1 sample (Dif2_23.2) showed the most 
extreme difference.  The USP16 heterozygotes were in general similar to wildtype but 
for the USP16 homozygotes the Day 0 and Day 1 samples were closer to each other in 
the network, indicating a reduced transition following PMA treatment.  
 
Next, the expression levels of the USP16 gene were calculated using the Zenbu data 
viewer. Figure 6-20 shows the USP16 expression based on CAGE sequencing in TPM. 
Homozygotes (Hom) had around half of USP16 expression in heterozygotes (Het) or 
wildtypes (WT), which supports the data from qRT-PCR (Figure 6-6, Figure 6-7, 
Figure 6-8). After one day of treatment with PMA (day 1), homozygotes had 
significantly lower USP16 expression than wildtype (two sample t-test, p-value 
0.008). Heterozygotes had around the same USP16 expression as WT. The highest 
TPM among homozygotes was in Hom 1 after differentiation, but still less than WT 
or its parental heterozygote Het C. This is in agreement with the notion that there is 
still a low level of USP16 mRNA in the knockout clones (Figure 6-6, Figure 6-7, 




Figure 6-20 USP16 expression in USP16 knockout clones based on CAGE sequencing. Expression is 
normalised and is given in Tags per million. Day 0 is bolder colour; Day 1 is paler. Wildtype values were 
calculated using mean of the different biological replicates (6 for day 0, 4 for day 1). Error bars for wildtype 
show standard deviation. 
 
 
Figure 6-21 USP12 expression in USP16 knockout clones based on CAGE sequencing. Expression is 
normalised and is given in Tags per million. Day 0 is bolder colour; Day 1 is paler. All wildtype values 
were calculated using mean of the different biological replicates (6 for day 0, 4 for day 1). Error bars for 
wildtype show standard deviation. 
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Figure 6-22 BAP1 expression in USP16 knockout clones based on CAGE sequencing. Expression is 
normalised and is given in Tags per million. Day 0 is bolder colour; Day 1 is paler. All wildtype values 
were calculated using mean of the different biological replicates (6 for day 0, 4 for day 1). Error bars for 
wildtype show standard deviation. 
 
The other H2A deubiquitinases, USP12 and BAP1, were upregulated in USP16 
homozygous and heterozygous clones (Figure 6-21, Figure 6-22). USP12 was 
significantly upregulated at day 0 (p-value = 0.006, two-sample t-test) but not at day 
1 (p-value = 0.170). BAP1 was significantly upregulated at both data points (p-value 
= 3.67956E-06 for day 0 and 0.047 for day 1). 
 
The results suggested that other genes of the deubiquitinase family might also be 
upregulated in USP16 knockout samples. MYSM1 was significantly higher than 
wildtype at day 0 only, whereas USP21 was higher at both time points (Table 6-7). 
USP22 was very slightly upregulated (not significant), but other enzymes like USP3 








  MYSM1   USP21   USP22   
  Day 0 Day 1 Day 0 Day 1 Day 0 Day 1 
HOM MEAN  61.841 68.952 32.324 32.081 84.169 72.064 
SD 4.610 5.347 9.251 6.964 11.474 8.269 
WT MEAN  43.256 72.300 20.159 24.931 102.609 91.453 
SD 15.212 25.186 5.256 4.225 17.706 18.588 
              
2-SAMPLE 
T TEST 
0.024 0.352 0.014 0.065 0.053 0.053 
Table 6-7 Average values for deubiquitinases in USP16 knockout homozygotes (Hom mean) with 
standard deviation (SD) vs average values for wildtype (WT mean) with standard deviation (SD). P-
values for the difference between homozygotes and wildtype was calculated using 2 –sample t test.  
 
To validate whether USP16 knockout cells were at a similar level of macrophage 
differentiation, the macrophage marker CSF1R and the progenitor cell marker MYB 
were looked at. CSF1R was lower in Hom 2, Hom 3 and Hom 4 samples on the second 
day compared to wildtype, indicating that they had not differentiated towards 
macrophages. However, Hom 1 retained the same expression profile as Het C (Figure 
6-23), consistent with results in section 6.3.4 showing that it had similar metabolic 
activity to the heterozygotes and wildtype. MYB was upregulated in USP16 knockout 
samples at both time points compared to wildtype (Figure 6-24), indicating that they 
had remained in a less differentiated state, although the profile for Hom 1 was again 




Figure 6-23 CSF1R expression in USP16 clones based on CAGE sequencing. Expression is normalised 
and is given in Tags per million. Day 0 is bolder colour; Day 1 is paler. All wildtype values were calculated 




Figure 6-24 MYB expression in USP16 clones based on CAGE sequencing. Expression is normalised 
and is given in Tags per million. Day 0 is bolder colour; Day 1 is paler. All wildtype values were calculated 




The USP16 knockout homozygous, heterozygous and wildtype clones were analysed 
using Miru. A gene-to-gene analysis was performed with Pearson’s correlation 
coefficient of 0.92 (Figure 6-25). Using MCL clustering in Miru (see section 2.5.5) it 
was determined that there were various clusters of CTSS correlated with each other. 
Cluster lists are available in Appendix 8.4. The cluster with the most nodes (CTSS) 
was Cluster 01 with 850 nodes, which includes CSF1R and contains genes which were 
upregulated after differentiation (Figure 6-26). The second most abundant cluster was 
Cluster 02 with 286 nodes, which shows genes mostly expressed in monocytic THP-1 
cells prior to differentiation (Figure 6-26). There was little indication of an effect of 
USP16 knockout on genes in these clusters.  
 
 
Figure 6-25 Image from Miru showing CTSS-CTSS correlation (nodes = CTSS). Including all USP16 
knockout and wildtype samples analysed using a Pearson’s correlation coefficient ≥ 0.92. Location of 





Figure 6-26 Average expression profiles of various clusters of co-expressed genes. USP16 knockout 
and wildtype samples only, with correlation coefficient ≥ 0.92. For clusters 16 and 30, red box denotes 
Hom 1 and its parental heterozygote, Het C.  
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Cluster 6 with 129 nodes and Cluster 19 with 44 nodes contained genes differently 
expressed between wildtype differentiated macrophages and USP16 homozygous and 
heterozygous knockout macrophages (day 1) (Figure 6-26). However, two of the 
wildtype biological replicates in Cluster 6 were more highly expressed than the other 
two. Nevertheless, genes within these two clusters were annotated for GO terms (Table 
6-8), and found to be enriched for terms involved with extracellular space, 
inflammatory response, intracellular signalling cascade and nucleoside binding.  
 
Table 6-8 GO annotation of clusters 6 and 19 by DAVID. Group score is an internal group score 
calculated by DAVID software, indicating the enrichment for related GO terms. A high score indicates 
high enrichment. GO terms with p-value smaller than 0.05 shown. 
 
To attempt to understand the close similarity of cell cycle analysis and proliferation 
analysis between Hom 1 and its parental heterozygote Het C, Clusters 16 and 30 were 
chosen for further analysis (Figure 6-26), since these clusters contain CTSS which are 
exclusively expressed in differentiated Hom 1 and Het C cells (Cluster 16 with 52 
nodes) or expressed only in differentiated wildtype and Hom 1 and Het C cells (Cluster 
30 with 29 nodes). Wildtype biological replicates did not behave similarly in Cluster 
Cluster 6 
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30, as it was in the case of Cluster 6, where two replicates had different expression 
pattern to the other two. However, when taken together, these clusters were 
significantly enriched for GO terms associated with von Willebrand factor domain, 
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Table 6-9 GO annotation of clusters 16 and 30 by DAVID. Group score is an internal group score by 
DAVID software, the higher the better. GO terms with p-value smaller than 0.05 shown. 
 
To determine how many CTSS were differentially expressed in USP16 knockouts 
compared with wildtype THP-1 cells, the EdgeR package for R was used. Table 6-10 
shows the number of CTSS differentially expressed (either upregulated or 
downregulated) between different groups of samples, with p-value below 0.01. There 
were 390 CTSS differentially expressed in USP16 homozygous monocytic THP-1s 
compared to wildtype, in comparison to 588 CTSS in USP16 homozygous 
differentiated macrophage THP-1 versus wildtype. Overall, thousands of CTSS 
changed expression between differentiated and undifferentiated state in both USP16 
clones and wildtype. However, there was a higher number of differentially expressed 
CTSS in wildtype differentiation than in USP16 homozygous knockouts’ 
differentiation. Smaller numbers of CTSS with altered expression were found when 
comparing heterozygotes with both homozygotes and wildtype than for homozygotes 
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versus wildtype, indicating the possibility of dominance relationships for expression 
level for some genes and a potential dose response for others. 
 
Comparison Hom 0 - WT 0 Hom 1 - WT 1 Hom 0 - Hom 1 WT 0 - WT 1 
-1 90 157 1819 2953 
1 300 431 2287 6998 
     
 
Hom 0 - Het 0 Hom 1 - Het 1 Het 0 - WT 0 Het 1 - WT 1 
-1 33 67 1 24 
1 18 15 90 300 
Table 6-10 Number of CTSS which were upregulated (1) or downregulated (-1) in comparison between 
USP16 homozygous knockouts (Hom), USP16 heterozygous knockouts (Het) or wildtype (WT) day 0 (0) 
or day 1 (1) with smaller p-value than 0.01 as calculated by EdgeR package. 
 
Looking at lists of most differentially expressed CTSS (ordered by the smallest False 
Discovery Rate (FDR) – thus the smallest probability that the difference in expression 
is due to chance), THP-1 USP16 knockout monocytes upregulated genes like EPHA7, 
IRF2BP2 and PGGHG (Table 6-11). THP-1 USP16 knockout macrophages 
downregulated genes like COL6A1, COL6A2, MAGED1 and EREG (Table 6-12). 
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Table 6-11 EdgeR list of CTSS with greatest difference in TPM between USP16 homozygous clones and 
wildtype THP-1 clones in undifferentiated state at day 0 before PMA treatment. The list is ordered by the 
lowest False Discovery Rate (FDR) value. Genes were manually annotated. Questionmark denotes a 
CTSS which was not found near any gene. 
 
 CTSS logFC logCPM P-Value FDR Gene 
chrX_51802996_51803395_+ -5.7955455 1.602815 6.24E-38 1.78E-31 MAGED1 
chr21_46003385_46005020_+ -3.8357612 2.801117 1.21E-34 1.73E-28 COL6A1 
chr17_7251246_7252164_- 0.9849368 6.837028 1.40E-33 1.34E-27 CTDNEP1 
chr5_98338656_98338731_+ 2.8190013 2.374547 2.58E-32 1.85E-26 ? 
chr19_17377247_17377429_- -4.6594492 1.191346 2.40E-26 1.38E-20 PLVAP 
chr21_46098057_46098456_+ -2.9903802 2.984407 8.38E-25 4.00E-19 COL6A2 
chr1_151458286_151459537_- 1.2490982 4.000285 1.43E-24 5.86E-19 POGZ 
chr4_74364625_74365329_+ -8.0689984 1.135303 1.35E-23 4.83E-18 EREG 
chr16_11585505_11587540_- 1.0172729 8.883237 1.01E-22 2.93E-17 LITAF 
chr3_160224136_160227192_- 1.4789862 6.080353 1.03E-22 2.93E-17 C3orf80 
Table 6-12 EdgeR list of CTSS with greatest difference in TPM between USP16 homozygous clones and 
Wildtype clones in differentiated state at day 1 post PMA treatment. The list is ordered by the lowest 
False Discovery Rate (FDR) value. Genes were manually annotated. Questionmark denotes a CTSS 
which was not found near any gene. 
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6.3.6 CRISPR editing of BAP1, USP12, KDM6B and UTY was associated 
with low viability after cell sorting and was not successful 
Since genome editing of THP-1 cells was successful for USP16, attempts were then 
made to edit the other chromatin modifying genes. Nucleofection of THP-1 cells with 
low passage number was achieved each time, although with very low rate of 
transfection – around 2% of live cells were GFP positive. Consequently, a very small 
number of cells was collected each time using FACS, and these cells were single cell 
sorted to make clonal lineages. There were not enough cells to analyse pooled DNA 
to assess whether indels had been created.  
 
Sorted single cells were cultured to create clonal lineages of THP-1 cells in the same 
manner as for the USP16 knockout experiment to see if the guides created knockout 
cell lines. These experiments were repeated multiple times over the course of almost 
two years. However, when these four genes were targeted, THP-1 cells did not grow 
up at suitable rates after single cell sorting, and in each experiment only a few cells 
out of the whole plate survived and successfully created a clonal cell line.  
 
BAP1 guide plasmids were electroporated into THP-1 cells a total of three times. The 
first sort had two 96-well plates and only 10 clones survived the sorting. The second 
time, three 96 well plates were used but none of the cells survived. The third time, 
again, three 96-well plates were used but only 2 clones lived. None of the surviving 
clones had the deletion of exon 4 (not pictured); all were wildtype.  
 
USP12 guides were used in an attempt to knockout USP12 in THP-1 cells total of four 
times over the course of 2 years. For the first two trials, only single guides were used. 
The first time, 6 plates were sorted with 35 clones sequenced, for the second time again 
6 plates were used with 43 clones surviving. None of these clones had an indel as 
confirmed by Sanger sequencing. The third sort using 9 plates had no survivors, and 
the last sort with 6 plates had 19 clones surviving. Again, no clones had a deletion.  
 
Both UTY and KDM6B potentially edited THP-1 cells were sorted in three batches 
over the course of a year. In sort 1, various combinations of KDM6B guides were 
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electroporated into THP-1 cells, and single GFP+ cells were sorted into 96-well plates. 
In total, out of ten 96-well plates, only 18 single clones grew to cover the whole well. 
These clones were genotyped and none of the clones had an edit. For second batch, 
out of nine 96-well plates containing single THP-1 cells, none of the cells grew up. 
For the third batch, out of six 96-well plates 6 clones grew up, and none had an edited 
genotype. UTY clones had similar fate to KDM6B clones. For the first sort, only 16 
clones survived out of ten plates and none had the edited genotype. For the second 
sort, no cells survived (out of 15 plates) and for the final sort only 7 clones survived, 
with no edits in the genome. It needs to be noted that no cells survived the second sort 
for either edited gene, probably due to the failure of the incubator during the week that 





6.4.1 Chapter overview 
In this chapter, CRISPR-Cas9 system has been used to create mutations in five genes 
of chosen chromatin modifying enzymes in acute monocytic leukaemia THP-1 cells. 
Only one knockout, of the H2A deubiquitinase USP16, was successfully achieved. 
USP16 knockout cells were able to differentiate into macrophages with the addition of 
PMA. Their ability to phagocytose particles was not disrupted in comparison with 
wildtype cells, but lack of USP16 did affect their cell proliferation. USP16 knockout 
cells were analysed using CAGE (Cap Analysis of Gene Expression) technology. 
CAGE libraries were successfully created and the results show that USP16 deficiency 
in THP-1 cells downregulates the levels of macrophage markers such as CSF1R at the 
same time point post PMA stimulation as wildtype. This is the first study of USP16 in 
monocytes and their differentiation into macrophages.  
 
6.4.2 Efficiency and limitations of CRISPR-Cas9 system in THP-1 cells 
Characterising functional roles of the three deubiquitinases and two demethylases in 
macrophage differentiation and leukaemia was attempted by creating knockout clones 
using CRISPR-Cas9 system. Bioinformatics analysis of these five genes was used to 
identify the important domains and gene structures and to design the guides (Chapters 
4 and 5).  
 
Following the successful creation of USP16 knockout lines, CRISPR-Cas9 technology 
was used in an attempt to knockout the USP12, BAP1, KDM6B and UTY genes in 
THP-1 cells to see whether the absence of one or other of these genes and hence of 
functional protein affects cell survival and proliferation or monocyte to macrophage 
transition. However, no edited lines could be created for these genes.  
 
One question is whether the guides were actually efficient in creating a double strand 
break. Since the percentage of GFP+ cells in the population was very low, most of the 
cells were single cell sorted onto plates. Therefore, it was impossible to collect enough 
cells in bulk to extract DNA and do a T7 endonuclease assay or TIDE analysis 
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(Brinkman et al., 2014) both of which detect indel formation. One of the solutions, 
which was not completed due to time constrains of this project, would be to use an 
easy-to-transfect cell line to check the efficiency of the guides and select only the ones 
which are most likely to create a double strand break. As UTY is found on Y 
chromosome, the ideal cell line would contain Y chromosome. Human cancerous 
pulmonary epithelial cell line A549 was considered, as it was collected from a male 
patient (Giard et al., 1973). However, PCR of genomic regions of Y chromosome 
showed that the cell line found in the laboratory differed from ATCC specifications 
and did not contain a Y chromosome (data not shown). Therefore, it was not possible 
to use this line to check the guide for UTY. Also, it is very likely that the efficiency of 
guides in creating a double strand break would differ between cell types, so in the end 
validation of the chosen guides in THP-1 would still be needed. 
 
It is possible that no indels were found among the small number of clonal lines that 
developed following CRISPR-Cas9 treatment because removal of functional enzymes 
was lethal to the cells. Since THP-1 cells lack KDM6A, the options for compensation 
using other demethylases are limited, and (as discussed in section 5.4.2) double 
knockout of Kdm6a-/Uty- is embryonic lethal in mice while homozygous Kdm6b 
deletion is lethal in the perinatal period. For H2A deubiquitinases, as previously 
mentioned in section 4.1, knockout of Bap1 in mice also results in embryonic death 
but Usp12 knockout mice are viable. Given the severe phenotype of these whole 
animal knockouts, it may have been unrealistic to create edited lines. However, 
knockout of Usp16 is also embryonic lethal, and yet it was possible to create a 
knockout cell line. This might suggest that USP16 is less important to survival of THP-
1 cells than the other enzymes, although it is necessary for the survival of the whole 
organism. However, it clearly does have a role in the differentiation process as the 
transcriptomic profile of the USP16 knockout cells was distinct from that of wildtype. 
Further exploration of the other chromatin modifying enzymes may require alternative 
approaches, including the use of conditional knockouts that could be activated at 
precise times during differentiation. 
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It was difficult to achieve a high transfection rate when THP-1 cells were transfected 
with a pX458 plasmid. The transfection efficiency was around 1-2% using optimized 
Nucleofection 4D system (Lonza), which was more efficient than using lipofection 
(data not shown). Using the smaller enhanced GFP plasmid included in the 
Nucleofection package, it was possible to achieve GFP+ rates of around 40% (not 
shown). Thus, the problem might be actually the size of the pX458 plasmid (9300 bp), 
which is quite large for transfection. One of the solutions would be using lentiviral 
approaches to deliver the plasmid into the cells, which has higher transfection 
efficiency overall. Another solution would be to nucleofect the Cas9 protein and 
sgRNA, and not the whole plasmid. Increasing the amount of DNA in nucleofection 
is not an option, as the higher amount of nucleic acid would result in higher cell death 
(personal email correspondence with a Lonza scientific advisor, 2016). Monocytes and 
THP-1 cells are able to sense cytoplasmic DNA, including the CRISPR-Cas9 plasmid 
through cGAS-STING axis (Paijo et al., 2016), and thus are sensitive to any attempts 
at transfection. 
 
One of the reasons why the CRISPR-Cas9 system is less efficient in THP-1 cells is 
that monocytes have impaired double strand break repair, a key component in 
establishing an edited cell line (Bauer et al., 2011). Regardless of delivery system this 
is likely to reduce the chance of editing the genome of these cells. However, since the 
beginning of this project, two studies have been able to create a THP-1 knockout cell 
lines, for example using lentiviral approach (Goetze et al., 2017) or electroporation 
(Schmidt et al., 2016). Exploration of the techniques used may reveal ways of 
increasing the success rate to continue these experiments. 
 
One of the biggest challenges in this project was to ensure the viability of THP-1 cells 
post sorting. As cell sorting at the Roslin Institute is only available in a not completely 
sterile environment, antibiotics must be used to prevent bacterial contamination, which 
might impede cell survival. As shown by Melanie Caruso, a student in the laboratory, 
for the mouse RAW264 macrophage cell line, monocyte and macrophage-like cell 
proliferation is reduced following single cell sorting (MSc thesis, Melanie Caruso, 
2017) although cells grown in batches of at least ten seem to survive at normal rate. 
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This experiment was also repeated in this project with THP-1 cells, with similar 
outcomes (not shown). Conditioned media and increased percentage of FBS in the 
media (up to 30%) was also tried at the beginning of this project, with similar rate of 
cell survival as THP-1 media (not shown). However, it seems that survival of cells was 
better at the beginning of the project than at the end. For example, sort number 2 was 
devastating for all sorted cells, edited or wildtype (section 6.3.6) probably due to 
incubator failure few days after sorting. The number of cells surviving the later sorts 
was much lower than the number of cells surviving for the USP16 or USP12 sorts 
(section 6.3.6). These discrepancies cannot be accounted by anything other than the 
date of the sort, as the passage number of cells, nucleofection and cell sorting 
procedure and variety of different plasmids were kept constant. Cells during sorting 
were also stained by propidium iodide to prevent sorting of dead cells into the wells. 
The buffer which was used for resuspending the cells prior to cell sorting also had 
increased amount of FBS to ensure the cells’ survival. 
 
Usually, all GFP positive cells would be collected together, and their DNA would be 
analysed by PCR to see if the CRISPR-Cas9 guides created a double strand break. 
However, this was not possible with THP-1 cells due to the low cell numbers.  
 
Therefore, further investigation of THP-1 survival post sorting and increasing the 
efficiency of nucleofection of the CRISPR-Cas9 parts would be necessary to properly 
create more edited clonal THP-1 cell lines.  
 
6.4.3 USP16 knockout clones in THP-1 clones 
6.4.3.1 USP16 deficiency does not prevent macrophage phagocytosis 
function, but it does affect cell proliferation 
USP16 homozygous clones were created with one CRISPR guide targeting twice and 
were passaged a few times before being used for experiments. All USP16 knockout 
homozygous or heterozygous cells changed their morphology and adhered to the 
surface with the addition of PMA. One hour treatment with zymosan-coated beads 
showed that USP16 knockout macrophages phagocytosed around the same number of 
beads like wildtype. However, the THP-1 cells seemed to be saturated with 100 beads 
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per cell quite quickly. It is possible that phagocytosis might be slower in the USP16 
knockout cells than in the wildtype. A time course experiment should be carried out to 
confirm this.  
 
During initial passaging, it had been noticed that the USP16 clones seemed to grow at 
a slower rate than wildtype THP-1 cells. This has thus been tested experimentally by 
a colorimetric MTT assay, which measures metabolic activity of cells. For the MTT 
assay, a precise number of cells per well is required and as counting cells with 
haemocytometer is not precise, metabolic activity was assayed on day 0 and day 2 of 
the same concentration of cells and then the rate of growth over two days was 
calculated. Other ways of measuring cell proliferation were considered, but they either 
did not work properly (Cell Trace system from Thermo Scientific) or were too 
expensive (BrdU kit). Results showed that three out of four USP16 clones with 
identical mutation in USP16 gene had significantly smaller cell growth than wildtype 
cells, but not the first one (Hom 1). Even with the Hom 1, overall the rate of growth 
of homozygous cells was significantly slower than wildtype. The test was repeated at 
a later date, with higher passage number, and the homozygous clones had again 
significantly slower rate of proliferation than wildtype, which is in concordance with 
results of other cells treated with USP16 RNAi (Joo et al., 2007). 
 
As stated in the introduction, USP16 has an important role in G2/M phase cell cycle 
progression (Xu et al., 2013) and knockdown in HeLa cells induced a cell cycle arrest 
resulting in fewer cells progressing to G2/M phase (Joo et al., 2007). To characterise 
the effect of USP16 deficiency in macrophage differentiation, percentage of cells in 
separate cell cycle phases were determined at undifferentiated state and two days post 
differentiation. As mentioned in Chapter 3 section 3.2.2, THP-1 cells stop proliferating 
after PMA activation and most cells stay in G1 phase, with almost no cells in S-phase. 
USP16 clones show variable results at different stages of their passage number with 
high standard deviation (Table 6-5, Table 6-6). However, three out of four 
homozygous clones (Hom 2, Hom 3 and Hom 4) did not have change in proportion of 
cells in S-phase after PMA stimulation, and stayed at around 20%, even though for 
wildtype and other cells this number decreased. The same happened for G2/M phase. 
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As discussed in Chapter 3, PMA stops the THP-1 cells at the G1 phase check point 
and cells do not progress into S-phase post-differentiation. These results raise an 
interesting question whether the cells lacking USP16 in the experiment either did not 
have enough time to go through the cell cycle and stop at G1 due to slow proliferation 
or the lack of USP16 either does not allow full differentiation into macrophages in the 
set time or USP16 also has a role in G1 check point. 
 
As with the rate of proliferation, homozygous clone 1 (Hom 1) and its parental 
heterozygote (Het C) had almost identical results to wildtype cells. The difference 
between homozygote 1 and other ones will be discussed in section 6.4.3.3.  
 
6.4.3.2 USP16 deficiency affects the level of differentiation markers in 
THP-1 macrophages 
The effect of USP16 on the cell cycle is independent to USP16 regulating function in 
activating gene expression (Xu et al., 2013). Thus, it was interesting to know whether 
USP16 knockout clones have different global gene expression levels to that of 
wildtype. Overall, hundreds of genes were differentially expressed in USP16 
homozygotes compared to wildtype samples in both day 0 and day 1, according to 
EdgeR differential expression analysis.  
 
In non-differentiated THP-1 cells, one of the differentially expressed genes was 
EPHA7, which was significantly upregulated in USP16 knockout homozygotes and 
one heterozygote (HetdE), but all wildtype samples had almost zero expression. 
EPHA7 is also expressed by USP16 knockout macrophages, but less than USP16 
monocytes. EPHA7 was found to be downregulated in maturation process of mouse 
peripheral bone marrow monocytes (Mukai et al., 2017), and also not expressed in 
human monocytes, but present in human hematopoietic stem cells (Nguyen et al., 
2017). Another gene significantly downregulated in USP16 knockout THP-1 
monocytes was GLUT10 (also known as SLC2A10), a glucose transporter. This gene 
was downregulated in all homozygous clones, but not wildtype or heterozygotes. 
GLUT10 transports the oxidised form of Vitamin C into mitochondria and protects the 
cell against oxidative stress (Lee et al., 2010). Mutations in GLUT10 are also 
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associated with perturbations in TGF-β signalling (Willaert et al., 2012). Together, 
these results indicate that USP16 deficiency causes less mature monocyte phenotype 
and potentially increased cell stress in THP-1 monocytes. 
 
USP16 knockout macrophages downregulate the expression of genes such as 
MAGED1, COL6A1, COL6A2, PLVAP and EREG. MAGED1 was also not expressed 
at all in USP16 knockout monocytes, but it was expressed in one heterozygote. 
MAGED1 is required for cell cycle inhibition from G1 to G0 and proper muscle 
differentiation (Nguyen et al., 2010). COL6A1 and COL6A2 code for collagen 
normally required for macrophage function of modulation cell-cell interactions 
(Schnoor et al., 2008). Plvap-deficient mice do not produce any fetal liver monocyte-
derived macrophages and is also needed for iron homeostasis (Rantakari et al., 2016). 
EREG is a strongly induced TLR-dependent gene, which is upregulated during 
macrophage stimulation with pathogens (Thuong et al., 2012). Together with GO 
terms found in Miru Clusters 6 and 19, it seems that USP16 deficiency results in 
incomplete differentiation into THP-1 macrophages. This is probably due to global 
gene expression changes which USP16 cannot facilitate properly by deubiquitinating 
H2A histones so that genes which should be turned on are not.  
 
With USP16 knockout, BAP1, USP12 and other deubiquitinases were found to be 
upregulated compared to wildtype. This raises an interesting question of whether H2A 
deubiquitinases can compensate for each other and thus the effect of USP16 depletion 
was not as severe as it would without a compensation mechanism from other 
deubiquitinases.  
 
6.4.3.3 Clonal variability in USP16 knockout cells 
It is interesting to note that despite the fact all USP16 homozygotes having the same 
genomic mutation, homozygous USP16 clone 1 (Hom 1) had similar cell cycle, 
proliferation and gene expression profile to its parental heterozygote Het C but not to 
other USP16 homozygous clones. Hom 1 had similar western blot profile to the other 
homozygotes, and there was no indication of producing any functional USP16 protein, 
so this anomaly cannot be explained by a leaky phenotype. It could be argued that it 
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was caused by an off-target mutation, but the USP16 guide used in this CRISPR study 
had a high score based on the CRISPR guide selection tool (section 6.2.1) with 89 total 
possible off-targets according to the tool, with only 7 in genes. BLAST on Ensembl 
database was used to find other possible genomic matches of the guide, but the search 
only yielded one result, the USP16 site. The highest score with a gene hit (0.9) was 
ENPP5, which is only marginally expressed in THP-1 wildtype cells and there was no 
difference in the gene expression between Hom 1 or Het C and other cells. The highest 
score with non-gene hit (2.3) is on chromosome 5 and does not appear to have any 
gene regulation features or SNP variants according to Ensembl.  
 
Miru software recognised the difference in transcriptomic signature between these two 
related clones and the others through two clusters – Cluster 16 with 52 CTSS and 
Cluster 30 with 29 CTSS. Significant GO terms for these clusters included von 
Willebrand factor (vWF) type A domain, which is found in various glycoproteins such 
as collagens. GO terms also included transcriptional regulation, which was not 
significant (eg transcription factors SOX13 or ZNF467). This could mean that the 
difference in clones might be down to few genes, as differential expression of 
transcription factors might change expression of a vast number of genes downstream. 
 
This difference in gene expression profile might be due to the nature of leukemic cell 
line; these cells are clonal and might drift from the parental cells’ gene signature. Even 
biological replicates in FANTOM4 study were not always correlated (Figure 1-3, 
Figure 1-4). Mutations might arise not only by the CRISPR-Cas9 system that was used 
but also by the adaptation of the cancer cell line to the harsh conditions of 
electroporation, FACS or post-sorting single cell growth. USP16 is a known tumour 
suppressor gene, which has a role in regulation of DNA damage (Zhang et al., 2014). 
It is possible that USP16 depletion in the Het C clone might have indirectly caused 
further accumulation of mutations. The other possibility is that the parental 
heterozygote of Hom 2, 3 and 4 (not included in the analysis) was the one that 
accumulated the mutations. The answer to this question would be answered by whole 
genome sequencing of these USP16 knockout cell lines and comparing them to the 
wildtype. Other way how to solve this might be to look at the genes which are 
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differentially expressed only in all homozygotes but not heterozygotes (as for example 
GLUT10 above). 
 
6.4.4 Conclusions and future directions 
Knockout of USP16 in THP-1 cells resulted in differential expression of multiple 
genes, especially in macrophage function. USP16 knockout THP-1 cells seemed to 
have lower levels of differentiation markers (e.g. CSF1R), and thus it might be 
hypothesized that USP16 deficiency results in slower or in non-complete 
differentiation in THP-1 macrophages. To further test this, subsequent LPS stimulation 
of these macrophages (THP-1 monocytes which would be activated by PMA for 1 or 
2 or multiple days) could be carried out, and their gene expression signature could be 
analysed to find out whether these USP16 knockout macrophages are able to fully 
perform their function. 
 
In several instances in the USP16 knockouts, when the levels of one deubiquitinase 
was lower, gene expression of other deubiquitinases was upregulated. This has been 
documented previously by literature – for example USP12 downregulation results in 
USP46 upregulation (Joo et al., 2011). As documented in Chapter 4.4.3 there are 
various deubiquitinases that might share redundant function between each other. 
Future knockdowns or knockouts of multiple deubiquitinases might answer this 
question. In cases where constitutive knockouts might lead to phenotypes affecting 
cell viability or proliferation, novel conditional or inducible gene editing tools might 
still allow to dissect mechanisms of gene/protein functions (Dai et al., 2017, Braun et 
al., 2017). 
 
In summary, this chapter explored the function of USP16, a deubiquitinase that has 
received very little study in the past. It presented the first analysis of USP16 function 




Chapter 7: General discussion and future studies 
 
7.1 Summary of findings 
The main objective of this thesis was to assess the importance of chromatin modifying 
enzymes during cellular differentiation. It was hypothesised that enzymes removing 
the repressive epigenetic modifications from chromatin would be regulated, in order 
to open the chromatin around genes that must be expressed to trigger a transition in 
cellular state. Using a genome-wide technique which quantifies transcription during 
differentiation of a human cell line can reveal the differences in expression of these 
genes and help elucidate their function. In the present study, a time course of THP-1 
monocytic cells differentiating into macrophage-like cells was used as a model for 
transition in cellular state and the changes in the transcriptome during differentiation 
were assessed using a technique that quantifies transcription start site usage.  
 
The first experimental chapter (Chapter 3) investigated transcriptomic changes during 
THP-1 differentiation using CAGE technology. The study provided 18 different time 
points, with multiple biological replicates, which makes it the most detailed study of 
THP-1 differentiation to date. It was an extension of an earlier study by the FANTOM4 
consortium (Suzuki et al., 2009), and full comparison with this study and other data 
from the FANTOM5 consortium still needs to be completed (Suzuki et al., 2009, 
Forrest et al., 2014). This vast and detailed resource of transcriptional dynamics is 
currently undergoing detailed analysis to describe the full scale of changes in the 
differentiating cells, especially to detect enhancer activation followed by target gene 
transcription (Arner et al., 2015). The analysis presented in this thesis shows examples 
manifesting the scope of the transcriptional activity captured by deepCAGE 
sequencing, including quantifying expression levels at the genome scale, detection of 
enhancers and identifying use of alternate promoters as differentiation progresses.  
 
The next two chapters (Chapter 4 and Chapter 5) took the information about six 
chromatin modifying enzymes provided by the transcriptomic analysis of THP-1 
differentiation, and looked in detail at their gene architecture and other information 
from publicly available sources. The enzymes studied were histone deubiquitinases 
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BAP1, USP12 and USP16 and histone demethylases KDM6A, KDM6B and UTY. It 
has been more than three years since H3K27me3 demethylase activity of UTY was 
reported (Walport et al., 2014), but the role of UTY has still not been widely 
recognised in research. The bioinformatics analysis and literature review of 
KDM6A/UTY publications presented in Chapter 5 emphasized UTY as an important 
enzyme with a definite role in human development.  
 
Following the bioinformatics analysis, both chapters then used RNAi technology to 
reduce the expression of these genes in differentiating cells. Unfortunately, this 
approach did not produce acceptable results, as either the levels of the genes were not 
knocked down to less than 50% of original transcription (Chapter 5 section 5.3.3) or 
the biological replicates were variable so significant differences between untreated and 
treated samples could not be detected (Chapter 4 section 4.3.2).  
 
Variable results from Chapters 4 and 5 led to a different approach to reducing the level 
of expression of the genes of interest. Chapter 6 presents the use of CRISPR-Cas9 
gene editing to knockout the genes of chromatin modifying enzymes. USP16 knockout 
was successfully created in THP-1 cells, one of the few examples of genetic editing in 
THP-1 cells, which has proved to be difficult in several laboratories (Schmidt et al., 
2016, Laugel et al., 2016, Goetze et al., 2017). This study shows the first investigation 
of role of USP16 in macrophages known to date. 
 
Overall the study presented in this thesis has generated a large resource of 
transcriptomic data for the process of differentiation in THP-1 cells, and used these 
results to investigate the role of one group of enzymes during this process. The data 
will now be made available for other researchers interested in cell state transitions. 
 
7.2 Methods of transcriptome-wide analysis of gene expression 
The method used for genome-wide analysis of gene expression in this study was 
CAGE. As mentioned in Chapter 1 section 1.4.1, CAGE allows for precisely 
monitoring the start of the transcription (Zhao et al., 2011) as well as quantifying the 
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level of expression at the promoter and gene level. However, there are various other 
techniques that also analyse genome wide gene transcription. 
 
The oldest method still in wide use is the expression microarray. Initially this 
technology used competitive two colour hybridisation to detect differential expression 
between two samples (Allison et al., 2006, Tarca et al., 2006). This technology was at 
best semiquatitative and has been superseded by more recent platforms where a single 
colour is used and many samples can be compared on the basis of expression levels. 
These platforms have greater sensitivity and dynamic range (Chen et al., 2017, Roy et 
al., 2011, Bradford et al., 2010) but are still based on hybridisation, in this case to 
oligonucleotide sequences. Hybridisation might produce large background levels 
which limit the accuracy for transcripts with low levels of expression (Marioni et al., 
2008, Allison et al., 2006). However, the major disadvantage of expression 
microarrays is that they can only detect already known gene structures and do not 
allow for novel features (Tarca et al., 2006). Although sequence-based methods are 
now increasing in use, microarrays are still cost-effective and have the advantage of 
well-established robust analysis platforms such as the Affymetrix Expression and 
Transcriptome Consoles (ThermoFisher, 2017). 
 
A number of approaches take advantage of high through-put sequencing. These 
include RNA sequencing (RNAseq) and CAGE. RNAseq was designed to sequence 
randomly fragmented pieces of RNA, which are then mapped to a reference genome 
and quantified to identify new transcript structures and determine gene expression 
levels (Marioni et al., 2008).  As discussed in earlier chapters, CAGE involves 
sequencing short fragments from the beginning of a transcript, which are then mapped 
to a reference genome. Gene expression levels are comparable between RNAseq and 
CAGE (Kawaji et al., 2014). In general, CAGEseq and RNAseq are considered to be 
complementary technologies, with CAGEseq predominantly used for analysis of TSS 
positions while RNAseq is used to detect alternatively spliced transcripts. Strategies 
based on sequencing have the disadvantage that the analysis is computationally 
demanding. Although pipelines exist for the preparation and analysis of the data, such 
as CAGEr (Haberle et al., 2015), they are not yet as easy to use as the platforms for 
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microarrays. They also depend on the quality of the reference genome to which the 
reads are mapped. 
 
Another method which can analyse TSS positions is called DeepRACE, which couples 
5’RACE (rapid amplification of cDNA ends) with high-throughput sequencing 
(Olivarius et al., 2009). RACE can specifically amplify 5’ ends of the transcripts (5’ 
RACE) and thus, like CAGE, analyse TSS (Olivarius et al., 2009). The difference is 
that this technique uses gene specific primers rather than random priming.  It was used 
to examine TSS diversity for as many as 17 genes (Olivarius et al., 2009). RACE-seq 
is another method, which combines RACE with long read RNA sequencing. Again 
this method is targeted to specific genes and has been used to determine the start, end 
and splice forms of long noncoding RNAs (Lagarde et al., 2016). Neither of these 
methods provides genome-wide transcript information, but they can be used to obtain 
further information about TSS and processing of transcripts of interest. 
 
In the present study, CAGE sequencing was used for transcriptomic analysis. 
However, there are a number of potential issues with this technology, as outlined 
below.  
 
Most current transcriptomic techniques require a high level of starting RNA. The 
CAGE protocol used in this study required 1-5 µg of RNA (Takahashi et al., 2012). 
This is not always available, especially if primary cells are being analysed. New 
protocols could be developed in this case. For example, Poulain et al. (2017) have 
published a CAGE technique with a minimal starting amount of RNA (50 ng) called 
nanoCAGE. Other techniques, such as RNAseq from a single cell are being rapidly 
developed and widely used in immune cells (Papalexi and Satija, 2017). This method, 
however, does not detect non-poly adenylated transcripts and might capture cell-
specific anomalies which are not consistent with the features of the population 
(Papalexi and Satija, 2017).  
 
Another disadvantage of CAGE is the PCR amplification step, where a high number 
of cycles might introduce DNA polymerase bias (Takahashi et al., 2012). Most CAGE 
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libraries in this project were amplified for 10 cycles, which was well below the 
recommended maximum number of 15 cycles for mammalian cells (Takahashi et al., 
2012). The FANTOM5 project initially used the Helicos single molecule sequencing 
technology to develop HeliScope CAGE, which did not require an amplification step 
(Kanamori-Katayama et al., 2011). Unfortunately, due to the failure of the company 
Helicon Biosciences Corporation, this technology is no longer available and more 
recent CAGE analysis has been performed using the Illumina platform, as in this 
thesis. In future, a different method of CAGE library preparation without the PCR 
amplification step could be used, for example nAnT-iCAGE (Murata et al., 2014). 
 
CAGE libraries are known to add a G nucleotide at the 5’end of the transcript due to 
the first reverse transcriptase activity (Figure 2-1) (Zhao et al., 2011). This G addition 
bias was corrected post-mapping stage using CAGEr (Haberle et al., 2015). However, 
efforts could be made to remove this G addition before mapping step in the future, in 
case it created an imprecise mapping of the sequenced tags. 
 
In summary, CAGE sequencing was chosen as the best method for analysis of 94 
samples for least cost. Using this approach enabled comparison with previous 
FANTOM data and TSS information. Every possible precaution was taken to minimise 
the biases known to happen in CAGE library preparation and sequencing.  
 
7.3 Chromatin modifying enzymes in THP-1 differentiation 
To assess the importance of the different chromatin modifying enzymes during 
differentiation, attempts were made to perturb the expression of the enzymes of 
interest, but showed disappointing results. The experiments described in Chapters 4 
and 5 showed variability in the level of siRNA knock down of the chromatin 
modifying enzymes and in the response to the inhibitors. Similarly, the use of gene 
editing technology to create inactivating mutations in the genes produced only one 
successful knockout, of USP16 (Chapter 6).  
 
One of the possible reasons why the results were so variable is that the THP-1 cells 
had been subjected to genetic drift. Cells in culture for multiple passages can exhibit 
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reduction in key functions (Hughes et al., 2007). To minimise this problem, THP-1 
cells in this thesis were not used for more than 7 passages, and cells for quantitative 
experiments were always at low passage number (from the time of single cell cloning 
to produce Clone 5), usually p10 or p11. THP-1 is a tumour cell line, which may have 
changes in mutation detection and DNA repair systems, known to be associated with 
tumourigenesis. Although the karyotype is relatively normal, there are a number of 
known mutations which may predispose to further genetic change after time in culture.  
 
As mentioned in section 6.4, the failure to produce null mutations for most of the 
enzymes using CRISPR-Cas9 editing may indicate that lack of these enzymes was 
lethal to cells, so that the genome edited clones failed to survive. Single cells after cell 
sorting are subjected to selective pressure, which might also explain the differences in 
phenotype of the USP16 clones (Hughes et al., 2007). The clonogenic potential of 
THP-1 cells is controlled at least in part by members of the polycomb complexes 
(Huang et al., 2014), and knockout of these genes encoding enzymes that reverse 
polycomb marks may have ablated their ability to form colonies from single cells. 
In spite of the difficulties in experimentally altering the levels of the enzymes of 
interest, this study provides some data that elucidates the role of chromatin 
modification in this model system of differentiation. The results in this study show that 
there are at least three different transcription patterns found in these chromatin 
modifying enzymes. Firstly, mRNA for two genes, USP12 and KDM6B, increased 
fairly early in the differentiation, with peaks of expression few hours after PMA 
stimulation. Secondly, there were cyclical patterns of expression. For example, BAP1 
mRNA peaked every 3-4 hours during differentiation. Thirdly, there were genes which 
were constitutively expressed with little fluctuation during differentiation (USP16 and 
to some extent, UTY).  
It could be speculated that enzymes such as KDM6B have specific gene targets which 
need to be activated first. These could include genes in Cluster 6 (section 3.3.3) which 
increase a couple of hours after the KDM6B peak. This group included genes involved 
in transcriptional regulation (Table 3-1), suggesting that KDM6B may trigger a wave 
of transcription factor production which would in turn activate other genes involved 
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in the differentiation process. USP12, which increases slightly later, may even be a 
target of KDM6B. USP12 may then have gene targets which are transcribed later in 
the differentiation process. These could include genes in Cluster 3, which were 
associated with lysosomes and endoplasmic reticulum.  
Oscillating enzymes such as BAP1 might be required periodically, as waves of 
repression and activation of genes progress during cell differentiation. Both Cluster 15 
(containing BAP1) and Cluster 36 (containing USP12) show a cyclical pattern, 
although this was so not evident in the expression of USP12 itself (Figure 3-32). Both 
clusters were associated with terms relating to ubiquitin, suggesting that adding and 
removing ubiquitin are important regulated functions during this differentiation.  
Then there were constitutively expressed enzymes (such as USP16) which might be 
required for basal expression of a wide range of genes and potentially function to keep 
the chromatin poised for transcription of key genes. Interestingly, USP16 was the only 
gene which was successfully knocked out by CRISPR-Cas9 technology. The cells 
lacking a functional copy of this enzyme showed reduced proliferation and an altered 
transcriptome after differentiation, including reduction in macrophage markers and 
intra and extracellular signalling (as discussed in Chapter 6 section 6.4.3.2), indicating 
possible targets for this enzyme.  
 
7.4 Additional areas of further investigation 
This study focussed on transcription as the driver for phenotypic change, but it is also 
important to ascertain whether the protein products are made and activated. Various 
post-translational modifications alter protein function. For example, as mentioned in 
section 1.2.2.2, USP12 alters the quantity of NOTCH receptor by deubiquitination 
(Moretti et al., 2012), which cannot be detected by mRNA-level gene expression 
studies. Further proteomic analysis in THP-1 cells should be carried out and compared 
to, for example THP-1 kinome analysis of differentiation (Richter et al., 2016) or THP-
1 cells’ response to LPS using mass spectrometry (Tarasova et al., 2015). Additionally, 
protein levels of the chromatin modifying enzymes should be assessed by semi-
quantitative western blotting and protein modifications by mass spectrometry to ensure 
the levels of the proteins in the cell increase in parallel with the mRNA during 
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differentiation and whether there are specific post-translational modifications 
potentially preventing their function. 
 
As mentioned in the Introduction (section 1.4.1), the FANTOM4 study was repeated 
here with the same conditions in order to be able to compare the datasets. In particular, 
the concentration of PMA that triggered the THP-1 response was the same, as altering 
the PMA concentration might have resulted in different dynamics of differentiation 
(Daigneault et al., 2010, Suzuki et al., 2009). Other culture conditions such as high or 
low confluence of the cells can also alter the way THP-1 cells respond to PMA (Aldo 
et al., 2013). This highlights the need for detailed description of the experimental 
techniques in biological research, especially working with cell lines that have been in 
culture for decades, to increase the reproducibility of scientific data. This anomaly in 
THP-1 cells could be further assessed by repeating the experiments in this thesis with 
changed culture conditions and different PMA concentrations. 
 
As discussed in Chapter 3 (section 3.4.6), this thesis did not completely address the 
macrophage markers and macrophage phenotype in the THP-1 differentiation study. 
Further investigation is needed, for example looking at networks of transcription factor 
up- or downregulation and subsequent changes in expression of their target genes. 
Comparing publicly available chromatin data (for example from the ENCODE project) 
with this dataset would be a non-expensive way to link chromatin modifying enzymes 
with their target modification. Comparing epigenetic marks of enhancers with the 
bidirectional promoter data in this study is beneficial for finding new important 
regulatory sequences which might cause leukaemia. For example, Zhang et al. (2016) 
identified copy number gains of noncoding regions including super enhancers near 
USP12 in colorectal carcinoma, which probably represents a common mechanism to 
increase tumorigenicity in cells. 
 
The THP-1 cell line is widely used in studying macrophage inflammatory reactions 
against various stimulants, such as pathogens and injury (Kim et al., 2016, Ma et al., 
2015), but also in inflammatory diseases, for example in vasculature (Qin, 2012, Borst 
et al., 2015). In the present study, the response of the cells to pathogens (or the 
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pathogen associated molecule LPS) or to other inflammatory signals was not tested in 
the normal or knockout cells. The USP16 knockout cell line is now a resource for 
further exploration of the intersection between chromatin modification and response 
to stimulation. Similarly, the extensive CAGE data generated by this project could be 
used to compare the THP-1 derived macrophage-like cells with tissue and bone 
marrow derived macrophages. Focusing on the macrophage-specific gene signatures 
in the CAGE dataset and their analysis might be of interest to a wide macrophage 
scientific community.  
 
This thesis primarily outlines the role of a limited number of chromatin modifying 
enzymes. However, other enzymes, for example enzymes of PRC1 or PRC2 such as 
EZH2 or RING1B, have also been implicated in cancer and other diseases (Brazel and 
Vernimmen, 2016). As these enzymes directly facilitate the creation of the marks that 
BAP1, USP12, USP16 or KDM6A, KDM6B and UTY remove, the result of inhibiting 
their function could be opposite. However, as a large number of genes are 
downregulated in THP-1 differentiation (section 3.3.3, Cluster 1), creating repressive 
chromatin marks is also required for cell differentiation. Further research into other 
components of PRC1 and PRC2 could show similar results of reduced differentiation 
potential similar to the THP-1 USP16 clones. A wide variety of inhibitors of these 
enzymes such as EZH2 inhibitor, which had been developed as a possible treatment 
for cancer, could be used (Stazi et al., 2017, Brazel and Vernimmen, 2016).  
 
As mentioned in the introduction section 1.2.2, other USPs deubiquitinating H2A have 
also been implicated in cancer. Since the beginning of the project, MYSM1 was found 
to be essential for foetal liver and adult bone marrow haematopoiesis (Forster et al., 
2015) and USP22 was found to stimulate breast cancer growth by positively regulating 
cMYC (Kim et al., 2017). It is highly probable that these two proteins also affect the 
THP-1 differentiation and their effect could be investigated in future studies. 
The USP16 knockout cells have a defective cell cycle arrest during differentiation, and 
reduced proliferation (section 6.3.4). The THP-1 line used here was a clone selected 
for high differentiation potential (Chapter 1 section 1.3.2) (Suzuki et al., 2009). The 
results for the USP16 knockout in THP-1 Clone 5 could be compared the stock THP-
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1 line available from the ATCC. The ATCC cell line could also be recloned to get 
clones with low and high differentiation response measured by adherence, and which 
could be compared with Clone 5 and the USP16 knockout clones. Such clones could 
also be used for further exploration of the role of other chromatin modifying enzymes 
in proliferation. 
This knowledge that at least one of the enzymes is involved in regulating cell division 
could be exploited for cancer treatment, where the goal is to reduce cell proliferation. 
There are as yet no inhibitors specifically against USP16, which could be potentially 
used in cancer therapy. CAGE technology can also be used to analyse functional 
features of the genome, such as enhancers (as discussed in section 3.4.7), and it would 
be beneficial to fully explore the differential transcriptome in USP16 knockout cells. 
As chromatin state affects complex processes such as promoter shifting and enhancer 
usage, these features could have also been affected in these cells, and may indicate 
targets for drug design.  
 
These chromatin modifying enzymes affect the chromatin marks, but no assessment 
of these marks was carried out yet in this work. ChIPseq of various chromatin marks 
like H3K27me3, H3K4me3, H2Aub and H2Bub could be carried out throughout the 
differentiation time course, (such as in Prasad et al. (2014)). CAGEseq data from this 
study could be further validated by DNaseI sequencing, which identifies open 
chromatin regions (Boyle et al., 2008). 
 
Interestingly, tumour suppressor genes that escape X inactivation like KDM6A 
contribute to cancer sex bias, as men carry higher risk of cancer than woman (Dunford 
et al., 2017). Other chromatin modifying enzymes, such as KDM5C and USP9X with 
genes located on the X chromosome, also have Y paralogues - KDM5D and USP9Y 
(section 5.4.2.3) (Arseneault et al., 2017, Hall et al., 2003). Full investigation into all 
XY chromatin modifying pairs might be beneficial for future differential gender-
dependent cancer treatments, as they are all implicated in tumorigenesis (Dunford et 
al., 2017).  
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A full transcriptomic time course of primary cells, separately for healthy female and 
male donors, could suggest whether THP-1 is the right model to study the 
differentiation. Primary monocytes from donors could also be targeted by CRISPR-
Cas9 lentivirus to validate the USP16 knockout data in differentiating macrophages. 
With the rise of personalised medicine, deep transcriptomic sequencing such as that 
presented in this study could in future become the norm for patients with leukaemia. 
For now, other leukaemia cell lines (such as U-937 and HL-60) and samples from 
leukaemia patients could be used to develop precise TSS monitoring in comparison 
with THP-1 and wildtype cells to determine the best model for the analysis of 
monocytic leukaemia and development of potential therapies.  
 
7.5 Conclusions 
We live in an era of big data, where the cost of sequencing is still going down and 
genome-wide transcriptional datasets are appearing at high rate (Schmidt and 
Hildebrandt, 2017). Transcriptional analysis is not only performed in human or mouse, 
as the main models for disease, but also other animals such as sheep, pig and dog 
(Freeman et al., 2012, Clark et al., 2017, Markby et al., 2017). New genome 
assemblies for various animals are available with more and more paralogues of human 
genes annotated, through which we can observe evolutionary constraints over many 
years (Yates et al., 2016, Lesch et al., 2016). The question is now whether we are able 
to interpret the data into a physiologically significant meaning. Studying potential 
functional roles of genes, such as was shown in this thesis, is one of the many ways to 
achieve this.  
 
In summary, results presented in this thesis provide a resource to study transcriptional 
changes in cell differentiation, particularly in macrophages. Throughout the whole 
thesis an acute monocytic leukaemia cell line was used as an experimental model, 
which might help in future therapeutic treatments of cancer. This study highlights the 
difficulties of certain experimental techniques (e.g. siRNA mRNA knock down and 
CRISPR-Cas9 genome editing) used in a haematopoietic cell line, but also reveals new 
data about chromatin modifying enzymes in THP-1 differentiation. The initial 
hypothesis that chromatin modifying enzymes are important for the differentiation of 
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THP-1 cells was supported, at least for the deubiquitinase USP16, and further studies 
using similar models and primary cells should extend these results and indicate 











Chapter 8: Appendices 
 
Appendices 8.1- 8.9 are in files contained in CD on the inside back cover of this 
thesis.  
 
8.1 List of oligonucleotide sequences in CAGE 
8.2 Split_library.pl programme used in sorting sequences 
8.3 CAGE samples summary 
8.4 Miru clusters gene names for Chapter 3 
8.5 Miru clusters gene names for Chapter 4 
8.6 FANTOM5 data for KDM6A and UTY for Chapter 5 
Data are in TPM (Tags per million) for all samples in FANTOM5. 
8.7 Ensembl KDM6A, KDM6B and UTY homology for Chapter 5 
8.8 Transcription factors and protein-protein interactions of 
KDM6A, KDM6B and UTY for Chapter 5 
8.9 Miru clusters gene names for Chapter 6 
 
8.10 Instructions for accessing normalised data in Zenbu 
Normalised results were deposited into Zenbu web browser (Severin et al., 2014). 
There is a collaboration project called Thesis, which contains two views – one is called 
Chapter 3 and the other called Chapter4_6 containing data for both siRNA treatment 
and KO samples, together with relevant samples from Chapter 3. Views are accessible 
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